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Abstract
Gene therapy is an approach to treating diseases in which an exogenous gene is introduced 
to correct for a defective or missing protein or to affect a biochemical pathway. Few 
successes have been reported in humans (0), as several technical issues limit its broader 
application.
One question is how to deliver DNA to the appropriate cells. Nature provides one solution 
in the form of viruses, which are in essence protected gene delivery packages with native 
ability to introduce their genomes into cells.
Once the desired gene is delivered to target cells, another issue that arises is the fate of the 
DNA.
Some strategies rely on long-term expression from extra-chromosomal DNA, but there are 
cases, such as dividing cells, where it would be highly beneficial to permanently insert the 
gene into chromosomes.
Certain viral genomes can be integrated into host DNA by non-homologous recombination 
or, in the case of retroviruses, by virally encoded integrases. While integration seems to be 
not dependent on target sequence, in vivo, retroviruses, such as HIV and murine leukemia 
virus, integrate preferentially into active genes (1, 2), introducing the possibility of 
insertional mutagenesis.
The theoretical danger inherent in retrovirus-based gene therapy has been concretely 
demonstrated in a recent clinical trial in which the modified retrovirus integrated into the 
LM02 locus, causing leukemia in three of the patients (4).
A powerful system to circumvent this critical issue could be to develop a system to site- 
specific integrate the exogenous gene into a safety zone into the genome.
To date, only one animal virus, the adenoassociated virus (AAV), has been identified that 
integrates its genome into a particular location into human chromosomal DNA. When cells 
are infected in the absence of helper virus, AAV establishes a latent infection in which the
AAV genome integrates into a locus known as AAVS1 on the q arm of chromosome 19 
(4). Recombinant AAV (rAAV) vectors too have a series of limitations as gene therapy 
vectors: they can accommodate only small genes and moreover eliminating most of wild- 
type AAV (wt AAV) sequences they have lost almost all the site-specific integration 
capability.
On the basis of AAV site-specific integration machinery a series of effort to re-introduce 
wt AAV’s integration efficiency have been done. Different viruses have been engineered 
using the AAV’s integration machinery to transform them to target and integrate site- 
specifically large genes into the chr 19.
Development of a maximized integrating, large capacity DNA viral vector is still an unmet 
goal of gene transfer technology.
The initial aim of this project was to characterize the combination of the attributes of both 
the AAV and adenovirus (Ad) gene therapy vectors to develop an Ad/AAV hybrid virus 
system able to target site-specifically a large fragment of DNA into the host cell genome.
In executing our experimental strategy, we found that, in addition to the known 
incompatibility of Rep expression and Ad growth, an equally large obstacle was presented 
by the inefficiency of the integration event when using traditional rAAV integrating 
elements. The finding that traditional rAAV plasmid vectors lack integration potency 
compared to wt AAV plasmid constructs led recently to the discovery of an AAV 
integration enhancer sequence element which functions in cis to an AAV inverted terminal 
repeat-flanked target gene. This study has addressed both of these problems.
Moreover the project aimed also the capability of such vectors to target a large integrating 
cassette and the differences in the system integration efficiency compairing the dimension 
of the integrating cassettes.
We demonstrated that an Ad can be generated that expresses Rep proteins and that Rep- 
mediated AAV persistence can occur in the presence of Ad vectors.
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We exploited the size limit capability introducing a large integrating cassette (12 kb) into 
the Ad/AAV vector and we obtained a good level of integration into the human genome. 
Specifically we succeeded in integrating it without any recombination event and in a site- 
specific fashion at good level.
The model we extensively tested in human cell lines was also used successfully into human 
primary cells where we obtained site-specific integration into human chromosome 19 as 
expected.
Another problem analysed was the flexibility of Ad vector system.
Adenoviral vectors maintain the cellular specificity of adenoviruses from which they 
derive. A good gene therapy vector should have a broad tropism to ensure a good 
transduction efficiency, and moreover should be able to transduce cells of interest, such as 
CD34+ cells and other primary cells.
We tried to expand Ad tropism engineering the commonly used Ad 5 vector (not able to 
transduce very well CD34+ and hematopoietic cells), transforming it to an Ad 5/35 
modified vector. This approach permitted us to have better CD34+ cell transduction and a 
very good efficiency with hematopoietic cell lines.
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Chapter 1
Introduction
1.1 Gene therapy: an overview.
Gene transfer in somatic cells has without any doubt a big potential to treat a number of 
genetic and acquired diseases. Among the several delivery systems developed for gene 
therapy purposes, viral vectors derived from retroviruses, moreover murine retroviruses, 
are the most widely used.
Retroviruses are distinguished from other viruses by two characteristic steps in their life 
cycle: reverse transcription, resulting in a double strand DNA copy of the viral RNA 
genome, and integration, leading to the covalent attachment of the viral DNA to host cell 
DNA.
Integration process is an unequalled, and often indispensable tool to obtain high efficiency1 
and stable gene transfer.
Up to now retroviral and lentiviral vectors are the only available tools to integrate foreign 
genes into human cells at reasonable efficiency. However their use involves some 
important problems and limitations:
1. Retroviral vectors (both gammaretroviral and lentiviral) can generally integrate only 
transgenes with a size limit of 5-7 kb.
2. Independent regulation of multiple transcription units is difficult in a retroviral vector 
context.
3. Integration of retroviral vectors into the target cell genome occurs randomly, 
preferentially into active genes. In the last years to this phenomenon has been 
associated an important risk of insertional mutagenesis and oncogenesis due to the 
deregulation of gene/s near the genomic region in which the provirus integrates (0, 1 , 
2, 3).
Alternative to retroviruses are present but at the moment not well studied and developed.
1.2 Adeno-Associated Viruses.
Adeno-Associated viruses (AAV), a single-stranded DNA virus of the family 
Parvoviridae, genus Dependovirus, is among the smallest known viruses. The serotype 2 
virus (AAV-2) has a genome of 4,680 bases contained in an icosahedral capsid of ~24 nm 
(20) (Fig. 1.1).
10 nm
Fig. 1.1 Schematic representation of an AAV particle.
The defining characteristic of this class of viruses is their dependence on co-infection with 
a helper virus (or certain perturbed cellular states) to provide the functions necessary for 
productive infection (21).
Although virus infection appears to be widespread, with over 80% of humans testing 
seropositive, AAV causes no known pathology (21). The infectivity, moderate 
immunogenicity, and apparent lack of pathogenicity have made AAV a promising 
candidate as a vector for human gene therapy (22).
Recently, random integration and subsequent activation of cellular genes have created 
safety concerns about retrovirus vectors (23), and recombinant AAV vectors have also 
been shown to disrupt cellular genes (24, 25). Randomly integrating recombinant AAV 
vectors are severely compromised in integration efficiency (26) and site-specific
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integration, as mediated by wt AAV, may have both safety and efficiency advantages in 
certain gene therapy applications.
AAV is unique among animal viruses in that its latent state involves insertion into the host 
genome at a preferred site (4, 5). This site, referred to as AAVS1, is found at chromosome 
19ql3.4qter and has been mapped to the first exon of myosin binding subunit 85 of protein 
phosphatase 1 (28) (Fig. 1.2).
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Fig. 1.2 Schematic representation of human chromosome 19. AAVS1 locus is located in chromosome 
19ql3.4qter.
Integration has been associated with gross disruptions in the AAVS1 locus, including both 
duplications and deletions (29). Disruption of a nearby gene has also been reported in only 
one case (30).
1.2.1 Viral DNA.
The viral DNA contains two open reading frames (ORFs), rep and cap, encoding the 
regulatory (Rep78, Rep68, Rep52, and Rep40) and structural (VP1, VP2, and VP3) 
proteins, respectively (Fig. 1.3).
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The genome is flanked by two inverted terminal repeats (ITRs) (31). The ITRs are 145 
nucleotides including the D element and are considered to be the only cis elements 
required for replication and site-specific integration of the AAV genome.
In addition to the ITR elements, the rep gene is necessary in trans to target the integration 
event to the AAVS1 site (19, 16, 14). The rep ORF encodes four non-structural proteins: 
Rep40, Rep52, Rep68, and Rep78, which are involved in the replication of the AAV 
genome (20). Rep68 and Rep78 are gene products of alternatively spliced mRNA 
transcribed from the AAV p5 promoter. A structural difference between Rep78 and Rep68 
is that Rep78 possesses a zinc finger-like motif at its carboxyl terminus.
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Fig. 1.3 Schematic representation of AAV genome structure and transcripts. Rep68 is the spliced form 
of Rep78 generated from the p5 promoter. Rep40 is the spliced form of Rep52 generated from the p i9 
promoter. The structural proteins (VPI, 2 and 3) are under the control of p40 promoter.
Both Rep proteins share essentially the same functions: strand-specific DNA binding (6), 
site-specific nicking and ATP-dependent helicase activity (7). Either Rep protein alone is 
sufficient for replication of the AAV genome (32) and for AAVS1-specific integration 
(14). The multifunctional Rep proteins inhibit cellular transformation by heterologous 
genes (33) and suppress heterologous promoters, including the c-fos, c-myc, H-ras and 
LTR of human immunodeficiency virus type 1 (HIV-1) (34, 35, 36). The Rep proteins also
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modulate cell cycle-regulating proteins (37). These results indicate that over-expression of 
Rep proteins has negative effects on cells and is, on occasion, lethal to cells.
1.2.2 AAV-2 DNA replication.
The current model for AAV-2 DNA replication predicts that viral DNA replicates by a 
self-priming displacement mechanism that is initiated from the ITR and requires cellular 
polymerases, helper virus-derived factors and AAV-2 Rep proteins (38, 39). In particular, 
two AAV-2 regulatory proteins, Rep78 and Rep68, are essential for the replication process. 
Transcription from the p i9 promoter generates Rep52 and Rep40 (Fig. 1.3); Rep52 is 
known to have helicase and ATPase activities but not DNA binding or endonuclease 
activity (16). Rep68 and Rep78 down-regulate the p5 and p l9  promoters (40), and this 
stringent control of Rep expression helps to minimize cell death caused by the cytotoxicity 
of the Rep proteins (41).
Although the precise molecular mechanisms of AAV site-specific integration are not well 
understood, it appears that Rep68 or Rep78 are critical. They were shown to bind the ITRs 
at a specific site, called the Rep binding site (RBS), and to cleave it at the terminal 
resolution site (trs) between two thymidine residues (34, 42, 43). This process is essential 
for the completion of the synthesis of a double-stranded monomer form, which is then used 
as the template for the reinitiation of DNA synthesis (38). Through poorly understood 
interactions, the Rep protein/AAV-DNA complex localizes to AAVS1 site, and a non- 
homologous deletion-insertion recombination event occurs, resulting in integration of the 
AAV genome (44, 45). The endonuclease activity of the two larger Rep proteins allows 
them to nick at the trs, which is positioned 8 or 11 bp away from the Rep Binding 
Elements (RBEs) in AAV and AAVS1 respectively. There then follows an interaction 
between Rep molecules that are bound to the AAV genome and those that are bound to the 
AAVS1 site, a non homologous recombination event occurs, resulting in integration of the 
AAV genome (45). It has been shown previously that head-to-tail concatamers of the wt
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AAV genome are able to site-specifically integrate in this manner (29). Preferred AAV 
recombination junction sites have been localized to both left and right AAV ITR elements 
as well as the p5-rep promoter region of the AAV genome (26, 47). Different studies have 
demonstrated that efficient nicking at the trs required, besides the Rep-binding site, the 
contact of Rep with a five-base sequence called RBE', present at the tip of one of the ITR 
anns (48, 49, 50). In addition, the sequence surrounding the trs was shown to be important 
for the formation of a stem-loop structure that exposed the trs on the single-stranded loop 
(51). Recent crystallographic data have confirmed that the N-terminal domain of Rep 
interacted with RBE' and suggested that this interaction was implicated in the orientation of 
the Rep molecules bound at the ITR as well as in the stimulation of the extrusion of the trs 
by the Rep helicase activity. Two of these elements, the RBS and the trs, are also present 
within the chromosome 19 AAVS1 locus, where wild-type AAV-2 was shown to site- 
specifically integrate (45, 5).
1.2.3 The role of Rep.
AAV vectors lacking the rep gene fail to integrate into AAVS1, showing an apparent 
random integration into the host chromosomal DNA (51). A non-viral plasmid-based 
system capable of integrating a transgene specifically into AAVS1 has been described; this 
was achieved by transferring the transgene flanked by the ITRs with transient expression of 
Rep78 or Rep68 (19, 16, 14). Thus, this system is potentially safer than integrating 
retrovirus and AAV vectors. A strategy utilizing two plasmids, one harbouring the 
transgene cassette between the ITR sequences and the other for Rep expression, allows 
only the transgene plasmid to integrate into the AAVS1 locus (14). This method 
successfully introduced the transgene into AAVS1 in haematopoietic K562 cells (53).
The frequency of AAVS1-specific integration by the plasmid-based methods has differed 
among studies.
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Shelling & Smith (18) reported that 9 of 12 cell clones (75%) obtained by transfecting 
HeLa or 293 cells with an AAV vector plasmid on which the Neo gene was placed under 
the control of the p40 promoter, the original promoter for Cap proteins, had rearranged 
AAVS1 and mentioned that approximately 50% of the rearranged bands also hybridized to 
an AAV probe.
Another strategy using one plasmid on which both a Rep cassette and an ITR-flanked 
transgene cassette were placed has targeted the transgene to AAVS1 in 6 of 21 (29%) 293 
cell clones (19). Similar methods applied to other cell lines, HeLa and Huh-7 cells, have 
been able to insert the transgene to AAVS1 in up to 20% of clones (16).
All the studies mentioned used a one plasmid system and the p5 promoter for Rep 
expression.
These results indicated that a high-level expression of the Rep proteins increased the 
frequency of AAVS1 rearrangement and rather decreased the frequency of AAVS1- 
specific integration of the transgene.
1.2.4 AAV nuclear transport.
Helper virus has been shown to potentially influence the biology of AAV by facilitating 
virus transport to the nucleus (54) and by enhancing conversion of the single-stranded 
AAV genome into a transcriptionally active duplex DNA substrate.
In the absence of helper virus, AAV is dependent on interaction with the cell for 
internalization and genome transport to the nucleus.
What are the steps that lead to AAV integration into AAVS1?
Studies in dividing cells demonstrate that AAV uptake is efficient, and virions localize to 
the perinuclear region within two hours post-internalization (54).
The efficiency of capsid uncoating and transport of viral DNA to the nucleus is a potential 
rate-limiting step that may be influenced by viral MOL The model presented in Fig. 1.4 
indicates a proposed sequence of events that occur during the process of AAV integration.
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Fig. 1.4 Proposed model for Rep-mediated AAVS1 disruption and AAV site-specific integration. (A)
Representation of the AAV genome with the inverted terminal repeats hairpinned. (A.l), minimum p5 
integration element including Rep binding sites (RBS), the transcription factor YY1, and the TATA box. (B) 
Representation of AAVS1, including the RBS and the nicking site for Rep endonuclease activity (trs). Panels 
(B .l) to (B.3) diagram Rep binding and replication initiated with host polymerase. Note that Rep is 
covalently attached to the 5' end of the nick site. Rep may reinitiate this process several times, perhaps 
accounting for amplification of AAVS1 (C.2). For integration to occur, a Rep-mediated recombination event 
between AAVS1 (B.3) and p5 (A.2) results in AAV sequence in the disrupted chromosome 19 locus (C.l). J 
Virol. 2004 August; 78(15): 7874-7882.
Following localization to the nucleus, cellular replication and/or DNA repair mechanisms 
are essential for second-strand synthesis of the AAV genome. Alternatively, in the absence 
of efficient second-strand synthesis, a second pathway for production of transcriptionally 
active duplex AAV genome would be through plus- and minus-strand hybridization. 
Subsequent to the formation of duplex genome production, the p5 promoter is activated to 
transcribe Rep (Fig. 1.4). Transcription from the p5 promoter and translation of Rep 
mRNA yield the multifunctional Rep proteins (the focus will be on Rep68 and 78 because 
they are able to mediate integration in the absence of the smaller Rep proteins) (20).
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Production of the duplex genome is a necessary prerequisite for p5 transcription of the rep 
gene and is a likely substrate target DNA for integration, as duplex plasmid DNA 
integrates with high efficiency. It is not possible to distinguish between duplex formation 
or Rep expression levels as a specific rate-limiting entity.
A limitation may simply be template copy number at low MOI. In a latent infection, Rep 
expression levels are presumably very low. Following Rep protein expression, there are 
three biologically active target DNAs that Rep can bind relevant to integration:
- Rep binds to the AAVS1 site on chromosome 19;
- Rep binds to the p5 Rep binding site of AAV;
- Rep binds to the inverted terminal repeat Rep binding site.
Data obtained through transfection of plasmid DNA corroborate previous studies which 
show that the inverted terminal repeat elements are not required for efficient integration; 
therefore, the role of the inverted terminal repeats is essential for maintaining the fidelity 
of the integrating genome and for rescue from latency but not as playing a role in 
mediating a Rep-dependent integration event.
Integration efficiency is defined by Rep interaction with the AAVS1 site (Fig. 1.4) and by 
Rep interaction with the p5 promoter (Fig. 1.4). Rep functions as a hexameric complex, but 
this has not been confirmed to be the complex that is acting on the AAVS1 site or on p5. 
Rep expression in the absence of helper virus or in the absence of integration substrate 
mediates a rearrangement of the AAVS1 site. The AAVS1 site rearrangements are 
consistent with a local amplification event (Fig. 1.4). When an integration substrate (Fig. 
1.4) is present in sufficient quantities, localization of the p5 promoter (p5IEE) integration 
substrate to the AAVS1 integration site takes place, and integration occurs through what is 
predicted to be a strand switch mechanism or perhaps ligation between cellular and viral 
DNA mediated by Rep (55).
One important level of autonomous regulation of AAV integration is through regulation of 
Rep expression. Rep binding to the p5IEE has been shown to bring about a stringent block
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to Rep transcription (40). The repression of rep transcription therefore implies that there is 
a narrow window of opportunity for Rep-mediated site-specific integration to occur. 
Consistent with this hypothesis, Huser et al. demonstrated that maximal integration of 
AAV into chromosome 19 occurs within the first 4 days post-infection. Studies by Giraud 
et al. demonstrated that targeting to plasmid-based AAVS1 targets occurred by 24 hours 
post-infection (56).
Because increasing the dose of virus does not yield an increase in the occurrence of 
integrants, it is possible to argue that there is an inherent limit to the number of discernible 
recombination events that can occur when a cell is infected, regardless of the number of 
available integration substrate targets. In this model, activation of AAVS1 establishes the 
kinetics of integration. Presentation of an integration substrate during the time of AAVS1 
rearrangement creates the opportunity for a copy choice mechanism to integrate the AAV 
substrate DNA.
1.3 ITR-Rep mediated integration.
In current AAV-based transgene systems, rep is deleted since the small viral capsid does 
not have space for an exogenous gene; retaining rep would result in a genome too large to 
be packaged (17). Thus, rep~ AAV-based vectors, which retain other inherent advantages 
of AAV, either do not integrate or integrate inefficiently in a nontargeted manner, a 
process that has been reported to occur preferentially into active genes (25). Promising 
alternatives are hybrid vectors that combine AAV ITRs and rep with a second virus with 
larger transgene capacity, such as adenovirus (57), herpes simplex virus (58), or 
baculovirus (59).
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1.3.1 Rep acts on AAV ITRs.
The varied activities of Rep are needed for reactions on unique DNA structures known as 
inverted terminal repeats (ITRs) found at the ends of the single-stranded viral genome that 
serve as the viral origins of replication (Fig. 1.5).
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Fig. 1.5 Sequence and Folded Structure of the AAV Inverted Terminal Repeat (A) One arm o f the
AAV-5 ITR contains the terminal resolution site (trs), at which Rep introduces a strand- and sequence- 
specific nick, and the Rep binding site (RBS), which contains a series of tetranucleotide repeats (shown in 
boxes; Chiorini et al., 1999). The other two arms of the three-way DNA junction consist o f short hairpins. 
The helicase activity of Rep generates an alternate structure around the trs in which the cleavage site is single 
stranded. The four shaded boxes correspond to stem loops tested for Rep binding. (B) Sequence of the AAV- 
2 ITR. The box indicates the 22 bp binding element identified by Ryan et al. (1996); dotted lines demark 
tetranucleotide repeats. The circled tip of one of the hairpin arms is designated RBE' (Brister and Muzyczka, 
2000). Molecular Cell Volume 13, Issue 3 , 13  February 2004, Pages 403-414
Each ITR contains interrupted palindromic sequences that allow the formation of a three- 
way DNA junction with two short (-.9 bp) hairpin arms. Within the ITRs are two 
sequences required for replication: a Rep binding site (RBS) consisting of several direct 
repeats of a 5'-GCTC-3' motif and a terminal resolution site, trs. Viral replication requires 
Rep binding at the RBS and subsequent cleavage of the top strand at the trs to generate the
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3'-0H group so that the viral ends can be converted into linear duplex DNA. Cleavage at 
the trs is strongly stimulated by the presence in cis of one of the ITR hairpin arms (49, 50, 
51), an effect attributed to a five base sequence known as the RBE', a Rep binding element, 
at the tip of the hairpin. The endonuclease domain recognizes its trs substrate in the context 
of ssDNA or a stem loop generated by the Rep helicase activity (7, 42). Two of the 
important DNA sequences within the ITR, the RBS and the trs, also occur at AAVS1, 
suggesting that the same Rep-mediated DNA recognition and cleavage occur during 
integration. The 33 bp region within AAVS1 that encompass these two sequences are 
necessary and sufficient for targeted integration.
Methylation interference experiments and DNasel protection assays indicate that AAV-2 
Rep preferentially contacts one of the two hairpin arms of the ITR and that this arm 
corresponds to the one furthest away from the trs, whether the ITR is in the flip or the flop 
orientation (6). Ryan et al. (49) showed that five bases, 5'-CTTTG-3', at the tip of one of 
the hairpin arms particularly contribute to Rep binding. The low efficiency of trs cleavage 
on linear duplex substrates compared to that on substrates with intact ITRs is unaffected by 
the addition of the hairpin arms in trans, suggesting that the Rep/RBE' interaction 
stimulates cleavage by imposing a geometric constraint on Rep assembled on the RBS. It is 
possible that this stimulation is indirect and that the Rep/RBE' interaction is important 
primarily to generate a single-stranded substrate rather than to stimulate the chemical steps 
of DNA cleavage (51). This is consistent with the idea that this structure, which shows that 
stem-loop binding does not induce any conformational changes at the enzyme active site. 
The fine tuning of the cleavage activity by the RBE' plays an important role in Rep’s ability 
to discriminate between fully replicated dsDNA viral genomes, which still possess RBS 
and trs sequences, and genomes whose terminal hairpin arms identify them as unreplicated. 
Nevertheless, the Rep/RBE' interaction must be modulatory rather than essential; 
otherwise, Rep would not be able to cleave the trs sequence present at the chromosomal 
AAVS1 site and the virus would be unable to integrate.
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1.4 Rearrangement of the AAVS1 site.
‘Abortive’ integration into AAVS1, i.e. rearrangement of AAVS1 without foreign gene 
insertion, has been described in 293 or HeLa cells (19 18, 14). A similar disruption of 
AAVS1 has been detected in cell lines latently infected with wild-type AAV (4). This 
phenomenon may be explained in three ways.
First, the integrated transgene or AAV genome is disrupted during or after an integration 
event such that Southern blot analysis cannot detect it.
Second, recombination between the AAVS1 region and other sites may cause 
rearrangement of AAVS1 without integration of the transgene at AAVS1.
Third, the Rep protein may excise the integrated plasmid DNA or AAV genome, resulting 
in the loss of the pre-integrated sequences.
Lamartina et al. (15) reported no apparent difference between Rep78 and Rep68 in the 
ability to deliver foreign DNA to AAVS1 in HeLa cells. Some other studies have reported 
the functional differences between Rep78 and Rep68. Rep68 seems to be efficient in 
processing dimers to monomer duplex DNA and possesses a stronger nicking activity (39), 
while the helicase activity of Rep78 is stronger.
The differential effects of Rep78 and Rep68 on the p5, p i9 and p40 promoters were 
described (61). In addition, Rep78 inhibits CREB-dependent transcription by interacting 
with protein kinase (62, 63). None of these findings explains why Rep78 appears to cause 
more abortive integration. Rep68 may be more suitable for the AAVS1 -targeted integration 
system. To confirm the usefulness of Rep68 in the AAVS1-targeted integration system, 
further analysis of a larger population of cell clones would be required. Also, the exact 
functions of the Rep protein in AAVS1-specific integration should be elucidated.
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1.5 The role of Rep Binding Elements (RBE) in Rep mediated 
integration.
The number of RBE sequences in the human genome, how Rep discriminates between 
these and the ch-19 target locus RBE sequence, and how Rep interacts with all sites and 
still facilitates targeted integration within a fixed time frame become of significant 
importance. Using a filter-binding assay and a highly purified source of Rep68 protein, it 
was established that genomic DNA will compete efficiently against a ch-19 target 
sequence. In this assay, a minimum Rep binding site of 8-bp in the context of large DNA 
fragments demonstrated competition, suggesting that as many as 200,000 potential binding 
sites may exist in the human genome.
Filter-binding analysis of genomic DNA successfully retained ch-19 target sequences, as 
well as a cellular RBE identified by BLAST analysis (69), corroborating the competition 
results.
Electron microscopy (EM) analysis was utilized to distinguish possible differences 
between Rep protein DNA interaction with ch-19 RBE compared to a minimum 8-bp RBE 
sequence. Identical multimeric Rep protein DNA complexes, which spanned about 60 bp, 
assembled on ch-19 target DNA, as well as a minimum RBE site, were observed, but never 
on heterologous DNA lacking these sequences.
Analysis of Rep expression in non-virus-infected cells demonstrated DNA rearrangement 
of the ch-19 target sequence, suggesting that this locus is a hot spot for Rep-induced DNA 
amplification and rearrangement that most likely influences AAV targeted integration. 
Although higher affinity for ch-19 RBE sequences (2.7-fold) than for heterologous DNA 
carrying identical elements using this assay, the difference appears to be insufficient to 
explain AAV targeting. In fact, these experimental conditions didn’t identify any features 
that would make the ch-19 locus a preferred site for Rep binding.
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For example, EM analysis of Rep-DNA complexes demonstrated highly uniform 
multimeric complexes on both ch-19 and non-ch-19 RBE sequences. These protein 
structures covered about 60 bp of DNA and appeared to be indistinguishable for ch-19, 
non-ch-19, and AAV ITR RBE sites. Rep binding to control DNA was never observed 
with substrates lacking the RBE site.
These results imply that Rep may interact with numerous RBE sites distributed across the 
human genome as part of the integration mechanism.
Rep levels in a latent infection. The amount of Rep in a latent infection could be 
considered as a rate-limiting step for AAV site-specific integration. For this reason, the 
amount of Rep expressed in the first 24 hours of a non-lytic infection was determined. 
Analysis suggested that 1 to 4,000 copies of Rep78 and Rep68 are available for facilitating 
targeted integration. At present, the rate association constant for Rep and cellular RBE
sites have not been determined. Other DNA-binding proteins (e.g., Drosophila doublesex
6 8and Lambda Cro) typically have rate association constants on the order of 10 (71) and 10 
(72), respectively. Extrapolating from other known DNA association constants and the 
time observed for AAV integration (24 hours) (73), this would suggest that the level of 
Rep78 and Rep68 present in a non-productive infection (1 to 4,000 molecules) should be 
sufficient to interact with all 200,000 potential RBE sites. Even if Rep is inefficient at 
binding, it is important to note that, in vivo, it is unlikely that all 200,000 sites are 
accessible to Rep binding due to their chromatin structure. In fact, a recent study has 
shown that the ch-19 site is DNase hypersensitive (74), implying a chromatin structure that 
is accessible for protein interactions. This observation implies that ch-19 is always 
available for Rep interaction, whereas other sites may be subject to local chromatin 
environment during the cell cycle. These factors strengthen the notion that 1,000 to 4,000 
molecules of Rep could be sufficient for targeting the viral genome in the absence of any 
other features.
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Rep protein complexes. Characterization of purified Rep-DNA complexes by EM 
analysis represented the first visual identification of a multimeric-protein complex 
interacting with the Rep binding site. The fact that Rep complexes were multimeric is not 
surprising since it has been reported that Rep forms multiple protein-DNA complexes and 
may potentially bind as a hexamer (60). The observation that Rep can span a region of 
DNA of about 60 bp, however, does provide an explanation as to why Rep does not bind 
efficiently to small oligonucleotides. It is possible that the RBE DNA induces 
multimerization of the Rep protein since the Rep protein concentration used in the EM 
experiments (16nM) was significantly lower than that for Rep when it exists as a monomer 
in solution (380nM or 25ng/pl). It is interesting to note that previous studies have 
suggested Rep-Rep interactions when there is binding to the DNA RBE motif. 
Observations clearly establish that Rep complexes interacting with either AAV ITR, ch-19 
RBE, or minimum RBE element derived from plasmid DNA form identical protein 
structures (Fig. 1.6).
w fe m
Fig. 1.6 EM analysis of Rep-DNA complexes at protein/DNA mass ratios of 1:1. (A) Rep68H6 protein 
bound to the center RBE of the 2.7 kb ch-19 integration fragment. (B) Rep68H6 protein bound to the 
asymmetric RBE of the 1.7 kb DNA fragment. (C) A 953-bp DNA fragment devoid of any RBE sequence 
and to which Rep68H6 did not bind. J Virol. 2000 May; 74(9): 3953-3966.
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The presence of a strong RBE increases the local concentration of Rep enough to allow 
interaction with low-affinity sites on the same DNA strand. This may be a factor that is 
important in vivo, where competition for Rep (RBE sites) and the initiation for site-specific 
recombination may be influenced by the local concentration of Rep molecules (Rep-Rep 
interactions). Regardless, as previously indicated by gel shift assays, EM analysis also 
revealed a higher affinity of Rep for the ITR when it was compared to either ch-19 or 
analogous RBE sequences. Based on this observation it was hypothesized that Rep levels 
in a newly infected cell will allow constant occupation of the AAV ITR sequences 
compared to transient binding to cellular RBE elements other than ch-19. This would 
imply that a preformed AAV ITR-Rep complex is a separate substrate that may interact 
with chromosomal RBE sites or chromosomal Rep-RBE complexes. If the ITR-Rep 
complex interacts with a Rep-chromosome complex as a separate entity, then the formation 
of the appropriate Rep-chromosome RBE complex would become the rate-limiting 
determinant for targeted recombination.
Cellular factors. All of binding analyses were performed with purified Rep only. Recent 
evidence has demonstrated a role for high-mobility group (HMG) proteins in NS1 nicking 
of the MVM genome (75). This protein has also enhanced Rep binding and nicking activity 
on the AAV ITR and has enhanced in vitro targeting of AAV substrates (76). HMG 
proteins have been implicated in bending DNA and making it more flexible (79). 
Therefore, observations with purified Rep would likely be enhanced in the presence of 
HMG. Cellular proteins could clearly impact the efficiency of Rep-mediated integration. 
Rep-dependent ch-19 replication. The ability to amplify ch-19 in the absence of viral 
integration substrates strongly suggest that Rep-mediated replication is a primary step for 
AAV targeting. These observations support studies by Urcelay et al. (46) that described an 
in vitro Rep-dependent replication of ch-19 DNA carrying the RBE-/ra site. From these 
observations, it appears that a critical step in the AAV integration process involves Rep- 
dependent nicking of the ch-19 substrate. Cellular amplification in the absence of viral
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targeting sequences, suggesting that Rep initiates a replication event on ch-19 that results 
in amplification and rearrangement. These observations aiso suggest the possibility that the 
head-to-tail configuration of viral integrants appears as a by-product of this replication 
event. Pro viral structures for AAV vectors devoided of Rep result in identical head-to-tail 
concatemers, albeit at random sites in the genome (4, 73). In addition, recent analysis of 
simian virus 40 integration has documented identical head-to-tail proviral structures, 
implying that this may be an universal cellular mechanism for “amplified” integration (77). 
These data imply that host machinery is responsible for the head-to-tail amplification and 
that the role of Rep is to direct the recombination event through initiation of replication on 
a virus-like origin (RBE-fr^) located on ch-19. These observations also provide an 
explanation as to why latent proviral structures (head to tail) generated by host enzymes do 
not resemble the Rep-dependent viral replication intermediates (head to head) seen in a 
lytic infection. EM data suggest that the Rep complex may be associated with the viral 
Terminal Repeats (TR) sequences prior to initiating replication on ch-19.
It is still undetermined whether the viral Rep-TR complex requires nicking in order to 
recombine with the ch-19 target sequence. While rescue of proviral AAV genomes 
requires functional terminal repeats for replication and packaging, the precise role in 
integration is still undefined. These data suggest that if Rep independently forms a 
complex on ch-19 and initiates replication, this may be a hot spot for Rep-Rep DNA 
complexes to assemble, in a manner similar to that of the punctate replication centers 
described by Hunter et al. (55), for wt AAV lytic infection.
At present, 1% of AAV infecting viral genomes integrate with approximately 70 to 90% of 
these pro viruses targeted to ch-19 (78). Though this is an efficient reaction for targeting, 
the overall integration frequency is marginal at best. Five successive steps can be identified 
that would impact AAV targeted integration after infection:
• Conversion of single-stranded to double-stranded DNA, providing a template 
competent for mRNA expression;
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• Expression of Rep proteins;
• Rep interaction and complex formation with viral ITR and/or chromosomal RBEs;
• Rep-dependent replication of the ch-19 locus;
• Rep-ITR complexes interacting with Rep-ch-19 replicated substrates, facilitating 
targeted recombination and resulting in head-to-tail proviral structures via host 
enzymes.
1.6 The role of the nicking sites (trs) recognition in Rep mediated 
integration.
Multiple evidence suggests that both binding and nicking of AAVS1 by Rep68/78 are 
required for preferential integration (46, 69). This has led to the current hypothesis that 
AAVS1 is the preferred integration locus for AAV-2 because it contains the best Rep68/78 
nicking site within the human genome.
Analysis of the trs region has been problematic because nicking site recognition appears to 
require that the DNA strands be separated in the region of the trs (9, 55 42). Rep68/78 
have two nucleoside triphosphate-dependent DNA helicase activities.
One helicase activity is non specific with regard to DNA sequence but requires a 3' single­
stranded tail (7, 50).
The second activity can unwind a blunt-ended fragment but requires an RBS.
The current model for nicking suggests that Rep68/78 first binds at the RBS and begins to 
separate bi-directionally the two strands (9, 42). Once the region of the trs is separated 
from its complementary strand, the ^-containing strand is hypothesized to fold into a 
stable secondary structure. Rep68 or Rep78 can then nick at a site that it recognizes by a 
combination of its base sequence and its secondary structural context (55). A putative
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stem-loop structure has been identified in the region of the trs for AAV serotypes 1 
through 6. Fig. 1.7 shows that a 5- to 7-bp stem could be formed by standard Watson-Crick 
base pairing (i.e. A-T and G-C) (69). Individual mutation of several of the bases within the 
putative stem of the AAV-2 trs region resulted in a reduction in the ability of the site to be 
nicked (69).
Comparison of the AAVS1 trs region with that of AAV-2 shows several regions of base 
identity (Fig. 1.7); the 5-GT TGG-3' core motif immediately flanking the trs (the gap 
represents the primary cut site), 2 of the 6 bases 5' of the core motif, and 3 of the 11 bases 
3' of the core motif. Most of the bases believed to be involved in the AAV-2 trs stem 
structure are not conserved in AA VS1 (46).
S I --18
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A A V Sl 5 1-GGCGGCGGT TGGGGCTCGGCGCT-3 1
1 1 H M l 4 H
AAV-2 5 ' -TGATGGAGT TGGCCACTCCCTCT-3 '
AAV-1 5 *-TGATGGAGT TGCCCACTCCCTCT-3'
AAV-3 5 ' -TGATGGAGT TGGCCACTCCCTCT-3 '
AAV-4 5 ' -TGATGGAGT TGGCCACTCCCTCT-3 ’
A A V -6 5 *-TGATGGAGT TGCCCACTCCCTCT-3*
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Fig. 1.7 Underlined bases have the potential to form a stem by Watson-Crick base pairing. Bases conserved 
between all sequences (S1/AAV1-6) and between all sequences except AAV-5 (S1/AAV1-4/6) are indicated. 
The double-pointed arrows indicate bases conserved between AAVS1 and the AAV-2-ITR. The 18-base 
segment of AAVSJ that is the focus of the present study (Sl-18) is bracketed. Bases C3, C6, T9, G12, C15, 
and G18 of Sl-18 are numbered. J Virol. 2005 March; 79(6): 3544-3556.
Furthermore, no stem-loop similar to those proposed for the AAV sequences could be 
formed in AA VS1 by using Watson-Crick base pairing. In spite of this, previous works 
showed only about a twofold difference in the ability of Rep78 to nick the linear form of 
the AAV-2 ITR trs/KBS versus the AAVS1 fr's/RBS. Maybe a stable secondary structure 
based, at least in part, on non-Watson-Crick base pairing, in the AAVS1 trs region is
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present. Elements of this secondary structure may also contribute to the ability of AA VS1 to 
be nicked by Rep68/78
1.7 p5 integration enhancer element.
Rep-mediated integration of recombinant AAV plasmids is extremely inefficient, with 
between 0,1 and 1% of transduced cells demonstrating rAAV genome persistence after 6 
weeks (26). In contrast, plasmids that carry the entire AAV genome integrate at 
efficiencies of greater than 10%. This difference led several groups to postulate the 
presence within the AAV-2 genome of an additional cw-acting replication element, besides 
the ITRs, and to demonstrate its presence within the 5' portion of the rep gene (64).
A 350-bp sequence (previously named CARE) encompassing the p5 promoter and the 5' 
portion of the rep ORF (nucleotides 190 to 540 of wild-type AAV-2) was able to promote 
Rep-dependent replication of a plasmid containing the ITR-deleted rep-cap genome and 
the encapsidation of these sequences during recombinant AAV production (64). This 
element contained the binding sites for transcription factors such as YY1, and the major 
late transcription factor, a TATA box, a Rep-binding site, and a /rs-like motif (66, 67). 
Binding of Rep78 and Rep68 to the p5 Rep-binding site was previously shown to mediate 
the transcriptional repression of the p5 promoter observed in both the absence and presence 
of adenovirus (68). The p5 /rs-like motif was identified because it enabled Rep-dependent 
AAV-2 replication in the absence of the left ITR (67). In addition to its ability to behave as 
a c/s-acting replication origin, the p5 region (nucleotides 151 to 289 of wild-type AAV-2) 
was recently shown to enhance Rep-mediated site-specific integration of plasmid DNA into 
the human chromosome 19 AAVS1 site (26, 27).
Replication assays performed in transfected cells (in vivo) indicated that a minimal 
functional p5 element was composed of a 55-bp region (nucleotides 250 to 304 of wild-
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type AAV-2) containing the TATA box, the Rep-binding site, the trs present at the 
transcription initiation site (tos+1), and a downstream 17-bp region that could potentially 
form a hairpin structure localizing the trs+] at the top of the loop. Interestingly, the TATA 
box was seen to be absolutely required for in vivo but dispensable for in vitro, i.e. cell-free, 
replication. Finally, there was the demonstration that Rep binding and nicking at the trs+x 
was enhanced in the presence of cellular TATA binding protein (TBP), and that the over­
expression of this cellular factor increased the in vivo replication of the minimal p5 
element. Together, these studies characterized the minimal AAV replication origin present 
within the p5 promoter region and demonstrated for the first time the involvement of the 
TATA box, in cis, and of the TBP, in trans, for the Rep-dependent replication of this 
element.
Philpot and co-workers (27) identified the p5 sequence investigating the hypothesis that an 
Ad vector could be adapted to utilize the integration mechanism of AAV and generate 
chimeric constructs that could bring closer to a system able to fulfil a long-term gene 
expression. An important finding emerged: traditional rAAV vectors are lacking an 
important integration efficiency element. In the presence of a p5-rep integration efficiency 
element, the vast majority of AAV integrants (over 90%) occurred in a site-specific 
manner.
Recchia and co-workers generated a helper-dependent Ad-Rep vector and tested its ability 
to mediate site-specific integration by co-infecting it with an Ad that contained ITR- 
flanked GFP and hygromycin resistance transgenes (57). In agreement with Philpott, 
Recchia et al. found a relatively low efficiency of persistently hygromycin-resistant cell 
lines (estimated at 0.3%). In their studies, a third of the selected cell lines contained GFP 
localized to chromosome 19, as indicated by fluorescent in situ hybridization analysis.
Using a vector containing p5-rep sequence (including the intact rep ORF) in cis but outside 
GFP-flanked ITRs, Balague and co-workers found that such a vector persisted in nine fold- 
more cell lines than did an equivalent plasmid without p5-rep sequence (19). In addition,
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the p5-rep sequence mediated site-specific integration at a level comparable to the 12% 
targeted integration efficiency observed.
In another study, Pieroni et al. used similar plasmid vectors consisting of neomycin 
resistance and GFP transgenes between ITRs with and without p5-rep sequence (again 
expressing the full rep ORF) outside the ITR elements (16). Despite using antibiotic 
selection, they found that the p5-rep sequence was critical for site-specific integration of 
transgenes in HeLa cells. Both of these studies came to the conclusion that Rep is 
necessary in trans for targeted AAV integration. A new series of papers claim that Rep in 
trans is necessary but not sufficient for efficient site-specific integration to occur. These 
authors showed that co-transfection of Rep-expressing plasmids with an ITR-flanked 
transgene does not result in efficient integration. It seems that the Balague and Pieroni 
systems supplied two distinct elements, the Rep protein in trans and an AAV integration 
efficiency element in cis. Interestingly, based on the constructs used in their studies, the cis 
integration element can be located inside or outside the ITR-flanked transgene, indicating 
functional flexibility in position and orientation of the integration element.
Importantly, the results characterizing integration by the rAAV construct pGFPCap 
indicate that the entire rep ORF is not required in cis for efficient integration. This 
construct contains the dispensable cap sequence element but lacks the majority of the Rep 
coding region. The pGFPCap construct also includes 526 bp of DNA containing the entire 
p5 promoter, which flanks the left AAV ITR. Analysis of clonal cell lines isolated from 
transfections of pGFPCap with Rep supplied in trans pAAV/Ad showed that 5% were 
positive for GFP and AAVS1 disruptions. Although the level of integration was below that 
seen with wt AAV or pRepGFP, this is the first construct that separates the p5-rep 
promoter element from Rep expression and maintains a high level of site-specific 
integration. Several factors may be contributing to the reduction in integration efficiency 
seen with pGFPCap, including the presence of additional sequence elements or the
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proximity of neighboring transcription units (CMV-GFP), and this is currently being 
investigated.
Involvement of the p5-rep promoter region in the wt AAV integration event has precedent. 
Studies by Giraud et al. (29) and Samulski et al. (5) demonstrated that junction fragments 
of wt AAV integrants into episomal AAVS1 plasmids or chromosomal regions occur 
predominantly within two AAV sequence elements, the ITRs and the p5 promoter region. 
More recently, Tsunoda and coworkers used HeLa cells subjected to lipofection to study 
junctions between the AAV plasmid and the AAVS1 site that formed during site-specific 
integration. Using a plasmid containing p5-rep and Neor genes flanked by AAV ITRs, they 
found that most junctions occurred within the p5 promoter region of the plasmid DNA. 
These studies suggest that the p5 promoter that contains an RBE might be a hot spot for 
targeted AAV integration. In addition, Tullis and Shenk (65) showed that a p5-rep 
sequence functions in cis to increase the efficiency of AAV replication. Finally, using an in 
vitro replication system Nony and co-workers recently published a study which suggested 
that a p5-rep sequence between nucleotides 190 and 540 of the wt AAV-2 genome 
promoted efficient replication of rAAV plasmid vectors (64, 65). Since the p5-rep 
sequence identified by Nony et al. is present in the pGFPCap and pRepGFP constructs, we 
propose that this cis-acting replication element is also functioning as an enhancer of 
integration.
Further studies will be required to fully understand the relationship between the newly 
identified enhancer element and the RBE-terminal resolution site of the ITR with respect to 
the mechanism of integration. It is also likely that the delicate balance of regulated rep gene 
expression that occurs during the life cycle of AAV contributes significantly to the overall 
efficiency of integration. Vectors that regulate Rep expression in a manner that optimizes 
integration and yet minimizes unwanted chromosomal disruptions are a critical area that 
has not been developed. Incorporating these new insights into a variety of gene transfer 
strategies, including the Ad-AAV chimeric strategy that initiated these studies, should
make a significant contribution toward achieving the long-term goal of site-specific 
integration of a therapeutic gene.
1.8 Rep Toxicity.
1.8.1 Rep can inhibit PKA and PrKx.
Viral interference is a frequent consequence following infection of an animal cell with 
more than one related or unrelated virus. Characterization of this interaction during 
influenza infection led to the discovery of the interferons and their role in viral interference 
(80).
Classically, viral interference can be either direct or indirect (interferon mediated).
Direct interference occurs when a viral protein or a viral-induced protein disrupts the 
replication of another virus.
Indirect interference takes place when a virus induces secretion of interferon and other 
cytokines that protect cells from subsequent infection.
While the molecular mechanisms of interferon-mediated interference are well known (81), 
mechanisms of direct interference have not been as extensively characterized.
Examples of direct interference include the inhibition of vaccinia (a poxvirus) and 
vescicular stomatitis virus (VSV) by poliovirus and vaccinia by Frog virus 3 (an iridovirus) 
(82, 83, 84). Recently, non-interferon-mediated interference was described in patients 
infected with HIV and the non-lytic virus hepatitis G (85).
A hallmark of the adeno-associated virus serotype 2 (AAV-2) life cycle is its interaction 
and inhibition of replication of other viruses.
AAV-2 is a dependent virus and requires the presence of a helper virus for productive 
replication. Helper viruses include adenovirus (Ad) (86), cytomegalovirus (87),
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herpesvirus (88), EpsteinBarr virus, varicella virus (89), pseudorabies virus (90), vaccinia 
virus (91) and papillomavirus (92).
However, during a co-infection, AAV can inhibit both Ad and simian virus 40 (SV40) 
propagation (93), while expression of AAV Rep proteins is sufficient to inhibit the DNA 
replication of HSV (94), BPV (95), HPV (96) and HIV (97). In addition to inhibiting 
helper virus replication, AAV co-infection can also suppress transformation by a number 
of viruses and viral oncoproteins (98).
In the absence of a helper virus, AAV-2 is able to establish a latent infection by integrating 
in a locus specific manner on the Q arm of human chromosome 19 (4). The four related 
viral non-structural Rep proteins (Rep78, 68, 52 and 40) are essential for both aspects of 
the AAV-2 life cycle.
It was described that a stable interaction takes place between the unspliced Rep proteins, 
Rep78 and Rep52, and the cAMP-dependent protein kinase A (PKA) and its novel 
homolog PrKX (62, 63). This interaction resulted in the inhibition of PKA kinase activity. 
No interaction was detected with the spliced Rep proteins, Rep68 and Rep40. A biological 
effect of Rep78 inhibition of PKA and PrKX activity is the decreased expression of cAMP 
responsive genes in Rep78-transfected cells (62). The interaction between Rep78/52 and 
PKA was found to have a physiologically relevant dissociation constant of 320 nM (62) 
and additional studies using steady state kinetic analysis and mutagenesis of Rep78 
demonstrated it could act as a competitive inhibitor with respect to a peptide kinase 
substrate (41).
In addition to its role in cellular signal transduction, the PKA pathway also has a role in 
viral infection. cAMP-responsive elements (CRE) regulate the expression of numerous 
viral genes. Recently, Ad has been shown to require cAMP-dependent protein kinase 
activation to facilitate its transport to the nucleus (99). In addition, the El a, E3 and E4 
promoters of Ad contain CREs and are PKA responsive (100).
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Thus, like their cellular homologs, viral genes also may be affected by Rep78 inhibition of 
PKA and PrKX activity. It was hypothesized that during an AAV-2/Ad coinfection, Rep78 
inhibition of cellular PKA and PrKX activities could result in both the down-regulation of 
specific Ad genes and an inhibition of Ad replication.
AAV-2 Rep78/52 proteins contain an inhibitory domain similar to that of the heat-stable 
PKA inhibitor PKI (101). This domain, while not directly necessary for AAV replication 
and packaging, is necessary for AAV-2 Rep78/52 inhibition of PKA and PrKX. 
Furthermore, mutated AAV-2 genomes lacking this region fail to inhibit Ad replication, 
suggesting that modulation of PKA activity is a mechanism by which AAV-2 interferes 
with helper virus replication. Finally, AAV-2's ability to inhibit Ad replication via 
modulation of PKA activity is necessary to preserve its replication fitness during an Ad co- 
infection.
1.8.2 Other causes of Rep-mediated cell death.
Apoptosis, or programmed cell death, is a highly regulated cellular suicide process. It is 
involved in normal tissue development as well as in the response of the cell to stress, 
growth factor deprivation, and DNA damage. Morphological changes typical for apoptotic 
cells include nuclear and cytoplasmatic condensation, which is followed by the 
fragmentation of the cell into apoptotic bodies. In vivo, these cell fragments are consumed 
by macrophages without the elicitation of an inflammatory response (102, 103). 
Biochemical characteristics include fragmentation of DNA, partial loss of plasma 
membrane asymmetry, and reduction of the mitochondrial transmembrane potential. 
Apoptosis can be triggered by external or cellular signals. Stimuli from both pathways are 
integrated and amplified by a family of cysteine proteases with aspartate specificity, 
referred to as caspases. Caspases are expressed as zymogens, inactive proenzymes which 
are proteolytically activated during the transduction of death signals. Caspases by 
proteolytically cleaving vital cellular proteins, are also involved in the execution of cell
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death. Among the caspase targets are actin, lamins, and poly(ADP-ribose) polymerase (4, 
104).
The majority of experiments analyzing the cytotoxicity of Rep78 have been done with 
inducible stable cell lines which either require a toxic heavy metal for induction of 
expression (105, 106) or have shown low-level expression (32).
The observed effects of Rep78 on cell survival and cell cycle progression in this transient 
system differ from the data obtained with stable Rep-inducible cell lines. Holscher et al. 
(32) described a stable HeLa cell line expressing Rep under the control of the 
glucocorticoid-responsive mouse mammary tumor virus promoter. Upon induction, no 
cytotoxic or antiproliferative effect of Rep was detected. Yang et al. (105) described 293- 
based cell lines that express the AAV Rep proteins under the control of an inducible mouse 
metallothionein transcription promoter. Upon induction with heavy metals, an 
accumulation of Rep-expressing cells in S phase was observed, but no toxicity was 
reported. However, Rep enhanced the toxicity of UV irradiation and incubation with 
cadmium (106). These differences in the effect of Rep on the cell may be due to the cell 
types used for the studies, expression efficiencies of the rep gene, and adaptation of the 
cell lines to background levels of Rep expression or alterations in the genomic rep gene. 
293 cells contain a colinear segment from human adenovirus type 5, from nt 1 to 4344, 
which is integrated into chromosome 19 (19ql3.2) (107). This segment contains the E1A- 
E1B region of the adenovirus genome.
The El A gene products bind to key elements such as members of the pRB family, inducing 
unscheduled cell cycle progression.
The E1B-55K protein was shown to bind and inhibit p53, while E1B-19K acts as a Bcl-2 
homolog in inhibiting apoptosis (82).
HeLa cells are a cervical-carcinoma-derived cell line containing multiple copies of 
integrated human papillomavirus (HPV) type 18 DNA. HPV type 18 encodes regulators of 
cell cycle progression and apoptosis which act similarly to the adenovirus-encoded El
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proteins (108). The viral gene products of both cell lines are likely to modulate the effect 
of Rep on the cell cycle and apoptosis and may explain the differences observed in the 
different systems.
In addition, an effect of the inducers of the stable Rep-expressing cell lines on cell growth 
and death is possible. Yang et al. used zinc and cadmium to induce Rep expression. 
Cadmium is a highly toxic heavy metal that has been shown to induce distortion of the cell 
cycle (109) and apoptosis by causing oxidative stress and DNA damage (110); zinc, in 
contrast, is efficient at inhibiting apoptosis (111). Interesting analogy between the effects 
of AAV-2 Rep78 and the nonstructural protein (NS-1) of the autonomous parvoviruses on 
the cell. Both proteins possess cytostatic and cytotoxic potential. Cell death caused by NS- 
1 expression was induced by apoptosis (112) which was mediated by and dependent on 
caspase-3. The cytostatic potential of NS-1 correlated with an accumulation of cells in G2 
and a block in cellular DNA replication which was proposed to be a consequence of NS-1- 
induced DNA damage (113).
1.9 Adenoviruses.
1.9.1 Structure.
Vectors based on different viruses have been developed to embrace a wide range of 
strategies for the gene therapy of a variety of diseases. Evaluation of many of these 
approaches has revealed a number of fundamental problems. These limitations are driving 
vector technology efforts toward a further evolution of the present systems and the 
generation of new classes of vectors that combine the best features of different viruses 
(114,59).
The modification of Ad vectors is an example of vector engineering directed to solving 
problems identified by preclinical studies. Ad is considered an attractive vehicle for several
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reasons. The viral life cycle is well characterized, its genome is easy to manipulate, and the 
resulting vector can be grown to high titers (115).
All Adenovirus particles are similar: non-enveloped, 60-90nm diameter. They have 
icosahedral symmetry easily visible in the electron microscope by negative staining and are 
composed of 252 capsomers: 240 "hexons" + 12 "pentons" at vertices of icosahedron.
The hexons consist of a trimer of polypeptide II with a central pore; VI, VIII and IX are 
minor polypeptides also associated with the hexon, thought to be involved in stabilization 
and/or assembly of the particle. The pentons are more complex; the base consists of a 
pentamer of peptide III, 5 molecules of Ilia are also associated with the penton base.
The pentons have a toxin-like activity.
A trimeric fibre protein extends from each of the 12 vertices (attached to the penton base 
proteins) and is responsible for recognition and binding to the cellular receptor. A globular 
domain at the end of the adenovirus fiber is responsible for recognition of the cellular 
receptor. (Fig. 1.8)
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Fig. 1.8 Schematic representation of Ad structure.
While there are over 51 serotype strains of adenovirus, most of which cause benign
respiratory tract infections in humans, subgroup C serotypes 2 or 5 are predominantly used
as vectors. The life cycle does not normally involve integration into the host genome,
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rather they replicate as episomal elements in the nucleus of the host cell and consequently 
there is no risk of insertional mutagenesis.
1.9.2 Ad genome.
Adenoviruses are non-enveloped viruses containing a linear double stranded DNA 
genome.
The wild-type adenovirus genome is a linear, non-segmented, d/s DNA, 30-38 kbp (size 
varies from group to group) which has the theoretical capacity to encode 30-40 genes. The 
terminal sequences of each strand are inverted repeats, hence the denatured single strands 
can form "panhandle" structures (100-140 bp). There is a 55 kDa protein covalently 
attached to the 5' end of each strand. Of the approximately 35 kb viral genomic DNA up to 
30 kb can be replaced with foreign DNA (116). The adenovirus particle limits the amount 
of DNA that can be packaged to -105% of the genome, only -1.8 kb more that the wild- 
type virus genome.
There are four early transcriptional units (El, E2, E3 and E4), which have regulatory 
functions, and a late transcript, which codes for structural proteins.
1.9.3 Genome transcription.
The adenovirus genome is transcribed in both directions and alternative splicing allows 
multiple transcripts to be generated from the same sequence. Any manipulation of the virus 
genome therefore requires the coding capacity of both DNA strands to be considered.
The E3 gene region is dispensable for adenovirus replication in vitro and can be deleted 
from both replication-competent and replication-deficient vectors to permit larger inserts. 
Adenovirus vectors may be either replication-competent or replication-deficient.
In replication-competent adenovirus recombinants, transgenes are usually inserted in the 
E3 region and very high levels of expression can be achieved with transcription driven by 
the late promoter. Replication-deficient adenovirus vectors are usually based on adenovirus
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E1-E3 deletion mutants. Deletion of the El gene region (both El A and E1B) permits 
vectors to accommodate significantly larger inserts, removes a region of the genome 
associated with cellular transformation and generates a vector that is not only replication- 
deficient but also cannot activate early phase gene expression. This defect in early phase 
gene expression generates a vector which can promote efficient transgene delivery and 
expression in the absence of significant vector gene expression. However, breakthrough to 
early and late phase gene expression can occur, particularly following infection at high 
MOI or if the target cell expresses an endogenous "ElA-like" function. Breakthrough 
expression from the vector genome has been associated with the induction of an immune 
response following in vivo gene delivery. Replication-deficient adenovirus vectors 
incorporating additional mutations or deletions have been generated to address this 
problem. The deletion of additional sequences from the vectors also permits the insertion 
of larger transgenes.
1.9.4 Ad vectors.
Ad genome was modified to obtain recombinant viral vectors (Fig 1.9).
• Progenitor vectors have either the El or E3 gene inactivated, with the missing gene 
being supplied in trans either by a helper virus, plasmid or integrated into a helper cell 
genome (human fetal kidney cells, line 293) (118).
• Second generation vectors additionally use an E2a temperature sensitive mutant (119) 
or an E4 deletion (120).
• The most recent "gutless" vectors contain only the inverted terminal repeats (ITRs) and 
a packaging sequence around the transgene, all the necessary viral genes being 
provided in trans by a helper virus (121).
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Fig. 1.9 Schematic representation of Ad wt and vector structure.
From the viewpoint of safety, size of transgene insertion and absence of vector gene 
expression, these so-called 'gutless' adenovirus vectors are attractive. They contain the 
inverted terminal repeats (ITRs) and adjacent sequences essential for replicating the 
adenovirus genome, including the cis-acting signal sequence (psi) which directs packaging 
of adenovirus DNA into virus particles. The gutless vectors require virtually all adenovirus 
gene functions to be provided for vector propagation and, since this cannot yet be achieved 
using a packaging cell line, they must be provided using a helper cell. Although their 
potential is enormous, current gutless vectors are complex and technically difficult to use. 
However, there are dangers associated with the use of adenovirus vectors, and a few deaths 
have occurred in clinical trials.
1.9.4.1 Adenoviral vectors of the first generation.
The genome of adenoviruses consists of 30-38 kb of double-stranded linear DNA with 
inverted terminal repeat (ITR) sequences at each end. Expression of genes occurs in two 
phases, early and late, defined by the onset of DNA replication (127).
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Early genes are encoded by four distinct transcription units, E1-E4, whereas the late gene 
products are generated from a single promoter. Importantly, proteins encoded by El region 
are indispensable for further viral gene expression and DNA replication (128).
Vector of the first generation is prepared by substitution of a transgene in the place of El 
(or El and E3) genes (Fig. 1.9). The resulting construct has a cloning capacity up to 9 kb. 
An El-deficient (AE1) vector is replication-defective and must be propagated in a 
permissive cell line, engineered to provide El functions in trans (129). Substitution for the 
E3 genes is not necessary, as they are involved in inhibition of host immune antiviral 
response, not in the replication of the adenoviral genome.
Among the 51 human adenovirus serotypes discovered to date, Ad5 and Ad2 are most 
commonly used for generation of vectors (128). Adenoviral vectors give the most efficient 
gene transfer in comparison with other systems (130). Moreover, they can transduce both 
dividing and post-mitotic cells of nearly all human tissues -  including skin, muscle, blood 
vessel, bone, nerve, and liver (127, 130). They can be also effective in delivering genes 
into some leukocytes (231). Following delivery, transgene expression is at a very high 
level. Unfortunately, it decreases rapidly after several days, being low or undetectable after 
several weeks (130).
Many studies have clearly demonstrated that adenoviral vectors of first generation induce 
innate and adaptive immune responses in vivo against viral capsids and transduced cells 
(11). Despite the deficiency in the El region, the vectors are, in fact, not completely 
replication defective (132). They deliver the transgene along with the residual viral genes 
and indeed synthesize some viral proteins. Even low level expression of these leads to 
activation of CTL and results in destruction of expressing cells, being the major cause of 
transgene silencing (130).
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1.9.4.2 Helper-dependent adenoviral vectors (HdAd).
Helper-dependent adenoviral vector (HdAd), called also “gutless” or “gutted” vector, is 
created by removing all viral genes and leaving only the ITRs necessary for vector 
propagation, and the sequence required for packaging (Fig. 1.9) (12). Any unused space 
is occupied by a transgene or by noncoding “stuffer” DNA sequence, to build the vector to 
a size suitable for packaging (Fig. 1.9). This strategy completely eliminates the production 
of viral proteins in infected cells. Therefore, HdAd elicits only minute or negligible CTL 
response and is capable of producing long-term gene expression (133). Additional 
advantage of HdAd is a high cloning capacity, extended up to 37 kb (12). The nature of the 
DNA backbone can have important effects on the functioning of the HdAd virus, which 
must be taken into account in the design of vectors. The most commonly used stuffer DNA 
originates from human hypoxanthine-guanine phosphoribosyltransferase (HPRT). The first 
step in generation of HdAd constructs is based on ligation of the expression cassette into 
large plasmids containing the viral ITRs flanking stuffer DNA. This process, although 
commonly applied, is generally very inefficient. It has been shown, however, that similarly 
as in the case of the AE1 adenoviral vectors, plasmids for generation of HdAd constructs 
can be obtained by homologous recombination in Escherichia coli, which potentially can 
facilitate the production (134).
A number of systems have been also developed for rescuing HdAd. The most common 
method for propagation and purification of HdAd utilizes two elements: i) a helper virus 
(AE1/AE3) with T  sequence flanked by loxP sites (Fig. 1.10), ii) a modified 293Cre cell 
line expressing Cre recombinase which catalyzes recombination between loxP sequences, 
excising the packaging site from helper DNA. Such a deletion renders the helper genome 
un-packagable but leaves all other viral functions intact, retaining the ability to replicate 
and provide helper functions.
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Fig. 1.10 Schematic representation of Hd-Ad virus production.
The efficacy of this technology is sufficient for experimental gene therapy, but is not 
suitable for production and purification of HdAd vectors at a scale necessary for clinical 
use (135).
To increase the efficiency of the system, both improved helper viruses and alternative 
gutless vector producer cell lines are necessary. One of the promising modifications is 
establishing the cells adapted to serum-free suspension culture, which can allow obtaining 
high-titer gutless vector preparations by using bioreactor technology (135).
An additional problem to be solved is contamination with helper AE1 virus, which may 
have substantial unwanted effects. Unfortunately, a helper virus, even lacking a packaging 
signal, still can be packaged, although at a low frequency (about 0.1%) (135). It seems that 
this level of impurity cannot be further decreased using the Cre/loxP system, as Cre 
recombinase in 293Cre cells permits some helper viruses to escape packaging signal 
excision and propagate (136). Thus, the resulting viral stocks must be additionally purified 
by ultracentrifugation in CsCl, which can produce HdAd stocks with very low (less than 
0.01%) helper contamination (Fig. 1.11). This separation step hinders, however, large scale 
production of clinical-grade HdAd virus.
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Fig. 1.11 Schematic representation of Ad purification by CsCI gradient.
One of the possible solutions is using a more efficient recombinase, e.g. modified FLP 
(FLPe), to remove T  from the helper virus in the producer cells. FLP has been shown to 
mediate maximum levels of excision close to 100% compared to 80% for Cre. Thus, it has 
been postulated that the FLPe-based system may yield HdAd with very low levels of 
helper virus contamination without the need for ultracentrifugation, which should allow 
large-scale generation of gutless vectors by means of column chromatography (137). 
Finally, the safety of the HdAd vectors can be further optimized by using double-deleted 
AE1 AE2a helper virus.
Gutless adenoviruses can infect a wide range of mammalian tissues, independent of the 
replicative state of the cells. Like AE1 particles, intravenously injected HdAd vectors 
transport the transgene preferentially to the liver, where infection efficacy may reach 
almost 100%.
Nevertheless, certain serotypes of adenoviruses have diverse tissue tropisms in vivo, and in 
some tissues, e.g. in skeletal muscles, the efficacy of adenoviral vectors is relatively low. 
Particularly resistant are some lymphoid cells (138). This is in contrast to the effects of 
AE1 vectors, secretion of pro-inflammatory cytokines was minimal after HdAd vector 
injection, resulting in reduced numbers of activated microglial cells, astrocytes, and 
infiltrating macrophages in brain tissue. These findings indicate that HdAd vehicles should 
provide a safe and effective means to transfer therapeutic genes into the brain (139).
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1.9.5 Immunogenicity.
Adenoviral vectors are very efficient at transducing target cells in vitro and in vivo, and can 
be produced at high titres (>10n/ml). Transgene expression in vivo from progenitor 
vectors tends to be transient (117). Following intravenous injection, 90% of the 
administered vector is degraded in the liver by a non-immune mediated mechanism (122). 
Thereafter, an MHC class I restricted immune response occurs, using CD8+ CTLs to 
eliminate virus infected cells and CD4+ cells to secrete IFN-alpha which results in anti- 
adenoviral antibodies (123). Alteration of the adenoviral vector can remove some CTL 
epitopes, however the epitopes recognised differ with the host MHC haplotype (124). The 
remaining vectors, in those cells that are not destroyed, have their promoter inactivated 
(120) and persisting antibody prevents subsequent administration of the vector.
Approaches to avoid the immune response involving transient immunosupressive therapies 
have been successful in prolonging transgene expression and achieving secondary gene 
transfer. A less interventionist method has been to induce oral tolerance by feeding the host 
UV inactivated vector (125). However, it is desirable to manipulate the vector rather than 
the host. Although only replication deficient vectors are used, viral proteins are expressed 
at a very low level which are presented to the immune system. The development of vectors 
containing fewer genes, culminating in the "gutless" vectors which contain no viral coding 
sequences, has resulted in prolonged in vivo transgene expression in liver tissue (13). The 
initial delivery of large amounts of DNA packaged within adenovirus proteins, the 
majority of which will be degraded and presented to the immune system may still cause 
problems for clinical trials. Moreover the human population is heterogeneous with respect 
to MHC haplotype and a proportion of the population will have been already exposed to 
the adenoviral strain (126).
Adenovirus genome is relatively easily manipulated in vitro and the genes coupled to the 
late promoter are efficiently expressed in large amounts.
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1.10 Ad Serotypes.
Human adenoviruses (Ads) are associated with a wide range of tropisms. They have been 
classified into six distinct subgroups A to F, with at least 51 serotypes (140), on the basis 
of their genetic variability, oncogenic potential, and G+C content of their DNA (140). A 
further sub-classification of subgroups B (BI and BII) and D (DI, DII, and Dili) has been 
made on the basis of differential hemagglutination patterns (141, 142). Ads have the ability 
to infect a wide range of different tissues and have been identified as causative agents of 
widely different diseases (140, 143). For example, serotypes Ad 2 and Ad 5 (subgroup C) 
are associated with upper-airway infections, as is serotype Ad 3 (subgroup B), although the 
latter appears to infect an anatomically distinct region of the airway (143). Serotypes Ad 8 
and Ad 9 (subgroup D) are associated with epidemic keratoconjunctivitis, Ad 4 (subgroup 
E) is associated with pneumonia, Ad 12 (subgroup A) is associated with cryptic enteric 
infection, and Ad 40 and Ad 41 (subgroup F) are associated with gastroenteritis (143). 
Detailed phylogenetic analysis of diverse Ad serotypes has yielded two phenotypic 
clusters; the gastrointestinal cluster, with subgroups A and F, and the respiratory cluster, 
with subgroups B, C, and E (144).
It has been suggested that the apparent tropism of different serotypes in different tissues 
results from virus interactions with distinct cellular receptors. Indeed, it has been shown 
convincingly that the Ad 2/5 and Ad 3 fiber proteins recognize different cellular receptor 
proteins (156, 148).
Attachment and uptake into cells of subgroup C Ads occur by separate but cooperative 
events that result from the interaction of the fiber protein with a receptor for attachment 
and the penton base protein with a receptor for internalization (Fig. 1.12). The 46-kDa 
coxsackievirus-adenovirus receptor (CAR) protein mediates fiber-dependent attachment of 
subgroup C Ad 2 and Ad 5 (145). The C-terminal knob of the fiber protein confers the 
specificity of the cellular receptor recognition (146, 147, 148). Analysis of the fiber 5 knob
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by X-ray crystallography has yielded a model for the structure of this protein and has 
identified several exposed amino acid residues and structural loops that have been 
theorized to be involved in cellular receptor recognition (149). Next, in a process that has 
been shown to be independent of fiber-cell recognition (150, 147), the viral penton base 
protein binds to cellular av-integrins through the RGD loop, a tripeptide motif that 
protrudes out of the tertiary peptide structure of the penton base, resulting in rapid 
internalization of the virus particle (151). Through cross-competition experiments, it has 
been shown that the fibers of Ad 2, Ad 5, and Ad 9, despite their distinct tropisms and 
classification into the different subgroups C and D (140), recognize the same cellular fiber 
receptor (148). Ad vectors based on serotype 5 (Ad 5) for an efficient infection with 
adenovirus requires the presence of coxsackievirus-adenovirus receptors (CAR) and a v 
integrins on cells (152).
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Fig. 1.12 Ad5 uptake and internalization mechanism.
Due to the lack of corresponding primary and/or secondary receptors, Ad 5 gene transfer is 
inefficient to a number of tissues, such as endothelia (153), smooth muscle (154), 
differentiated airway epithelia (155), brain tissue (156), and peripheral blood cells. 
Recently, group B Adenovirus derivates have gained interest as attractive gene therapy 
vectors because they can transduce target tissue, such hematopoietic stem cells, dendritic 
cells and malignant tumor cells, that are refractory to infection by commonly used
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adenoviral vectors. Since the cell types that can be infected with Ad 5 vectors are restricted 
by the presence of CAR and av integrins, attempts were made to broaden the tropism of Ad 
vectors. These approaches included complexing Ad with lipids or polycations (157), using 
bi-specific antibodies directed against Ad fiber and an internalizing cellular receptor (157), 
and engineering peptide ligands into the fiber (158), hexon (159), or penton (160). Most of 
these approaches did not abrogate CAR tropism. The most commonly used method to 
retarget Ad tropism is by swapping part or all of the fiber from one serotype to another 
(156, 147, 153). The various serotypes of human Ad show differences in tissue tropism and 
cause different pathologies mostly localized to the gastrointestinal tract, respiratory tract, 
genitourinary tract, or conjunctiva and cornea (161). Since the nucleotide and amino acid 
sequences of fibers differ significantly among different Ad serotypes, it has been suggested 
that they can recognize different receptors (144). This implies that fiber substitution would 
be sufficient to change virus tropism and has been convincingly shown for Ad 5-Ad 3 
chimeras (153), Ad 5-Ad 7 chimeras (162), and Ad 5-Ad 17 fiber chimeras (156). It was 
shown that it is possible to genetically substitute by heterologous sequences derived from 
the other serotype the Ad 5 fiber or fiber knob was. Whereas, as told before, may Ad infect 
cells through the coxsackievirus and adenovirus receptor (CAR), group B adenoviruses use 
an alternate, attachement receptor. Human CD46 seems to be a cellular receptor for most 
group B adenoviruses. Serotype 35 emerged as the variant with the highest tropism for 
CD34+ cells. A chimeric vector (Ad 5/35) which contained the short-shafted Ad 35 fiber 
incorporated into an Ad 5 capsid was generated. This substitution was sufficient to 
transplant all infection properties from Ad 35 to the chimeric vector. The retargeted, 
chimeric vector attached to a receptor different from CAR and entered cells by an a v 
integrin-independent pathway (163).
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1.11 Collagen VII.
The collagens comprise a family of closely related, yet genetically distinct, 
macromolecules.
At least 14 different vertebrate collagens have been identified (Fig. 1.13). All collagen 
molecules consist of three subunit polypeptides, called chains, and there are as many as 25 
different genes within the human genome that code for these subunits (164, 165).
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Fig. 1.13 Schematic representation of some proteins of the collagen’s family.
The genetically distinct collagens have characteristic tissue distributions. The more 
abundant collagens, as exemplified by types I and III collagens, have a rather widespread 
distribution, while some minor collagens have a limited anatomical location. For example, 
type VII collagen appears to be restricted to the basement membrane zone beneath 
stratified squamous epithelia. Within the cutaneous basement membrane zone, type VII 
collagen localizes to the lamina densa and sub-lamina densa areas in the upper papillary 
dermis (166). More precisely, immuno-localization studies have demonstrated that type 
VII collagen is the major collagenous component of anchoring fibrils, morphologically 
distinct structures that extend from the lamina densa and project perpendicularly into the 
upper papillary dermis (167).
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Anchoring fibrils attach the epidermal basement membrane of the skin to the underlying 
dermal connective tissue (164, 165). As visualized by electron microscopy, anchoring 
fibrils appear as centro-symmetrically banded elements displaying variable diameters and 
degrees of curvature.
Anchoring fibrils are seen along the basement membrane, where they appear to originate at 
the lamina densa and to extend into the stroma where they terminate in anchoring plaques. 
The anchoring plaques are basement membrane-like, electron-dense regions that contain 
type IV collagen and perhaps other intrinsic basement membrane proteins. Additional 
anchoring fibrils originate in the anchoring plaques and then extend further into the stroma, 
terminating in other anchoring plaques. Anchoring fibrils also originate in the lamina 
densa, extend into the stroma, and appear to arch back to reinsert into the lamina densa. 
Collagen VII is a large homo-trimeric protein with a central triple helix and flanking 
amino- and carboxyl-terminal globular domains.
Comparisons of the banding patterns of segment-longspacing crystallites of type VII 
collagen with those of anchoring fibrils indicate that the portion of the anchoring fibril not 
contained within the basement membrane or the anchoring plaques represents the triple­
helical domain.
Type VII collagen (Burgeson, 1987) is a gene located on the p arm of the chromosome 3 
(3p21.3) and is constituted by 118 exons translated in a 9 kb c-DNA. Collagen VII is 
synthesized and secreted as a precursor, thought to be a homopolymer of three pro-a(VII) 
chains, M.W. 350,000. The aminoacid sequence is very abundant in Gly-Pro-Y motifs 
(Fig. 1.14).
59
Glycine
Hydroxyproline
Proline
•Alanine
Hydroxyproline
Proline
Fig 1.14 Schematic representation of aminoacid distribution in collagen VII.
Approximately one out of every 3 residues is a glycine and the proline content is also high. 
Stretches of the collagen polypeptide sequence are repeats of Gly-X-Y (X and Y 
frequently proline and hydroxyproline). In the triple helix, every third aminoacid contacts 
the center of the structure. This area is so small that only a glycine can fit, which explains 
why every third amino acid in collagen’s structure is a glycine residue (Fig. 1.14). 
Hydrogen bonding involving hydroxyproline can occur, which further stabilizes the 
proteins structure.
The N-terminal sequence of al(VII) contains two vWF-A, ten Fnlll repeats, and one 
sequence of aminoacid homologue to the proteins in the cartilage matrix. This region is 
folded separately in separates 36 nm arms.
The pro-collagen molecule contains three distinct domains: NC-2, the small amino- 
terminal non-triple-helical domain (M.W. 95,000); the triple-helical domain (M.W.
510.000); and NC-1, the complex, trident-like carboxyl-terminal globular domain (M.W.
450.000).
The triple-helical domain contains a major discontinuity in that conformation near the 
center of the domain as detected by sensitivity to pepsin and trypsin digestion (176) which 
generates the fragments PI and P2. Additional discontinuities are detected by digestion
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under more severe conditions. These triplex pro-collagen molecules further dimerize 
through an association of the amino termini such that the triple-helical domains overlap by 
60 nm. This overlap may be specified by an interaction of the NC-2 domains with the triple 
helix and is subsequently stabilized by two or more intermolecular disulfide bonds. The 
NC-2 domains are then removed, and the dimers assemble into anchoring fibrils by 
unstaggered lateral associations (177).
After secretion, pro-collagen VII undergoes proteolytic trimming to collagen VII and 
assembles to polymers (Fig. 1.15) (164).
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Fig. 1.15 Schematic representation of maturation and secretion of collagen VII. The triplex pro-collagen 
molecules dimerize through an association of the amino termini such that the triple-helical domains overlap 
by 60 nm. This overlap may be specified by an interaction of the NC-2 domains with the triple helix and is 
subsequently stabilized by two or more intermolecular disulfide bonds. The NC-2 domains are then removed, 
and the dimers assemble into anchoring fibrils by unstaggered lateral associations. After secretion, pro­
collagen VII undergoes proteolytic trimming to collagen VII and assembles to polymers.
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This is a multistep process during which collagen VII monomers first form di- 
sulfidebonded antiparallel dimers and then laterally aggregate into anchoring fibrils, which 
interact with laminin 5 to secure the dermo-epidermal adhesion (164, 166). Further 
stabilization of anchoring fibrils and presumably of intermolecular aggregates is achieved 
through cross-linking by transglutaminase-2.
The structure of type VII collagen must account for the apparent flexibility of the 
anchoring fibrils and for their contact with the lamina densa and the anchoring plaques.
The tortuous shapes of the fibrils seen ultra-structurally are assumed to result from the 
discontinuities within the triple-helical domain. This assumption is supported by studies of 
type IV collagen, in which flexible sites correlate well with disruptions in the triple-helical 
structure known from the primary structure of the type IV chains (Fig. 1.16) (178).
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Fig. 1.16 Schematic representation of anchoring plaques.
Anchoring fibrils are functionally deficient in hereditary dystrophic epidermolysis bullosa 
(DEB) a heterogeneous group of bullous skin disorders (167) with mechanically induced 
blistering and scarring of the skin. In the most severe forms of the disease, both collagen
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VII protein and anchoring fibrils are absent from the skin (168), whereas in milder forms, 
collagen VII is expressed, but the morphology of the anchoring fibrils may be altered 
(169).
Mutations in COL7A1 encoding collagen VII have been disclosed in both recessive and 
dominant DEB subtypes (170, 171, 172).
In recessive subtypes, homozygous or compound heterozygous mutations leading to 
premature termination codons underlie very severe skin blistering and scarring (173), 
whereas homozygous or compound heterozygous missense mutations cause milder 
phenotypic manifestations.
In dominant DEB (DDEB), only about a dozen mutations have been identified, most of 
them causing substitution of a glycine in the triple helical domain of collagen VII (172). 
However, despite a growing number of known collagen VII mutations, the biological 
consequences of these mutations and the pathogenic pathways from the gene defect to 
dermo-epidermal tissue separation in the skin have remained elusive.
Glycine substitution mutations in other collagen genes underlie heritable connective tissue 
diseases, such as osteogenesis imperfecta, chondrodysplasias, certain subtypes of Ehlers- 
Danlos syndrome, or Alport’s syndrome (174, 175). These mutations cause pathologic 
phenotypes through dominant-negative interference. Therefore, the prediction was that 
glycine substitution mutations in COL7A1 had similar effects. Surprisingly, however, 
molecular genetic analyses of a number of DEB families disclosed several compound 
heterozygous glycine substitution mutations in COL7A1 that did not cause a pathologic 
phenotype in obligate carriers.
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Chapter 2
Materials and methods
2.1 Reagents suppliers
2.1.1 Chemicals.
All chemicals were obtained from FLUKA, Sigma Chemicals Co. or Roche. 
Others chemicals used during the study were obtained from the following sources:
Agarose for gel electrophoresis SeaKem LE Agarose Cambrex BioScience Rocland
DNA markers
1 kb Gene Ruler DNA Ladder Fermentas 
lOObp Ladder Invitrogen
Protein markers Biorad Rainbow
X-Ray film Kodak and Amersham
Hydrolysed milk powder Merck
Nitrocellulose for Western Blot Protran BA85 Cellulose Nitrate Scheleicher & Schuell
Nylon for Southern/Northern Blot Stratagene or Hybond
Acrylamide Applichem
2.1.2 Radiochemicals.
a 32P dCTP (Amersham)
2.1.3 Enzymes.
All DNA modification enzymes and buffers were received from either Roche and New 
England Biololabs (NEB).
2.1.4 Restriction enzymes and buffers.
All restriction enzymes and buffers were obtained from either Roche and New England 
Biololabs (NEB).
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2.1.5 Bacterial strains and growth.
The DH5a strain (F \ hsdR17,rk-mk+, recAl, endAl) was used for all transformations, and 
growth both in Luria Bertani (L.B) or Terrific Broth (T.B) media prepared within the 
institute.
TOPIO strain (F'mcrA A(mrr-hsdRMS-mcrBC) c|)801acZAM15 AlacX74 recAl araD139 
A(ara-leu)7697 galU galK rpsL (StrR) endAl nupG) was used for all transformation of 
TOPO-TA cloning vector following manufacturers instructions.
2.1.6 Plasmids.
Creation of other plasmids are described below (Section 2.5.1). The following were 
provided by the laboratory of Professor Mavilio.
Human Collagen containing plasmid was provided by Professor Meneguzzi G. INSERM 
U634, Faculty of Medicine, Nice, France
2.1.7 Solutions and Buffers.
Buffer for flow cytometric analysis (FACS) PBS 0.1% (w/v) BSA
50x TAE for Agarose gel (1 litre)
242 g Tris base 
57.1 ml Glacial Acetic Acid 
100 ml 0.5M EDTA, pH 8.0 
Water to final volume (1 litre)
Tris-HCl
Trizma Base to the molarity required 
and HC1 to the required pH
lOOx TBE for Agarose gel (1 litre)
108 g Trizma base 
55 g Boric Acid 
40 ml EDTA 0.5 M pH 8.0
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10% SDS (1 litre)
100 g SDS powder 
Water to final volume (1 litre)
5 M NaCl (1 litre)
292.2 g
Water to final volume (1 litre)
TE Buffer lOx (200ml)
10 ml Tris-HCl pH 7.9 2M (10 mM final) 
4 ml EDTA 0.5 M (1 mM final) 
Water to 200 ml
IONNaOH (100ml)
40 g NaOH 
Water to final volume
2.2 Tissue culture reagents.
2.2.1 Plastic ware.
All standard tissue culture ware (tissue culture flasks, tissue culture plates, tubes etc..) was 
obtained from Coming Costar and Falcon.
2.2.2 Media.
X-VIVO 10 Bio whittaker
DMEM Cambrex
IMDM Cambrex
RPMI Cambrex
2.2.3 Sera, Supplements and antibiotics.
Fetal Bovine Semm Hyclone
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Trypsin Cambrex
L-Glutamine Cambrex
Penicillin/Streptomycin Biological Industries
HEPES SIGMA
Doxycicline SIGMA
2.2.4 Growth factors.
Recombinant human Stem cell factor (SCF)
R&D Systems, and Pepro Tech, 
England
Recombinant human Flt-3 Ligand (Flt3-L) Pepro Tech, England
Recombinant human interleukin-3 (rhIL-3) Pepro Tech, England
Recombinant human interleukin-6 (rhIL-6) R&D Systems
2.2.5 Other.
Phosphate buffered Saline (PBS) was obtained from Cambrex.
FICOLL was obtained from Limphoprep Fresenius Kabi Norge AS.
Fugene 6 was obtained from Roche.
Effectene Transfection reagent was obtained from Qiagen.
2.3 Antibodies and antisera.
Anti human NGF antibody was obtained from BD (Primary and R-PE conjugated).
Goat Anti mouse IgG (FITC. R-PE conjugated) was obtained from Southern 
Biotechnology Associates, Inc.
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Anti human CD38, R-PE, FITC. or Tricolor conjugated was obtained from Caltag 
laboratories, U.S.A
Anti human CD34, R-PE, FITC. or Tricolor conjugated was obtained from Caltag 
laboratories, U.S.A
Anti human Collagen VII Ab-1 (LH7.2) was obtained from Neomarkers.
Anti mouse HRPO was obtained from SIGMA
2.4 Cells.
2.4.1 Stable cell lines:
HeLa Human carcinoma From ATCC
293Cre4 Human Kidney
From laboratory of 
Professor Mavilio
NIH3T3 Murine Fibroblasts
From laboratory of 
Professor Mavilio
293T Human Kidney From ATCC
K562
Human Chronic 
Myelogenous Leukemia
From ATCC
HEL Human Herythroleukemia From ATCC
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2.4.2 Primary cells.
Human CD34+ cells.
Were most kindly purified and prepared from umbilical cord blood (UCB) source by 
myself, by FICOLL density separation followed by magnetic selection based on the 
Miltenyi MACS kit for cell separation, following the manufacturers recommended 
protocol. Samples were either used fresh or frozen in FCS containing 10% DMSO, and 
stored in liquid Nitrogen until required for use.
Keratinocvtes
Most of the keratinocytes experiments were done by Dr. Stefano Ferrari (Epithelial Stem 
Cell Research Centre, Veneto Eye Bank Foundation, Venice, Italy).
2.5 Methods
Methods are divided into 3 sections:
2.5.1 Molecular methods
2.5.2 Tissue culture methods
2.5.3 Gene transfer methods
2.5.1 Molecular Methods
2.5.1.1 Transformation of competent bacteria and small scale bacteria preparations.
DNA to be transformed was mixed with 100 ul of competent DH5a cells prepared 
specifically for the heat shock mediated transformation method (Maniatis et al. 1982). The 
mix was incubated 20 minutes on ice, then 1 minutes in watherbath at 42°C, and then 
returned to ice for further 2 minutes. The mix was then added to 1 ml of SOC media and
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incubated at 37°C with agitation for 1 hour. The mix was the plated onto agar plates 
supplemented with the required antibiotic and placed overnight in a 37°C bacterial 
incubator. The following day, colonies were picked up and placed into 2 ml of LB media 
containing antibiotic, and grown overnight with agitation at 37°C. The small bacterial 
preparations were subjected to small or large scale DNA preparation as required.
2.5.1.2 Small scale (miniprep) preparation of plasmid DNA from bacteria.
Small amounts of plasmid DNA were purified from bacteria, for restriction analysis, 
following the alkaline lysis method for DNA (Maniatis et al. 1982).
2.5.1.3 Large scale (maxiprep) preparation of plasmid DNA from bacteria.
This method is a scaled up method of the alkaline lysis method, using identical solutions 
unless stated. Typically 500 ml of an overnight growth of DH5a bacteria in antibiotic 
containing TB media was used per preparation. The bacteria were pelleted at 6000 rpm for 
10 minutes in a Sorvall centrifuge. The residual media was discarded and the centrifuge 
tube inverted to drain as much media as possible away from the pellet. 20 ml of 
resuspension solution (Solution I) containing Lysozyme at the final volume of 12.5 ug/ml 
was added to the pellet, and the pellet was resuspended pipetting and vortexing. The 
bacterial mix was left at room temperature for 10 minutes. 40 ml of alkaline lysis solution 
2 was added, the sample mixed and returned at room temperature for further 10 minutes. 
30 ml of ice cold solution 3 was added, the sample again thoroughly mixed, and put on ice 
for 10 minutes.
The tube was centrifuged at 4500 rpm for 45 minutes, the lysate filtered through medical 
gauze into 200 ml Falcon tubes (the residual pellet was discarded) and the same volume of 
isopropanol alcohol was added to precipitate the nucleic acid. The sample was left 10-20 
minutes on ice and then the tube was centrifuged at 4500 rpm for 45’ minutes at 4°C. The 
liquid was discarded and the pellet properly drained was resuspended in 10 ml of TE
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buffer. Beckman quick seal tubes were prepared as follows. 11 g of Caesium Chloride 
(CsCl) were measured into 50 ml Falcon tubes to which was added 10ml of resuspended 
pellet and 300 ml of ethidium bromide (10 mg/ml stock). After CsCl had dissolved, the 
solution was centrifuged for 30 minutes to 4500 rpm to pellet all the debris. The solution 
was taken up with a 10 ml syringe and injected into the Beckman quick seal tube, the tubes 
balanced and then sealed using the Beckman heat sealing device.
Samples were centrifuged in a Beckman NVT 65 rotor at 50000 rpm for at least 14 hours. 
The tubes were gently removed from the rotor, a hole punched in the top of the tube using 
a large gauged needle, and a syringe with the needle attached was inserted just below the 
DNA band which was clearly distinguished from the rest of the gradient due to the intense 
red colour following the ethidium bromide intercalation. The DNA band was gently 
removed and injected into 15 ml Falcon tube. 10 ml of butanol CsCl saturated in water was 
added to the tube, the tube shacked, left to settle and the upper phase discarded (clearly 
red-pink coloured). This process was repeated several times until no pink colour was 
visible. The process was then repeated one more time after this to be sure of ethidium 
bromide removal. Then the samples were loaded into dialysis membrane (MWCO 10000) 
and dialysed overnight in 4 litres of lx TE Buffer. The day after dialysed samples were 
precipitated. Water was added to the tubes to a final volume of 5 ml, 250 ul of 3 M Sodium 
acetate added, and a further 10 ml absolute ethanol added on top. Tubes were mixed and 
placed at -20°C for 30 minutes. The tubes were centrifuged 45’ 4500 rpm. The pellet 
obtained was washed twice with 70% ethanol. Purified DNA was resuspended in water and 
quantified using the standard 260/280 nm absorbance method on a spectrophotometer. 
DNA was stored at 4°C if required immediately or stored at -20°C for longer use and 
storage.
18.2 g Glucose (50 mM final)
GTE (2 litres) Solution I. 50 ml 1 M Tris-HCl pH 7.5 (25 mM final)
0.5 M EDTA pH 8.0 (10 mM final)
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Water to final volume
Lysis Solution (40 ml). Solution III.
0.8 ml NaOH 10 N (0.2 M final) 
4 ml 10% SDS (1% final)
Water to final volume
Neutralisation Solution (2 litres). Solution III.
588.84 g Potassium Acetate 
230 ml Acetic Acid 
Water to final volume
Butanol CsCl saturated
Butanol and water 1:1 (v/v) and CsCl 
to saturation
lxT E 1:10 (v/v) from 1 Ox TE
3 M Sodium acetate NaAc in water to the final volume
2.5.1.4 Southern Blot analysis.
Extraction of genomic DNA from cells:
1-I0xl06 cells were lysed in 3 ml of the following buffer:
50 mM Tris HC1 pH 8.0 
100 mM EDTA 
400 mM NaCl 
1% w/v SDS
25 ul of proteinase K (10 mg/ml stock) was added and the mix incubated overnight at 37°C 
or 6 hours at 55°C.
An equal volume of phenol was added to the solution and mixed vigorously. The sample 
was then centrifuged for 5’ at 14000 rpm. The aqueous phase was recovered and an equal 
volume of phenol/chloroform added. The above step was performed, the aqueous phase 
taken and an equal volume of chloroform added, the samples mixed and centrifuged as 
above, the aqueous phase taken and nucleic acid precipitated by the addition of an equal
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volume of absolute ethanol 0,3 M Sodium acetate. A glass Pasteur pipette was blunted by 
inserting it into Bunsen flame and precipitated DNA extracted by dipping the Pasteur and 
gently pulling. The genomic DNA was clearly visible, it was allowed to air dry briefly, and 
then the inserted into 300 ul of 70% ethanol, dried and the DNA resuspended in 200 ul of 
water. It was allowed the DNA to dissolve overnight at room temperature. Nucleic acid 
concentration was determined using 260/280 nm absorbance measurements on a 
sp ectrophotometer.
Probes isolation:
Plasmid DNAs were digested with the opportune enzyme to release the probe fragment. 
After running in 0.8-1% w/v agarose gel in TAE or TBE buffer, the band corresponding to 
the required DNA was excised using a scalpel, and the DNA fragment purified using the 
“crash” method. Concentration was measured running 1 ul sample on 0.8% agarose gel.
“Crash” method for DNA gel extraction:
All the DNA fragment used in this work were purified using this technique. Digested DNA 
were loaded on agarose gel and run to separate the bands. The band corresponding to the 
required DNA was excised using a scalpel and the obtained agarose-DNA was crashed 
using a 1 ml syringe. The gel-DNA mixture was loaded on a glass wool cushion placed 
into a 1.5 ml eppendorf tube pierced on the bottom. The eppendorf placed over another 2 
ml eppendorf tube was centrifuged 30 minutes at the top speed. To the obtained liquid 
phase was added the same volume of phenol, centrifuged again 2’ and traited with phenol 
and phenol/chloroform. The cleaned aqueous phase was precipitated adding the same 
volume of absolute ethanol and 1/10 v/v 3 M Sodium Acetate. After precipitation at -20°C 
for 30’ the DNA was centrifuged, the pellet washed twice with ethanol 70% and 
resuspended in water.
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Digestion of genomic DNA and gel electrophoresis:
10-20 ug of genomic DNA was digested with the opportune enzyme (10 U/ug genomic 
DNA). The digestion generally was performed overnight. The digested DNA was loaded 
and run on a 0.8-1% agarose gel in TAE or TBE buffer ethidium bromide containing 
overnight at 40 volts. The gel was photographed.
Southern blotting:
The DNA was denatured by incubating gel in 0.2 M NaOH, 0.6 M NaCl with addiction of 
thimol blue for 1 hour shacking with one exchange of denaturating buffer. The gel was 
then neutralised by incubating the gel for 1 hour with 1.0 M TrisHCl pH 7.5, 1.5 M NaCl 
shacking. Southern blot assembly performed as described (Maniatis et al. 1982) using 
Duralon-UV Membranes (Stratagene) pre-soaked in distilled water and lOx SSC. Blot was 
performed overnight in lOx SSC. After blotting the filter was rinsed in 6x SSC and UV 
crosslinked using Stratalinker.
Hybridisation:
The filter was washed with O.lx SSC, 0.5% w/v SDS at 65°C for 30 minutes (2 incubation 
of 15 minutes each) shacking. Followed by 4-6 hours of incubation in pre-hybridisation 
solution at 42°C rolling.
The prehybridisation solution was removed and replaced with hybridisation solution 
containing the radioactive labelled probe. The filter was incubated overnight at 42°C 
followed by 30 minutes room temperature wash shaking in 2x SSC, 0.1% SDS (one change 
after 15 minutes) and 1 hour wash at 52°C shaking with O.lx SSC, 0.1% SDS (1 change 
every 20 minutes). The filter was blot dried and exposed to Kodak autograph film, for 
various times and the films developed.
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Radioactive labelling of probe:
Radioactive labelling was performed using Roche Random primed DNA labelling kit and 
the quick spin columns, following the manufactures instructions.
lOOx Denhardt
1 g FICOLL400 
1 g Polyvinylpyrrolidone (PVP) 
1 g BSA (fraction V)
Up to 50 ml with water
20x SSC (2 1)
350.6 g NaCl
176.5 g Citric Acid (trisodium salt) 
Distilled water up to 2 litres
20x SSCP (1 1)
88.2 g Sodium Citrate (trisodium salt) 
140.3 g NaCl
43.7 gNa2HP04
12.7 gN a2HP0 4 ’H20  
Distilled water up to 1 litres
S256 (lOx)
16 mg PolyA
16 mg PolyC
400 mg yeast t-RNA
100 mg Salmon Sperm DNA
9 mg E.coli DNA
Water to 200 ml
Pre-hybridisation solution 
(for 20 ml)
5 ml 20x SSCP 
1 ml lOOx Denhart 
10 ml Deionised Formamide 
Water to 20 ml
Hybridisation Solution 
(for 20 ml)
6 ml 20x SSC
0.2 ml lOOx Denhardt’s
10 ml deionised formamide
1 ml 10% w/v SDS
2 g Dextran Sulphate
1 ml S256 + Radioactive labelled 
probe*
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* Note: The radioactive probe is mixed with S256 boiled for 10 minutes and quenched on ice, prior to adding 
to hybridisation solution. This is to ensure the probe is denatured.
2.5.1.5 Polyacrylamide gel electrophoresis (PAGE) and western blotting.
Different polyacrylamide gel concentrations were made following the published 
instructions (Maniatis et al. 1982), and assembled on the Biorad miniprotean II gel 
apparatus following the manufacturers instructions. 
l-5xl06 cell sample were first lysed in 200 ul of protein lysis buffer.
150 mM NaCl
1% v/v Nonidet P-40
Lysis Buffer 0.5% w/v DOC
0.1% w/v SDS
50 mM Tris HC1 pH 8.0
The protein samples were mixed with 4x loading buffer p-Mercaptoethanol containing, and 
loaded into the well of the PAGE using a Hamilton syringe.
1 ml 1 M Tris-HCl pH 6.8
1 ml P-Mercaptoethanol
4x Loading Buffer (Laemli Buffer) 0.4 g SDS
for 5 ml 0.02 g Bromo Phenol Blue
2 ml Glycerol
Water to 5 ml
Resolving 7.5% 10% 12.5% Stack 3.8%
Acr-Bis 1.25 ml 1.6 ml 2 ml 158 ul
Resolving Buff. 625 ul 625 ul 625 ul 312.5 ul Stacking Buffer
SDS 10% 50 ul 50 ul 50 ul 50 ul
H20 Up to 5 ml Up to 5 ml Up to 5 ml Up to 5 ml
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APS 10% 37.3 ul 37.3 ul 37.3 ul 9.3 ul
TEMED 4.15 ul 4.15 ul 4.15 ul 0.9 ul
The gel was run in Tris-Glycine Buffer (27.9 g glycine, 6 g Trizma base, dissolved in 1 
litre of water), containing 0.1% v/v SDS, at 55 mA, until the Bromo Phenol Blue dye had 
run out of the gel. As a molecular weight marker, 4 ul of Rainbow marker (Biorad) was 
used.
Blotting:
Nitrocellulose membrane cut to the same size as the PAGE gel were pre-soaked in transfer 
buffer:
3 g Trizma Base 
14.4 g Glycine 
200 ml Methanol 
800 ml Water
Tranfer Buffer (1 Litre)
Blotting was performed using the Biorad western blotting apparatus and assembled 
following the manufacturers instructions. Upon assembly the inside of the apparatus was 
filled up with transfer buffer, and run per 1 hour at 200 volts.
Antibodies staining:
After transfer of the proteins had been performed, the membrane was blocked in PBS 
containing milk (2.5% v/w) for 1 hour. The primary and secondary antibodies were 
incubated in PBS 0.1% Tween-100 for 1 hour each. Between one incubation and the other 
3 wash were performed in the same PBS 0.1% Tween-100 shaking. After the incubation 
with the secondary antibodies 2 wash in PBS 0.1% Tween-100 was performed and another 
in PBS alone before developing with ECL kit (Amersham) following the manufacturers 
instructions.
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Dot blot analysis:
Dot blot analysis was performed for a fast screen of clones human collagen VII producing. 
Nitrocellulose membrane cut to the same size as vacuum plates apparatus were pre-soaked 
in PBS. Samples were prepared diluting collagen enriched medium (serum free medium 
with ascorbic acid used to cultivate cells for 24-48 hours) in PBS to a final volume of 500 
ul. Vacuum was not switched off until all the samples were dried. Nitrocellulose was 
Poinceau stained washed twice in PBS-0.1% Tween-20 and blocked in 5% milk PBS-0.1% 
Tween for one hour following classical Western blot protocol. All the following steps are 
the same of western blot.
2.5.1.6 Polymerase Chain Reaction Methods:
2.5.1.6.1 Nested PCR for AAVS1/ITR junctions.
Primers specific for ITR and AAVS1 locus site were obtained from PRIMM, Italy.
Right AAV ITR: 16s 5 ’-GTAGCATGGCGGGTTAATCA-3 ’
17s 5 ’-TTAACTACAAGGAACCCCTAGTGATGG-3 ’.
AAVS1 region: a 5’-GCCCCACTGCCGCAGCTGCTCCC-3’ 
b 5 ’-CCGCACAGGCCGCCAGGAACTCG-3 ’ 
c 5 ’-GCGCGQCAGAAGCCAGTAGAGC-3 ’ 
d 5 ’ CTGGCTCAGGTTCAGGAGAGG-3 ’ 
e 5 ’-CGCTCAGAGGACATCACGTG-3 ’ 
f  5 ’-GGGACACAGGATCCCTGGAQGG-3 ’.
All the primers had a melting temperature of 60°C. I round PCR enables amplification of 
integrated 3’ integrated cassette.
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dNTPs were obtained from Roche, water was injection grade, while the Taq was the 
AmpliTaq Gold polymerase (Applied Biosystems, Roche, NJ, USA).
Genomic DNA was extracted following protocols (See Materials and Methods 2.5.1.5).
I Round of PCR mix was obtained as follows:
I Round For primer (3 uM) 5 ul
I Round Rev primer (3 uM) 5 ul
1 Ox Taq buffer 5 ul
Taq polymerase (5 U/ul) 0.5 ul (2.5U)
dNTPs (10 mM) 1 ul
DNA 500 ng
Water To 50 ul
MgCl2 7 ul
II Round of PCR mix was obtained as follows:
II Round For primer (3 uM) 5 ul
II Round Rev primer (3 uM) 5 ul
1 Ox Taq buffer 5 ul
Taq polymerase 0.5 ul
dNTPs (10 mM) 1 ul
Template 1:100 from I Round PCR 5 ul
Water To 50 ul
MgCl2 7 ul
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The mix was placed in 200 ul Perkin Elmer PCR tubes, and PCR was performed in a 
Perkin Elmer GeneAmp 9700 termal cycler following the programme below (both for I 
and II Round):
Denaturation step of 10’ 95°C 
35 cycles:
Denaturation step of 30” 94°C 
Annealing step of 30” 60°C 
Extension step of 1 ’ 72°C 
A final step:
Extension step of 5’ 72°C
At the end of II Round amplification PCR samples were mixed with DNA loading dye and 
run 1.5% w/v agarose gel in TBE buffer, containing ethidium bromide, and visualised on a 
UV lamp.
Negative control for PCR reaction was water alone.
2.5.1.6.2 PCR for p5 element amplification.
Primers specific for 5’ and 3’ of p5 element were obtained from PRIMM, Italy in SDS- 
PAGE purified grade and had the following sequences:
P5ATATAfor:GCTCTAGAGCCGACATTTTGCGACACCATGTGGTCACGCTGG
GAAAAAAAGCCCGAGTGA
P5ATATArev:CGCAAGGCCTTCCCCTAGGGCGGCTGCGCGTTCAAACCTCC 
GCTTC AAAAT GGAGACCCT GCT C ACTCGGGC 
The primers had a melting temperature of 40°C. PCR enables amplification of not 
overlapping sequence to obtain full length p5 mutated sequence.
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dNTPs were obtained from Roche, water was injection grade, while the Taq enzyme was 
the Amplitaq Gold (Applied Biosystems, Roche, NJ, USA).
In this protocol no template DNA was used, overlapping primers were sufficient to ensure 
amplification.
PCR mix was obtained as follows:
For primer 5 ul
Rev primer 5 ul
1 Ox Taq buffer 5 ul
Taq polymerase 0.5 ul
dNTPs (10 mM) 2 ul
Water To 50 ul
MgCl2 5 ul
The mix was placed in 200 ul Perkin Elmer PCR tubes, and PCR was performed in a 
Perkin Elmer GeneAmp 9700 termal cycler following the programme below:
Denaturation step of 10’ 95°C 
5 cycles:
Denaturation step of 1 ’ 95°C 
Annealing step of 45” 40°C 
Extension step of 1’ 55°C 
35 cycles:
Denaturation step of 1 ’ 95°C 
Annealing step of 45” 40°C (+0.8°C/cycle)
Extension step of 1* 55°C (+0.5°C/cycle)
A final step:
Extension step of 10’ 72°C
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PCR samples were mixed with DNA loading dye and run 2.5% w/v agarose gel in TBE 
buffer, containing ethidium bromide, and visualised on a UV lamp.
Negative control for PCR reaction was water alone.
2.5.1.7 TOPO-TA cloning method.
Cloning of PCR products into TOPO TA vector (invitrogen) were obtained following 
manufactures instruction.
2.5.2 Tissue culture methods.
2.5.2.1 Maintenance of cell lines.
HeLa, 293 Cre4, 293T, NIH3T3 were maintained in DMEM media supplemented with 
10% FCS with penicillin/streptomycin at 25 U/ml, and L-Glutamine at 2 mM. Cells were 
typically splitted twice a week by washing once in PBS, adding Trypsin solution 
incubating 5 minutes and then resuspending in fresh media.
All the cells we used were maintained at 37°C in a humidified incubator with 5% CO2 .
Hel, K562 were maintained in RPMI-1640 with 10% FCS with penicillin/streptomycin at 
25 U/ml, and L-Glutamine at 2 mM.
All these cells were splitted 1:10 twice a week depending on the experimental 
requirements.
2.5.3 Gene transfer methods.
2.5.3.1 Generation of Adenoviral stocks.
Viral stocks were prepared by transfecting 293Cre4 cells and co-infecting with helper 
virus.
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DNA tranfection using Calcium Phosphate precipitation method:
1. Seed and incubate 5xl06 293Cre cells in 10 cm dish, approximately 24 hours before 
transfection in DMEM, 10% FCS, penicillin (25 U/ml), Streptomycin (25 U/ml).
2. Change medium 4 hours before transfection.
3. The plasmid DNA mix is prepared by adding DNA and water to a final volume of 450 ul 
per dish in a 15 ml Falcon tube. Finally add 50 ul 2.5M CaCl2.
4. The precipitates are formed by adding dropwise of 500 ul of DNA-water-CaC12 mixture 
to 500 ul 2xHBS vortexing at full speed. The precipitate should be added immediately to 
cells. High magnification microscopy of cells should reveal a very small granular 
precipitate initially above the cells monolayer and after incubation in 37°C incubator 
overnight, on the bottom of the plate in the space between the cells.
5. The precipitated plasmid DNA should be allowed to stay on the cells for 14-16 hours, 
after which the media should be replaced with fresh media.
2x HBS (for 50 ml)
5 ml Hepes pH 7.1 (100 mM final) 
2.8 ml NaCl (280 mM final)
150 ul Na2HP04 (1.5 mM final) 
pH 7.1 with HC1
2.5 MCaCl2 (for 100ml)
36.8 g
Water to 100 ml
Helper virus co-infection:
Cells after transfection should be infected with helper virus for Adeno production.
Media must be removed and cells washed twice in PBS.
After second wash helper virus at the suitable MOI can be added in PBS and dishes can be 
incubated for 1 hour in 37°C incubator. After incubation without removing PBS freshly 
media can be added and cells can be incubated in 37°C incubator.
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2.5.3.2 Viral harvest and concentration.
Rescue and amplification of the HD-Ad viruses were carried out by transfection of 
293Cre4 and infection with AdH14 first-generation helper virus (Merck, West Point, PA, 
USA), as previously described (179)
2.5.3.3 Titration of Adenoviral vectors.
1. Plate 5xl04 cells per well the day before in a 6-well plate (the day after you will have 
approximately 105 cells/well).
2. The following day, prepare serial ten-fold dilutions of viral stocks in PBS.
3. Titrating the viral stock you should have 500 ul-1 ml of the PBS dilute viral stock per 
each well.
4. Incubate the Hela cells with PBS dilute virus for 1 hour at 37°C 5% CO2 incubator.
5. Add fresh medium to 3-4 ml.
6. Incubate 36-48 hours at 37°C 5% CO2 incubator.
7. Wash well with 2 ml PBS.
8. Add 500 ul of Trypsin to each well. Wait until cells are detached from plates (5’ 37°C).
9. Add 2 ml PBS to each well and harvest cells in FACS tubes.
10. FACS samples and calculate the titer.
Notes:
The MOI (multiplicity of infection): TU/ml/n. cells to be infected for the following ranges: 
10'3 ul-1 ul infection. Efficiency is primarily controlled by vector concentration (TU/ml). 
MOI should be considered only for certain ranges of concentration of cells (>104 cells/ml) 
and vector (>106 TU/ml)
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2.5.3.4 CD34+ stem/progenitor cells purification and transduction.
1. Human CD34+ stem/progenitor cells were purified from the FICOLL mononuclear cell 
fraction of umbilical cord blood by positive selection using the CD34 magnetic cell 
isolation kit.
2. CD34+ cells were infected with viral stocks at a MOI of 50-300 in serum-free IMDM 
20% BIT serum substitute containing, supplemented with 20 ng/ml rhIL-6, 20 ng/ml 
rhTPO, 100 ng/ml Stem Cell Factor and Flt3-L for 24 hours.
3. Transduced CD34+ cells were washed in IMDM with 10% Fetal Bovine Serum, plated at 
a density of 1,000 cells/ml in methylcellulose medium containing 4 U/ml rhEpo, 10 ng/ml 
GM-CSF, 10 ng/ml rhIL-3, 50 ng/ml rhSCF, and scored by light fluorescent microscopy 10 
to 14 days after plating.
4. Transduced CD34+ cells were grown in liquid culture in the same medium used for 
transduction to maintain an undifferentiated phenotype.
2.5.3.5 Transfection techniques.
Stable cell lines were generally transfected using Calcium Phosphate precipitation (See
2.5.3.1 Generation of Adenoviral vectors for details).
HeLa cells were also tranfected with other techniques to obtain higher levels of positivity 
of bulk population.
FUGENE transfection:
1. Seed and incubate 3xl05 HeLa cells in 6 cm dish, approximately 24 hours before 
transfection in DMEM, 10% FCS, penicillin (25 U/ml), Streptomycin (25 U/ml).
2. Change medium 4 hours before transfection.
3. The plasmid DNA mix is prepared in 1.5 ml eppendorf tubes by adding not 
supplemented media (100 ul/ug DNA) to the plasmid DNA.
86
4. The precipitates are formed by adding dropwise 30 ul/ug DNA of FUGENE reagent 
following the manufacturers instructions. JBubbling_was_performed using p200 pipette 
pipetting 4-5 times in the bottom of eppendorf tube. High magnification microscopy of 
cells should reveal a very small granular precipitate. After precipitate addition cells must 
be incubated in 37°C incubator overnight.
5. The precipitated plasmid DNA should be allowed to stay on the cells for 14-16 hours, 
after which the media should be replaced with fresh media.
Effectene transfection:
1. Seed and incubate 3xl05 HeLa cells in 6 cm dish, approximately 24 hours before 
transfection in DMEM, 10% FCS, penicillin (25 U/ml), Streptomycin (25 U/ml).
2. Incubate the cells under their normal growth conditions.
3. Dilute 1 ug DNA dissolved in TE buffer, pH 7.0 to 8.0 with the DNA condensation 
buffer, Buffer EC, to a total volume of 150 ul. Add 8 ul Enhancer and mix by vortexing for 
1” .
4. Incubate to room temperature for 2-5’ then spin down the mixture to remove drops.
5. Add 25 ul Effectene Transfection Reagent. Mix by pipetting up and down 5 times or by 
vortexing 10” .
6. Incubate the samples for 5-10’ at room temperature to allow transfection-complex 
formation.
7. Aspirate medium from cells and wash once with PBS.
8. Add 1 ml growth medium to the tube containing the transfection complexes. Mix by 
pipetting up and down twice, and immediately add the transfection complexes drop-wise 
onto the cells in the 60 mm dishes. Swirl the dish to ensure uniform distribution of the 
transfection complexes.
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For 6 cm dishes
DNA ug: 1 --------------------------------------
Enhancer ul: 3.2
Final Volume DNA in EC Buffer ul: 100 
Volume of Effectene ul: 10 
Volume of medium to add to cells ul: 1600 
Volume of medium to add to complexes: 600
2.5.3.6 Stable cell lines.
1. HeLa cells were maintained in DMEM supplemented with 10% FCS, and 
transfected/transduced in 6-10 cm Petri dishes as indicated.
2. Cells were kept in culture to lose not integrated plasmids/viruses.
3. Cells were FACS sorted and the enriched bulks were limited diluted. 0.3 cells per well 
(in 96 wells plates) were plated.
4. Isolated clones were subsequent grow up and expanded in bigger plates, till 10 cm 
plates.
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Chapter 3
Aim of the work
Rationale.
Gene transfer in somatic cells has without any doubt a big potential to treat a number of 
genetic and acquired diseases. Among the several delivery systems developed, viral 
vectors derived from retroviruses, moreover murine retroviruses, are the most widely used. 
Retroviruses are peculiar in respect to other viruses by two characteristic steps in their life 
cycle: reverse transcription, resulting in a double strand DNA copy of the viral RNA 
genome, and integration, leading to the covalent attachment of the viral DNA to host cell 
DNA.
Integration process is an unequalled, and often indispensable tool to obtain high efficiency 
and stable gene transfer.
Up to now retroviral and lentiviral vectors are the only available tools to integrate foreign 
genes into human cells at reasonable efficiency. However their use involves some 
important problems and limitations:
1. Retroviral vectors (both gammaretroviral and lentiviral) can generally integrate only 
transgenes with a size limit of 5-7 kb.
2. Independent regulation of multiple transcription units is difficult in a retroviral vector 
context.
3. Integration of retroviral vectors into the target cell genome occurs randomly, 
preferentially into active genes. In the last years to this phenomenon has been 
associated an important risk of insertional mutagenesis and oncogenesis due to the 
deregulation of gene/s near the genomic region in which the pro virus integrates (0).
Alternative to retroviruses are present but at the moment not well studied and developed. 
Due to these limitations we decided to explore other viral systems to achieve high 
efficiency and stable gene transfer. In particular our aims were to obtain a good system to 
achieve site-specific integration and a vector without stringent limitation in cassette 
accommodation.
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We explored the possibility of other viral systems using a large cassette and trying to target 
it in a site-specific way.
Due to the know how of our laboratory, we choose to use a new kind of vectors, the 
Ad/AAV hybrid vectors. In fact they theoretically possess all the requisition we need: large 
capacity and site-specific integration machinery.
The wild-type AAV genome is a linear, single-stranded DNA filament of 4.7 kb, which 
contains at both ends a 145-base inverted terminal repeat (ITR) sequence, encoding the 
origin of replication and the packaging signals, and two AAV-specific genes, rep and cap 
(31). Rep gene encodes four overlapping proteins of 78, 68, 52, and 40 kDa, generated by 
alternative splicing of transcripts from two alternative promoters. The ITRs and either 
Rep78 or Rep68 are sufficient for replication of the AAV genome and mediating its 
integration into a specific site (AAVS1) on human chromosome 19ql3.3-qter (45, 5).
Due to the very limited packaging size of wt AAV particles, recombinant AAV vectors are 
deleted of all viral genes and have therefore lost the Rep-mediated, site-specific integration 
property of the wt viruses.
The recombinant AAV vectors maintain only a residual capacity for ITR-mediated 
integration in some target cells (e.g. liver), although at low efficiency and with virtually no 
site-specificity (26).
The AAV ITRs and Rep functions have been previously incorporated into hybrid, large- 
capacity viral vectors, such as baculoviral and HSV-1 amplicon vectors (57, 59), or into a 
split Ad/AAV vector system, in which an AAV ITR-flanked integration cassette and a 
Rep78/68 expression cassette were carried by two different HD-Ad vectors (57) (Fig. 3.1).
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Fig. 3.1 Schematic representation of Ad/AAV integration machinery in a split vector design. In this 
vector design the integration cassette is contained between the AAV ITRs and subcloned inside the Ad ITRs 
to be packaged. The Rep78 integration protein is supplied in trans using a non integrating Ad vector. Rep act 
on AAV ITR and AAVS1 sequences permitting the cassette integration into human Chrl9.
In these systems the inhibitory effect of Rep on viral replication prevented or significantly 
affected the production of Ad and HSV-1 vectors incorporating all the elements of the 
AAV integration machinery.
Background
Recently in this laboratory it was described the development of a single hybrid Ad/AAV 
vector (an alternative to the split Ad/AAV system) carrying a double reporter gene 
integration cassette flanked by AAV ITRs and, outside to the AAV ITRs (into the non 
integrating region) a tightly regulated, drug-inducible Rep expression cassette (Fig. 3.2). 
This hybrid vectors were successfully packaged and purified at a titer of 109 transducing 
units/ml. Upon infection at low multiplicity of susceptible human primary cells and cell 
lines, Rep-dependent, AAVS1-specific integration of the ITR-flanked cassettes of intact 
size and function was obtained in the absence of any cell selection.
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Fig. 3.2 Schematic representation of Ad/AAV integration machinery in a single vector design. In this 
vector design the integration cassette is always contained between the AAV ITRs and subcloned inside the 
Ad ITRs to be packaged. Rep78 gene is subcloned in the same vector outside the integrating AAV region.
The Ad/AAV vector system posses two interesting and powerful characteristics that justify 
our interest on this system:
1. The possibility to integrate in a site-specific way different types of gene expressing 
cassettes.
2. The possibility to package and target into the target cell a very large DNA fragment (up 
to 30-35 kb) eventually together with regulatory sequences/elements.
Specific goals.
In this work I tried to explore, characterise and improve all the characteristic of the ITRs- 
Rep mediated integration of Ad/AAV hybrid vector system in a large cassette contest.
In the hybrid Ad/AAV system the elements responsible for the site-specific integration 
derive from the AAV virus: ITRs and Rep protein.
The integrating cassette is flanked by the two AAV ITRs and subcloned inside to the Ad 
vector that pennits the accommodation of a very large cassette (Fig. 3.3). A limitation, that 
we want here to explore was the capacity of AAV integration machinery to integrate such a 
large gene in respect to its wt genome.
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Fig. 3.3 Schematic representation of Ad/AAV vector. The integrating region limited by the AAV ITRs is 
inserted in the space where was the Adeno genome. In this way there is the possibility to insert very large 
genes.
Concerning Rep, there are two possibilities to express this protein: subcloning a tightly 
regulated Rep expressing gene into the non integrating region of Ad/AAV vector (16) (Fig.
3.4 upper panel), or co-transducing cells with both the ITRs flanking cassette and an Ad 
non integrating vector expressing Rep in a tightly regulated way. (Fig. 3.4 lower panel).
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Fig. 3.4 Schematic representation of Rep expression alternatives. Rep can be both administered 
subcloning it in the non integrating region of an Ad/AAV vector (upper panel) or co-transducing target cells 
with an Adeno non integrating vector expressing the Rep cDNA (lower panel). The second option can 
circumvent most of the problems linked to the packaging of the vector in which there is a residual Rep 
expression.
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The development of an efficient integrating, large-capacity viral vector is still an unmet 
goal of gene transfer technology. The design of helper-dependent (HD), fully deleted Ad 
vectors has significantly reduced the limitations associated with the first-generation Ad 
vectors system (e.g. acute toxicity, inflammatory and cytotoxic immune response against 
the viral proteins) and offers an interesting opportunity to investigate the possibility to 
transform an Ad non integrating vector into an Ad/AAV hybrid integrating vector.
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Chapters 4-7
Results
Chapter 4.
Construction of a large capacity Ad/AAV
4.1 Ad/AAV hybrid vector.
In this first part of my thesis project I decided to design a large capacity Ad/AAV vector to 
explore the possibility to obtain a high titer virus stock production and compare the 
efficiency and abilities of the Ad/AAV hybrid vector system in targeting site-specifically 
an integrating cassette in respect to its size.
In particular I decided to compare the published data regarding the Ad/AAV expressing an 
integrating cassette constituted by two reporter genes GFP and NGFR (around 4 kb) with a 
new designed larger ITR-ITR cassette containing the human collagen VII cDNA and the 
GFP reporter gene (12 kb).
4.1.1 Vector design.
To test the efficiency of Ad/AAV hybrid system as a gene transfer system able to target 
and integrate efficiently a large expressing cassette into human genome I decided to 
produce an Ad/AAV viral stock using a Helper Dependent (HD) system.
This system consists of one plasmid expressing the fully deleted Ad vector genome in 
which we introduced the transgene flanked by the AAV region responsible for integration 
into the human genome (ITRs).
I decided to subclone inside this kind of vector a constitutively expressed human cDNA 
collagen VII gene with a second gene, the GPF (Green Fluorescent Protein) as a marker. 
Collagen VII-GFP represents a very large cassette to be targeted and integrated into a host 
cell in respect to smaller previously tested vectors (Fig. 4.1 e 4.11).
It is unknown if this system (AAV-ITR + Rep), designed for a genome that is 1/3 of the 
cassette I tested, was able to integrate such as large transgene, and to do it efficiently and 
in a site-specific fashion.
98
Integrating cassette (ITR-ITR)
Fig. 4.1 Schematic representation of large integrating vector. The integrating cassette, flanked by AAV 
ITRs is composed by a large expressing gene (hCol7) under the control of CMV promoter and by a selective 
marker (GFP) under the control of PGK promoter. In this case Rep is expressed in trans by a non integrating 
HD-Ad vector.
4.1.2 Large cassette construction.
Cassette was mounted following numerous passages into a pBS SK- plasmid.
First of all the human collagen VII cDNA (from Prof. Meneguzzi G. INSERM U634, 
Faculty of Medicine, Nice, France) was subcloned as an EcoRJ fragment into the EcoRI 
site of pBS SK- in reverse orientation (pBShcol7REV).
The CMV promoter was recovered as a NruI-EcoRV fragment from the pIRESneo plasmid 
and subcloned into the EcoRV site of pBS SK- containing human collagen VII 
(pBSCMVhcol7). The bovine Growth Hormone poly A signal (bGHpolyA) was added to 
the construct digesting it Xbal and blunting the site. bGHpolyA was obtained from 
pIRESneo cutting Xhol and Xbal and blunting them.
The cassette was completed (pBSCMVhCOL7pAPGKGFP) introducing to the 3’ of 
CMVhColVIIpolyA the PGKGFPsv40polyA obtained by digesting with EcoRV from 
pBSPGKGFP. The subcloning was obtained into the EagI blunted site of 
pBSCMVHCol7PolyA. The two expression cassettes were cloned in the same orientation. 
The complete large cassette was then extracted by EcoRV digestion from the 
pBSCMVhCOL7pAPGKGFP vector and subcloned between AAV ITRs. The two ITRs 
were obtained depriving pBSAAV2 of the whole AAV genome cutting it out with Xbal 
and filling with klenow to obtain blunt ends.
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The ITRs flanking cassette was then cut Notl-Clal to extract the ITR-flanked cassette and 
subcloned into the Xbal blunted site of a pBGshuttle vector to perform homologous 
recombination with the final Ad vector (pA28short) (Fig 4.2).
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Fig. 4.2 Schematic representation of the large integrating vector.
4.1.3 Homologous recombination.
The final Ad vector was obtained by homologous recombination between the pBG shuttle 
vector and the pA28 vector. The pBGshuttle vector was linearised using the PacI site (Fig. 
4.3) to offer free homology regions.
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Fig. 4.3 Schematic representation of pD28 vector and pBGshuttle. In the figure the homology regions 
responsible for the homology recombination event are indicated. On the right panel the Xbal and Xhol 
cloning site are indicated.
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4.2 Vector expression.
Prior to packaging, the Ad/AAV virus vector functionality was tested by transient 
transfection in 293T and HeLa cells to check for GFP and human collagen VII expression. 
293T transfection was done using calcium phosphate method in 10 cm plates. HeLa cells 
transfection was done using the FUGENE method in 6 cm plates.
Transfection was done with a GFP (pEGFPC3) as a positive control for GFP expression 
and tranfection efficiency.
Two series of cited cell plates were prepared: one series was analysed by FACS for GFP 
expression and one series was analysed for human collagen VII expression.
GFP expression:
The day after transfection the cells were washed three times in PBS and 10 ml of fresh 
medium was added. 24 hours after medium changing cells were detached and analysed by 
FACS for GFP expressions. Cells were washed twice in PBS and detached with Trypsin. 
5x105 cells were resuspended in PBS 1% BSA and analysed by FACS (Fig. 4.4).
10 to  10 10 10
FL1-HeightSSC-Height
Region % Gated XMaan
R1 100.00 171,99
R2 60.49 254.98
Fig. 4.4 FACS analysis for GFP expression. 293T cells were analysed for GFP expression. R1 gated the 
living cell population. R2 gated the GFP positive celle population in which there is a FL1 shift. All the 
transfection demonstrated the correct and efficient expression of GFP by the large capacity Ad/AAV vector.
The vector was able to express correctly GFP.
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Human Collagen VII expression:
The day after transfection cells were washed three times in PBS and 5 ml (for 10 cm 
plates) or 2 ml (for 6 cm plates) of freshly serum free medium containing 50 mg/ml of 
ascorbic acid. 24-48 hours after medium changing the conditioned medium was harvested 
and 0.45 um filtered to eliminate debris. 1 ml of the conditioned medium harvested from 
negative control and hColVII-GFP tranfected cells was dot blotted onto a nitrocellulose 
membrane. The membrane was treated following a Western blot protocol (See materials 
and methods) and probed for human collagen VII expression with a monoclonal antibody 
for human collagen VII (See Materials and Methods) (Fig. 4.5).
Negative Control HeLa cells 
Keratinocytes 
Transfected HeLa cells
Fig. 4.5 Dot blot analysis for human collagen VII expression and secretion. HeLa cells were analysed for 
human collagen expression. 1 ml of supernatant from transfected cells was loaded onto nitrocellulose 
membrane connected to a dotblot apparatus. The samples from transfected cells demonstrated the correct 
human collagen VII secretion into the medium. Negative control is supernatant from HeLa cells mock 
transfected. Supernatant from keratinocytesis were used as positive control for human collagen VII 
expression.
The vector was able to drive correctly synthesis and secretion of human collagen VII into 
the culture medium.
4.3 Large capacity vector packaging.
Certain of the vector functionality we passed to the HD-Ad virus production.
Ad/AAV virus stock was produced by transfection/infection of the 293Cre4 cell line, as 
previously described (24).
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293Cre4 cells were transfected in 6 cm Petri dishes with pD28shortITRCOL7GFP using 
calcium phosphate method. The day after cells were washed three times in PBS and 5 ml 
of fresh medium added. 36-48 hours after transfection cells were co-infected with the 
helper virus for virus stock production and amplification (as illustrated in Fig. 4.6). 1 ml of 
PBS containing the helper virus (M.O.I 1) was added to the cells and incubated 30-45’ in 
5% CO2 37°C incubator.
All the scale up passages were monitored for GFP expression. Following the increase of 
GFP positive cells during the scale up passages other helper virus (MOI 1) was added to 
ensure the constant increase in GFP positive cell number (indicative of Adeno containing 
transgene amplification). For the scale up process we started from 6 cm dish to end up to 
30 15 cm dishes. Cells and supernatants were harvested and processed (See Materials and 
Methods).
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Fig. 4.6 Schematic representation of Adeno Helper Dependent production. Vector plasmid containing 
transgene is transfected into 293Cre cells. Cells are co-transduced with the helper virus expressing in trans 
all the accessory genes needed for the virus packaging (in our case we utilised MOI 1). The Helper virus has 
the \|/ packaging signal between the two lox p sequences. In presence of Cre recombinase expressed in 293 
Cre cells Helper virus can’t be efficiently packaged. It is possible to reduce in this way the Helper virus 
contamination.
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4.4 Control of Rep78 expression.
Rep interferes with Ad packaging and is a toxic protein for the host cell, and it is therefore 
necessary to tightly control its expression (25-27). We decided to use a tet-on control 
expressing system to administer Rep in a turning on/off system (Fig 4.7).
- dox
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Fig. 4.7 Schematic representation of Tet regulating Rep expression. To overcome or limit the toxic effect 
in Rep expression we used a tet-on system to switch on/off the Rep production. Rep is expressed in a non 
integrating Ad and the production was switched on for few days after Ad/AAV transduction adding 
doxicyclin into the medium.
We tested two kind of vectors for Rep production: CMVRepTS and TKRepTS. The first 
one containing the transcriptional silencer (tTS) gene expressed under the control of a 
CMV promoter, while in the TKRepTS vector the Rep78 gene was under the control of the 
minimal promoter (-81) of the HSV-1 thymidine kinase gene (TK) linked to the tetO 
element (tetOTK) (Fig. 4.8).
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Fig. 4.8 Schematic representation of vector structures. Expression cassettes were inserted into the 
pSTK120 (25.8 kb) or pSTK119 (23.3 kb) The CMVRep vector contains an AAV Rep78 ORF under the 
control of the CMV immediate-early enhancer/promoter (-675). In the other vectors an inducible Rep 
expression cassette is constituted in which the Rep78 ORF is driven by a minimal CMV (-53) or TK (-81) 
promoter controlled by a bacterial tet operator (tetO) sequence CMVRepTS and TKRepTS.
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A control vector, CMVRep, containing only a Rep78 expression cassette driven by the 
CMV promoter/enhancer in the STK-120 backbone was used to measure the Rep 
expression level.
Basal Rep78 expression was very well controlled and induced by Dox 48 hours post­
transfection at levels comparable to those obtained by an unmodified CMV promoter (Fig. 
4.9).
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Fig. 4.9 Western blot analysis of Rep expression in 293T cells. The CMVRep vector contains an AAV 
Rep78 ORF under the control of the CMV immediate-early enhancer/promoter (-675). In the other vectors an 
inducible Rep expression cassette is constituted in which the Rep78 ORF is driven by a minimal CMV (-53) 
or TK (-81) promoter controlled by a bacterial tet operator (tetO) sequence CMVRepTS and TKRepTS. 50 
ug of protein extract was loaded after measurement by the Bradford method. This Western blot show clearly 
the possibility to induce Rep in presence of Dox, limiting the Rep expression and cellular toxicity. HMG1 
was utilysed as loading control.
To express Rep78 protein we chose to use the CMVRepTS vector.
4.5 Packaging of the Rep78 expressing vectors.
We produced the HD-Ad expressing Rep (CMVRepTS) vector by transfection/infection of 
the 293Cre4 cell line, as previously described (12 and Fig. 4.6).
The approach in viral amplification in this case, without a marker gene, was different. 
After five serial passages of viral amplification, the integrity of the episomal Ad vectors
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was controlled by Southern blot analysis of Hirt DNA extracted from crude lysates of the 
packaging cells. Both the CMVRepTS and TKRepTS viruses yielded the predicted 
restriction fragments when grown in the absence of Dox, while they rearranged when 
grown in the presence of Dox (results not shown). This data confirmed the known 
problems of Rep interference with Ad packaging.
Rep production:
6 cm Petri dishes transfected with CMVRepTS and TKRepTS were analysed for Dox Rep 
induction. After precipitate were washed out one plate per vector type was cultivated in 
presence of Dox and the other one without. Cells were harvested 24 or 48 hours. Nuclear 
extracts were analysed by Western blotting using a rabbit anti-Rep polyclonal antiserum. 
Basal expression level of Rep78 (without Dox) was low from the tetO-CMV promoter and 
virtually undetectable from the tetO-TK promoter (Fig. 4.10).
Rep 78
HMG1
Fig. 4.10 Western blot analysis of Rep expression in 293Cre cells. Cells in which were transfected the two 
constructs were monitored for Rep expression during virus growth. + and -  stand for dox or not dox added. 
50 ug of protein extract was loaded after measurement by the Bradford method. HMG1 was utilysed as 
loading control to normalize the expression of Rep.
4.6 Description of Ad/AAV control vector.
The prototype of integrating vector contained an AAV ITR-flanked integration cassette 
with two different reporter genes, the green fluorescent protein (GFP) and a truncated
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version of the p75 low-affinity nerve growth factor receptor (ALNGFR) under the control 
of the phosphoglycerokinase (PGK) and the SV40 early promoter, respectively, cloned into 
the STK-120 HD-Ad backbone (Fig. 4.11). In respect to the described large capacity vector 
this vector possesses the Rep expressing cassette in the non integrating region of the virus. 
The ITRGNCMVRepTS vector contained only the tTS gene under the control of a CMV 
promoter, while in the ITRGNTKRepTS vector the Rep78 gene was under the control of 
the minimal promoter (-81) of the HSV-1 thymidine kinase gene (TK) linked to the tetO 
element (tetOTK) (Fig. 4.11). The control vector, CMVRep, contained only a Rep78 
expression cassette driven by the CMV promoter/enhancer in the STK-120 backbone (Fig. 
4.11).
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Fig. 4.11 Schematic representation of splitted and single vectors ITR-ITR integrating cassette. In the
single vector model Rep is in the non integrating region.
4.7 Viral titration.
Titration to determine the number of transducing units (TU)/ml in the viral vector stock
consists of testing serial dilutions on appropriate target cells. The method and time it takes
to determine the titer depends on the particular marker gene encoded in the transfer vector
and, of course, on the type of transcriptional regulation of the marker gene. For example,
vectors with GFP or luciferase markers, under transcriptional control of a constitutive
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promoter, can be harvested about 2-3 days post-infection, while for vectors with drug 
resistant markers it takes approximately two weeks for drug-resistance colony formation. 
For vectors in which the marker gene is regulated in a cell-lineage specific fashion, the use 
of the appropriate cell target is needed. For example, viral titers of vectors with erythroid- 
specific expression of the marker gene should be calculated by transduction of an 
erythroblastic cell line.
However, under normal conditions, the most common target cells used to determine viral 
titers are HeLa and 293T cells.
In our case, viral supernatant titers were determined by transduction of HeLa cells. A fixed 
number, generally lx l0 5, of HeLa cells were transduced with serial dilutions of the viral 
stock preparations. Dilutions of viral supernatant started from 10'1 up to 10’3. HeLa cells 
were transduced with diluted supernatant in PBS for one hour in 37°C 5% CO2 incubator 
(See materials and methods).
Transduction efficiency was determined by FACS analysis for GFP expression. Viral titers 
are usually calculated at that dilution where there is a linear regression of GFP expression 
and are expressed as transducing units per ml (TU/ml) of viral stock. This is a conventional 
unit calculated by dividing the number of GFP-expressing cells to the dilution of viral 
preparation used to transduce cells.
4.8 Large cassette expression after keratinocytes transduction.
Immortalised collagen VII deficient human keratinocytes were transduced at different MOI 
to test Ad stock proteins production.
Cells were transduced in serum free DMEM for 5 hours in 37°C 5% CO2 incubator. 10%
FCS (final concentration) was supplemented and cells were incubated for 72 hours in 37°C
5% CO2 incubator prior to gene transfer analysis. 3 MOI were tested 50, 100 and 200.
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Control for GFP expression was obtained transducing at MOI 200 with Ad GFP human 
keratinocytes in the same conditions.
GFP expression:
72 hours after transduction cells were monitored for GFP expression by FACS analysis. 
Cells were washed twice in PBS and harvested with trypsin. 5xl05 cells were resuspended 
in PBS 1% BSA and FACS analysed (Fig. 4.12)
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Fig. 4.12 Graphic representation of GFP positive keratinocyte 72 hours after transduction.
Keratinocytes were FACS analysed 72 hours after transduction with Ad/AAV expressing human collagen 
VII and GFP. 3 MOI were tested for Ad/AAV and one (MOI 100) for GFP control to see the expressions of 
the entire cassette.
Good levels of GFP expression were obtained with GFP control and AdCol7GFP. Raising 
MOI did not increase the percentage of GFP positive cells, but not toxic effect was 
observed.
Human collagen VII expression:
72 hours after transduction cells were washed three times in PBS and 10 ml of freshly 
serum free medium supplemented with 50 mg/ml of ascorbic acid added.
48 hours after medium changing the conditioned medium was harvested and 0.45 um 
filtered to eliminate debris. All the medium harvested from control GFP and AdCOL7GFP
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transduced cells was concentrated by centrifugation in 100 MWCO Amicon columns. 
Concentrated supernatant was measured by the Bradford method in the spectrophotometer 
and 30 ug of proteins were loaded on SDS PAGE gel (Fig. 4.13). Western blot was 
performed following a standard protocol (see Materials and Methods).
H u m a n  ColVII -
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Fig. 4.13 Western blot on transduced keratinocytes concentrated supernatant. Transduced keratinocytes 
collagen VII deficient were cultived in FCS free medium with 50 mg/ml of ascorbic acid. After 48 hours 
medium was harvested and concentrated on Amicon 100 MWCO colums. 30 ug of proteins (measured by 
Bradford method) were loaded on SDS PAGE gel and revealed with anti human collagen VII antibody. K71 
and K100 are keratinocytes collagen VII deficient from two different donors. The positive control was 
represented by HeLa cells transfected with the vector expressing collagen VII.
The vector was able to express correctly human full length collagen VII at very good 
levels.
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Chapter 5
Analysis of Ad/AAV vector integration.
5.1 HeLa cell clones generation.
To compare the efficiency of transgene integration between large capacity 
(AdITRCOL7GFP) and control (ITRGNRep) vectors we analysed what happened at single 
cell level.
HeLa cells were transduced with AdITRCOL7GFP and co-transduced with CMVRepTS at 
MOI 20 for both viruses.
HeLa cell bulk cultures were kept in the presence and absence of Dox to monitor the effect 
of Rep on overall and site-specific integration.
Bulk culture were monitored for one month for GFP and human collagen VII expression 
respectively by FACS and dot blot analysis (data not shown).
1.5-2.0% of the cells cultured in presence of Dox, maintained reporter gene expression, 
while cells cultured without Dox, scored negative already 3 weeks after infection. HeLa 
cells kept in the presence of Dox maintained GFP expression after one month. After this 
period HeLa cells were sorted for GFP positivity, and subcloned in 96 well plates at 0.2- 
0.3 cells/well cell density by limiting dilution (Fig. 5.1).
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Fig. 5.1 Experimental scheme of clones isolation. HeLa cell clones were transduced with both Rep and 
collagen + GFP expressing vector. Cells cultured for about a month in presence of Dox were sorted. Sorted 
HeLa clones were isolated by sorting from the sorted bulk. R1 gated the viable population and R2 gated the 
GFP population in which there was a shift on X axis.
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Single clones were isolated after two weeks of culture and grown for up to one month for 
further analysis.
More than 50 clones were scored for GFP expression by microscope and FACS analysis 
(data not shown) and for human collagen VII expression by dot blot (Fig. 5.2). Since the 
sorted bulk culture was virtually 100% transduced, the vast majority of clones analysed co­
expressed GFP and human collagen VII. The presence of GFP and human collagen VII 
expression was very important because represented a first clue of correct cassette 
integration.
N.C. P.C.
Fig. 5.2 Dot blot analysis for human collagen VII expression and secretion. HeLa cell clones were 
analysed for human collagen VII expression and secretion. 1 ml of supernatant from transduced cells was dot 
blotted onto nitrocellulose membrane and recognised following a Western blot procedure with a monoclonal 
antibody detecting human collagn VII. N.C. is the negative control, 1 ml of supernatant from HeLa cells 
mock transduced. P.C. is the positive control, 1 ml of supernatant from HeLa cells human collagen VII 
transfected. Each spot represent a single cell clone.
5.2 Integrity analysis of the integrated ITR-flanked Col7-GFP in HeLa 
cells.
28 clones were further expanded and genomic Southern blot analysis was performed to 
determine the integrity of the integrated cassette for each clone. The integrity of the 
cassette was determined by digestion of genomic DNA with Ncol. Ncol cut twice into the 
vector releasing a 10 kb fragment encompassing most of the human collagen VII and GFP 
cDNAs (Fig. 5.3).
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Fig. 5.3 Schematic representation of integrated large cassette. Genomic DNA was digested Ncol to cut 
the entire cassette from the whole host genomic DNA. Ncol enzyme cut inside CMV promoter and 3’ ITR 
region. Using a human collagen VII specific probe is possible to see a 10 kb band.
This 10 kb DNA fragment can be probed using a human collagen VII specific probe (Fig. 
5.3). In all the analysed clones, Southern blot showed no evidence of cassette 
rearrangement, all the Ncol fragments were of the expected size. This is a very important 
result. Genome stability of such a large integration cassette was in fact unpredictable, also 
considering the peculiar nature of its cDNA content. The human collagen VII cDNA 
sequence has a very repetitive structure, potentially leading to instability and 
recombination.
MW pi. 1 2  3 4 5 6 7 8 9 10 11 12 1314 N.C 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Endogenous 
collagen VII
Fig. 5.4 Southern blot analysis of HeLa clones Ncol digested for integrated cassette integrity, pi. stands 
for plasmid and represent the AdHD plasmid digested with Ncol, N.C. is genomic DNA from Hela cells 
mock transduced with the virus. 1 28 are different HeLa clones. All the 28 HeLa clones showed a 10 kb
band corresponding to the correct size of the integrated cassette.
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5.3 Human collagen VII expression.
Each positive cell clone was tested by dot blot analysis for human collagen VII secretion 
(data not shown). 5x10s HeLa cell clones were plated in 6 well plates. The day after plating 
cells were washed twice in PBS and cells were maintained 24 hours in 2 ml serum free 
medium with 50 mg/ml of ascorbic acid. 1 ml of the conditioned medium harvested from 
cells was dot blotted onto a nitrocellulose membrane and probed following the Western 
blot analysis standard protocol. All the clones analysed expressed human collagen VII. The 
level of expression was different depending on the clone analysed.
To ensure that what we had seen in dot blot analysis was a correct size protein, we tested 
by Western blot the clone supernatants.
5xl06 cells of each HeLa clone were plated onto 10 cm Petri dishes. The day after growth 
cells were washed twice in PBS. 10 ml/plate of serum free medium with 50 mg/ml of 
ascorbic acid was added and cells were cultivated 24-48 hours in 5% CO2 37°C incubator. 
The conditioned samples were collected and 0.45 um filtered to eliminate debris. 
Supernatants were concentrated with Amicon 100 MWCO columns by centrifugation. 
Protein-enriched supernatants were measured by the Bradford method and 30 ug of 
proteins loaded on SDS-PAGE gel. Western blot analysis was performed following 
standard methods.
HeLa MW 5 6 14 15 21 24 28
human collagen VII- 
220kDa -
Fig. 4.5 Western blot analysis of concentrated supernatant from HeLa clones. HeLa are wt cells mock 
transduced, representing the negative control for collagen expression. 5, 6, 14, 15, 21, 24, 28 are 
AdColVIIGFP transduced HeLa clones selected for analysis. Cells were kept 24 hours in DMEM serum free 
50 mg/ml ascorbic acid supplemented. 10 cm plates were incubated 24 hours after transfection with 5 ml 
media and after incubation time all the medium was 0.45 urn filtered and concentrated. 30 ug of total protein 
sample was run on SDS-PAGE gel. The band under 220kDa is a degraded form of collagen VII.
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Western blot analysis confirmed that what we had seen with dot blot screening was 
effectively a correct human collagen production. Monoclonal antibody we used correctly 
recognized a band migrating around 300 kDa as expected in all the clones we analysed.
5.4 Site-specific integration of the AAV ITR-ITR large cassette in HeLa 
cells.
Previously extracted DNA from each HeLa clone was analysed by Southern blotting after 
restriction with EcoRI, which releases a 9 kb fragment encompassing part of the 
chromosome 19 AAVS1 site and part of the integrated ITR-ITR cassette (Fig. 5.6). 
Hybridization with an AAVS1-specific probe and followed by a GFP specific probe 
showed co-localization in 6 of 23 independent HeLa clones (5 clones after Southern blot 
analysis revealed the same restriction fragment profile), indicating rearrangement of the 
AAVS1 region in at least one chromosome 19, in which we obtained site-specific 
integration (26%).
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Fig. 5.6 Schematic representation of restriction mapping profile of AAVS1 region with large cassette 
integration. In the case of AAVS1 site specific integration the vector introduces 2 new EcoRI sites. Co- 
hybridising Southern blot membrane with both GFP and AAVS1 specific probes is possible to isolate clones 
with site specific integration.
The same DNA was also digested with AccI which releases a 3.1 kb fragment 
encompassing most of the chromosome 19 AAVS1. AAVS1 probe showed a size shift of 
the 3.1 kb band in 16 of 23 independent HeLa clones (70%), indicating rearrangement of
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the AAVS1 region in at least one chromosome 19. The rearranged bands hybridized also to 
a GFP-specific probe in 6 of the 23 clones (26%), indicating the integration of the AAV 
ITR-flanked cassette in the AAVS1 region.
In 10 clones (43%), the AAVS1 site showed a rearranged band that did not hybridize to the 
GFP probe, indicating Rep-mediated disruption of the AAVS1 region in the absence of 
integration. Conversely, 8 of 23 clones showed bands corresponding to intact AAV ITR- 
flanked cassettes integrated elsewhere in the genome (34%) (Fig. 5.7).
HW CN  Rl 1 2 3 4 5 27 MW CN Rl 1 2 3 4 5 27
EcoRI Probe AAVS1
17 16 15 14 13 12 1Kb 17 16 15 14 13 12 1Kb
•M
EcoRI Probe AAVS1 EcoRI Probe GFP
Clone AAVS1 Rearrangement Integration
1=2,4,5 Not Present Random
2=1,4,5 Not Present Random
3 PRESENT CHR19
4=5,1,2 Not Present Random
5=1,2,4 Not Present Random
6 Present Random
7 Present Random
8=11 Not Present Random
9 Present Random
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10 Present Random
11=8 Not Present Random
12 Not Present Random
13 Present Random
14 Present Random
15 Present Random
16 Present Random
12 PRESENT CHR19
18 Not Present Random
19 PRESENT CHR19
20 Not Present Random
21 Not Present Random
22 PRESENT CHR19
23 Not Present Random
25 PRESENT CHR19
26 Present Random
27 PRESENT CHR19
28 Present Random
Fig. 5.7 Summarising scheme for large cassette integration. Genomic DNA from HeLa clones was 
digested both with AccI and EcoRI to study the integration of the large cassette into the host genome. In the 
first panel 2 Soutem blot on the left are hybridised with the AAVS1 probe. Southern blot on the right are the 
same filters stripped and re-probed with the GFP probe. Site-specific integration was determined when co­
hybridisation with AAVS1 probe and GFP probe was present. MW stands for molecular DNA weight, Rl is 
the Adeno plasmid digested with EcoRI, the numbers are single HeLa clones.
5.5 Site-specific integration into human keratinocytes with small cassette 
vector.
K71 deficient collagen VII keratinocytes were infected with the single vector expressing 
ITRGN (non integrating vector) alone and with TKRep (expressing the Rep protein able to
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integrate the previous vector) at an MOI of 100 and 200. Transduced cells were grown for
5 days in the presence o f Dox for Rep expression.
GFP expression:
We tested for GFP expression by FACS analysis 5 days after infection (Fig. 5.8). Cells 
were washed twice in PBS and harvested with trypsin. 5x105 cells were resuspended in 
PBS 1% BSA and FACS analysed.
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Fig. 5.8 K71 keratinocytes (collagen VII deficient) were transduced with the small cassette vector.
ITRGN is the vector without Rep expressing cassette. Two different MOIs were tested. Cells were cultived in 
presence of Dox for Rep expression where it was present.
Keratinocytes were efficiently transduced with the viruses.
Integrations:
High molecular-weight DNA was extracted from these cells and analyzed it by nested-set 
PCR with AAVS1- and AAV ITR-specific primers (See Material and Methods).
DNA bands were amplified from keratinocytes transduced by the single vector expressing 
the ITRGN and TKRep in the presence of Dox.
No signal was detected in cells transduced by the control ITRGN non integrating vector. 
We analyzed the distribution of integrants throughout the AAVS1 region by nested PCR 
using two forward primers on the AAV ITR and three couples of reverse nested primers 
annealing to different positions within AAVS1 (a and b at nt 526-615, c and d at nt 1175— 
1349, and e and f  at nt 1612-2089, see Fig. 5.9).
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Fig. 5.9 Schematic representation of AAVS1 and AAV 3’ ITR nested primers, a-f are 6 primers Rev 
spanning the AAVS1 region. The For primers are located on the 3’ AAV ITR.
Specific DNA bands (200 to 700 bp long) were amplified from all cells only by the c + d 
and e + f  sets of primers (not shown).
To further characterize the integrations, we cloned and sequenced PCR-amplified bands. 
Analysis of the integration junctions showed that the insertions clustered within a 1 kb 
region of the AAVS1 (nucleotides 1068 to 2000), downstream of the Rep-binding site 
(RBS; nucleotides 398-413) (Fig. 5.10).
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Fig. 5.10 Summarising scheme for cassette site specific integration. Site specific integration was 
investigated by nested PCR approach and the amplified junctions were sequenced. A clustered insertion point 
was found within a 1 kb region. Each line represents a different insertion site.
5.6 Site-specific integration into human keratinocytes with the large 
cassette vector.
K71 deficient collagen VII keratinocytes were infected with the single vector expressing 
the human collagen VII and GFP alone (non integrating vector) and with TKRep
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(expressing the Rep protein able to integrate the previous vector) at an MOI o f 100 and
200. Transduced cells were grew for 5 days in the presence of Dox for Rep expression.
GFP expression:
We tested for GFP expression by FACS analysis 5 days after infection (data not shown). 
Cells were washed twice in PBS and harvested with trypsin. 5xl05 cells were resuspended 
in PBS 1% BSA and FACS analysed (data not shown).
Integrations:
High molecular-weight DNA was extracted from these cells and analyzed it by nested-set 
PCR with AAVS1- and AAV ITR-specific primers (See Material and Methods).
DNA bands were amplified from keratinocytes transduced by the single vector expressing 
the human collagen VII and TKRep in the presence of Dox.
No signal was detected in cells transduced by the control ITRCol7GFP non integrating 
vector.
We analyzed the distribution of integrants throughout the AAVS1 region by nested PCR 
using two forward primers on the AAV ITR and three couples of reverse nested primers 
annealing to different positions within AAVS1 (a and b at nt 526-615, c and d at nt 1175— 
1349, and e and f  at nt 1612-2089, see Fig. 5.9).
Specific DNA bands (200 to 700 bp long) were amplified from all cells only by the c + d 
and e + f  sets of primers (not shown).
To further characterize the integrations, we cloned and sequenced PCR-amplified bands. 
Analysis of the integration junctions showed that the insertions clustered within a 1 kb 
region of the AAVS1 (nucleotides 1054 to 1900), downstream of the Rep-binding site 
(RBS; nucleotides 398-413) (Fig. 5.11).
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A A V S 1 1 0 5 4
GGCCTCCAGGGATCCTGTGTCCC
A A V S 1 1 9 0 0i •
CTGCCCTTCCTTGACGAAAAC ACACAGCATAACCTCATTCTGCAAAGAA1 
    ______________________________
Fig. 5.11 Summarising scheme for cassette site specific integration. Site specific integration was 
investigated by nested PCR approach and the amplified junctions were sequenced. A clustered insertion point 
was find within a 1 kb region. Each line represents a different insertion site.
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Chapter 6
Optimisation of vector integration.
6.1 p5 element an enhancer on overall and site specific integration?
As we already know Rep mediated integration is extremely inefficient. This inefficiency is 
worst in a large cassette model.
In my work I tried to find out a system to improve this situation. Two ways were possible 
to improve the integration efficiency: to act on the integration system, and enhance the 
transduction efficiency to have more cells with the vectors inside.
Rep-mediated integration of rAAV plasmids is extremely inefficient, with between 0,1 and 
1% of transduced cells demonstrating rAAV genome persistence after 6 weeks (48).
In contrast, plasmids that carry the entire AAV genome integrate at efficiencies of greater 
than 10%. This difference between rAAV plasmids and wt AAV plasmids led to the 
discovery of a previously unknown cis sequence domain in the left end of the AAV 
genome that enhances integration efficiency (48). The p5 trs-like motif was identified 
because it enabled Rep-dependent AAV-2 replication in the absence of the left ITR (132). 
In addition to its ability to behave as a cis-acting replication origin, the p5 region 
(nucleotides 151 to 289 of wild-type AAV-2) was recently shown to enhance Rep- 
mediated site-specific integration of plasmid DNA into the human chromosome 19 AAVS1 
site (48,49).
To test the effect of this element in our system we wanted to test a new vector 
structure/design on overall and site-specific integration percentage re-integrating a mutated 
form of p5 promoter sequence (p5ATATA) into its viral wild-type position, flanking the 5’ 
AAV ITR (Fig. 6.1).
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Fig. 6.1 Schematic representation p5 modified sequence. p5 sequence was modified to abolish TATA box 
by mutating its sequence. The obtained p5ATATA was subcloned near the 5’ ITR and the ITRp5ATATA-ITR 
was used to flank a two reporter 4 kb integrating cassette.
6.2 ITRp5ATATA containing plasmids.
p5ATATA promoter sequence was synthesised amplifying two partially overlapping 
primers into the TATA box mutated region (See Material and Methods). The obtained PCR 
product was subcloned into a TOPO TA cloning vector. The p5ATATA sequence was cut 
Sall-Avrll blunted and subcloned to the 3’ region of 5’ AAV ITR into the pBSAAV vector 
cut Xbal and blunted to obtain pBSAAVp5 (Fig. 6.1).
The 5’ unmodified ITR was cut Spe-Xbal and subcloned into a TOPOp5 vector to obtain 
TOPOp5ATATAITR.
The construct pBSITRp5ATATAGFPNGFR was obtained digesting the vector 
pBSITRgfppoliAngfrpoliAinv Sail blunted and Xbal to cut off the 5’ITR and introduce the 
ITRp5ATATA cut Drall blunt and Spel.
pBSITRp5ATATAGFPNGFR was utilised to test the difference in respect to the original 
construct pBSITRGFPNGFR by transient transfection in HeLa cells co-transduced with the 
non integrating Ad expressing Rep78 protein. Tranfection experiments were performed in 
presence and in absence of Dox to switching on/off the Rep production.
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5xl06 Hela cells were seeded on 10 cm Petri dishes the day before transfection.
The same amount of the two plasmids (10 ug) was transfected using Calcium Phosphate 
protocol. HeLa control cells were transfected with a plasmid containing GFPANGFR but 
without ITRs. After an over night incubation of HeLa cells in presence of precipitates cells 
were washed twice with PBS and fresh medium added for 6 hours and kept at 37°C 5% 
CO2. Cells were washed twice with PBS and trasduced with TetRep in PBS (1 ml per 10 
cm Petri dish) and incubated for 1 hour at 37°C 5% CO2. After transduction time 10 ml of 
fresh medium Dox supplemented was added to PBS containing virus. Transfected 
transduced HeLa cells were kept in culture one month in presence of Dox to ensure the 
elimination of non integrated DNA and monitored for GFP expression (data not shown). 
After this period the GFP positive cells (around 1,5% in the case of wild type ITR and 
2,5% for p5ATATA) were FACS sorted.
6.3 HeLa cell clones generation.
Cell bulks after FACS sorting were subcloned at 0.2-0.3 cells/well by limiting dilution. 
Single clones were isolated after two weeks of culture and grown for up to one month for 
further analysis.
More than 50 clones were scored for GFP expression by FACS analysis (not shown). Since 
the-sorted bulk culture was virtually 100% transduced, the vast majority of clones analysed 
were GFP positives.
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6.4 Site-Specific Integration of the AAV ITR-Flanked Cassette in HeLa 
cells.
25 clones for pBSITRp5ATATAGFPNGFR transfected HeLa and 25 for 
pBSITRGFPNGFR were further expanded and genomic Southern blot analysis was 
performed to determine the genome integration of the ITR flaked cassettes for each clone. 
The site-specific integration of the cassette was determined by digestion of genomic DNA 
with Accl. AccI cut releases a 3.1 kb fragment encompassing most of the chromosome 19 
AAVS1 site.
Southern blot were probed with an AAVS1 and a GFP specific probes.
Unmodified ITR:
In the case of clones obtained from unmodified ITR AAVS1, the probe showed a size shift 
of the 3.1 kb band in 23 of 25 independent HeLa clones (92%), indicating rearrangement 
of the AAVS1 region in at least one chromosome 19. The rearranged bands hybridized also 
to a GFP-specific probe in 16 of the 25 clones (64%), indicating the integration of the 
AAV ITR-flanked cassette in the AAVS1 region. Further restriction analysis indicated that 
the AAV ITR-flanked cassette had integrated as a monomer or a dimer in the AAVS1 site 
and conserved an intact structure in all cases (not shown).
In 7 clones (28%), the AAVS1 site showed a rearranged band that did not hybridize to the 
GFP probe, indicating Rep-mediated disruption of the AAVS1 region in the absence of 
integration. Conversely, 2 of 25 clones showed bands corresponding to intact AAV ITR- 
flanked cassettes integrated elsewhere in the genome (8%). 7 out 25 clones (28%) showed 
both AAVS1-specific and non-specific integrants (Fig. 6.2).
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Fig. 6.2 Southern blot analysis of clones obtained from unmodified ITR.
HeLa were transfected with pBSITRGFPNGFR plasmid and transduced with TetRep Ad non integrating 
vector. 25clones (1A -> 25A) were co-hybridised with AAVS1 and GFP specific probes to analyse 
integrations. Southern blot on the right are the same filters stripped and re-probed with the GFP probe.
P5ATATA modified ITR:
In the case of clones obtained from p5 ATATA modified ITR AAVS1 probe showed a size 
shift of the 3.1 kb band in 21 of 25 independent HeLa clones (88%), indicating 
rearrangement of the AAVS1 region in at least one chromosome 19. The rearranged bands 
hybridized also to a GFP-specific probe in 13 of the 25 clones (52%), indicating the
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integration of the AAV ITR-flanked cassette in the AAVS1 region. In 6 clones (24%), the 
AAVS1 site showed a rearranged band that did not hybridize to the GFP probe, indicating 
Rep-mediated disruption of the AAVS1 region in the absence of integration. Conversely, 4 
out 25 clones showed bands corresponding to intact AAV ITR-flanked cassettes integrated 
elsewhere in the genome (16%). One clone showed both AAVS1-specific and non-specific 
integrants (4%).
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Fig. 6.3 Southern blot analysis of clones obtained from p5ATATA modified ITR.
HeLa were transfected with pBSITRp5ATATAGFPNGFR plasmid and transduced with TetRep Ad non 
integrating vector. 25 clones (1 -> 25) were co-hybridased with AAVS1 and GFP specific probes to analyse 
integrations. Southern blot on the right are the same filters stripped and re-probed with the GFP probe.
Analysing the size of the AAVS1 integrated cassette we noticed a big increase in the size 
of integrated cassette when the cassette is surrounded by the ITRp5ATATA. This 
phenomen is probably due to the integration of multimers of the integration cassette in the 
AAVS1 locus (Fig. 6.3 and 6.4).
N.C.1A N.C. MW 2A 3A 4A 5A 6A 7A 8A MW 1
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GFP probeUnmodified ITR GFP probe Modified ITR
Fig. 6.4 Comparison of integrated size between non modified and modified ITR vectors.
The two vectors are very different in respect to size of the integrated cassette. ITR not modified vector 
display a classical monomer-dimer integrant, ITR modified vector display a different integration in which are 
very abundant multimers.
Using this version of the integration enhancer we did not obtaine any important effect on 
the percentage of overall or site specific integration, but a considerable effect on the copy 
number in the AAVS1 site. Notably another effect we noticed using ITRp5 is the almost
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complete absence of mixed phenomenon (AAVS1 integrants + elsewhere integration) (Fig 
6.5).
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Fig. 6.5 Summarizing scheme of ITR and ITRp5DTATA integration analysis.
6.5 p5 without ITR which effect?
It seems that a minimal functional p5 element was composed of a 55 bp region 
(nucleotides 250 to 304 of wild-type AAV-2) containing the TATA box, the Rep-binding 
site, the trs present at the transcription initiation site (frs+l), and a downstream 17 bp 
region that could potentially form a hairpin structure localizing the trs+\ at the top of the 
loop.
Interestingly, the TATA box was absolutely required for in vivo but dispensable for in 
vitro, i.e., cell-free, replication (180).
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Rep binding and nicking at the trs+\ was enhanced in the presence of cellular TATA 
binding protein (TBP), and that the over-expression of this cellular factor increased the in 
vivo replication of the minimal p5 element (180).
Using a series of serials constructs spanning different regions of the p5 region (Fig. 6.6) we 
wanted to define the minimal elements within the p5 region required for Rep-dependent 
replication. This aspect could be very important to clarify if the integration phenomenon is 
dependent on replication of the integrating cassette or if it is possible to obtain site-specific 
integration independently of this aspect.
Four constructs were generated containing the four p5 regions subcloning this region to the 
5’ of a double expressing marker construct pBSGFPANGFR.
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Fig. 6.6 Graphic representation of p5 region mapping. Four different constructs were built to isolate the 
key region in the p5 element responsible for integration.
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Fig. 6.7 Graphic representation of four constructs used for p5 region mapping. p5 regions were 
subloned to the 5’ of the GFPANGFR cassette.
6.5.1 HeLa cell clone generation.
The p5 deleted region constructs were tested in transient transfection in HeLa cells.
HeLa transfection was done using Effectene transfection reagent in 6 cm plates.
The day before transfection 3xl05 HeLa cells were seeded on 6 cm Petri dishes. 1 ug of 
plasmid DNA/dish was transfected.
After over night incubation cells were washed and fresh medium added for 4 hours and 
kept at 37°C 5% CO2. Cells were washed twice with PBS and transduced with TetRep 
MOI 10 in PBS (1 ml per 10 cm Petri dish) and incubated for 1 hour at 37°C 5% CO2. 
After transduction time fresh medium Dox supplemented was added to PBS containing 
virus. Transfected and transduced HeLa cells were kept in culture one month in presence 
of Dox and monitored for GFP expression.
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The same kind of experiment was done co-transfecting 0.2 ug of Rep expression plasmid 
with the p5 plasmids to study the difference between the two approaches.
Bulk culture were monitored for two weeks for GFP and ANGF-R expression by FACS 
(data not shown).
Bulk cell population was NGF-R selected.
6.6 HeLa cell clones selection.
After another week of culture cell bulks were subcloned at 0.2-0.3 cells/well by limiting 
dilution. Single clones were isolated after two weeks of culture and grown for up to one 
month for further analysis.
More than 50 clones for each construct were scored for GFP expression by FACS analysis. 
Since the sorted bulk culture was virtually 100% transduced, the vast majority of clones 
analysed expressed GFP.
6.7 Integration analysis in HeLa cells of different p5 region fragments.
25 clones for each p5 fragment plasmids were further expanded and genomic Southern blot 
analysis was performed to determine the genome integration of the p5 flanked cassettes for 
each clone. The site-specific integration of the cassette was determined by digestion of 
genomic DNA with Accl. AccI cut releases a 3.1 kb fragment encompassing most of the 
chromosome 19 AAVS1 site.
Southern blot were probed with an AAVS1 and GFP specific probes.
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Full length n5:
In the case of clones obtained from the plasmid containing the full length wild-type p5 
AAVS1 probe showed a size shift of the 3.1 kb band in 23 of 25 independent HeLa clones 
(92%), indicating rearrangement of the AAVS1 region in at least one chromosome 19. The 
rearranged bands hybridized also to a GFP-specific probe in 13 of the 25 clones (52%), 
indicating the integration of the p5-flanked cassette in the AAVS1 region. Further 
restriction analysis indicated that the p5-flanked cassette had integrated as a monomer or a 
dimer in the AAVS1 site and conserved an intact structure in all cases (not shown).
In 7 clones (28%), the AAVS1 site showed a rearranged band that did not hybridize to the 
GFP probe, indicating Rep-mediated disruption of the AAVS1 region in the absence of 
integration. Conversely, 3 of 25 clones showed bands corresponding to intact p5-flanked 
cassettes integrated elsewhere in the genome (12%). 3 out 25 clones (12%) showed both 
AAVS1-specific and non-specific integrants (Fig. 6.3).
P5ATATA:
In the case of clones obtained from the plasmid containing the p5ATATA sequence 
AAVS1 probe showed a size shift of the 3.1 kb band in 21 of 25 independent HeLa clones 
(84%), indicating rearrangement of the AAVS1 region in at least one chromosome 19. The 
rearranged bands hybridized also to a GFP-specific probe in 10 of the 25 clones (40%), 
indicating the integration of the p5-flanked cassette in the AAVS1 region. In 6 clones 
(24%), the AAVS1 site showed a rearranged band that did not hybridize to the GFP probe, 
indicating Rep-mediated disruption of the AAVS1 region in the absence of integration. 
Conversely, 5 out 25 clones showed bands corresponding to intact p5-flanked cassettes 
integrated elsewhere in the genome (20%). No clone showed both AAVS1-specific and 
non-specific integrants.
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In the case of clones obtained from the plasmid containing the p5D10 sequence AAVS1 
probe showed a size shift of the 3.1 kb band in 22 of 25 independent HeLa clones (84%), 
indicating rearrangement of the AAVS1 region in at least one chromosome 19. The 
rearranged bands hybridized also to a GFP-specific probe in 13 of the 25 clones (52%), 
indicating the integration of the p5-flanked cassette in the AAVS1 region. In 7 clones 
(28%), the AAVS1 site showed a rearranged band that did not hybridize to the GFP probe, 
indicating Rep-mediated disruption of the AAVS1 region in the absence of integration. 
Conversely, 3 out 25 clones showed bands corresponding to intact p5-flanked cassettes 
integrated elsewhere in the genome (12%). One clone showed both AAVS1-specific and 
non-specific integrants (4%).
P5D12:
In the case of clones obtained from the plasmid containing the p5D12 sequence AAVS1 
probe showed a size shift of the 3.1 kb band in 18 of 25 independent HeLa clones (72%), 
indicating rearrangement of the AAVS1 region i$ at least one chromosome 19. The 
rearranged bands hybridized also to a GFP-specific probe in 9 of the 25 clones (36%), 
indicating the integration of the p5-flanked cassette in the AAVS1 region. In 6 clones 
(24%), the AAVS1 site showed a rearranged band that did not hybridize to the GFP probe, 
indicating Rep-mediated disruption of the AAVS1 region in the absence of integration. 
Conversely, 3 out 25 clones showed bands corresponding to intact p5-flanked cassettes 
integrated elsewhere in the genome (12%). No clone showed both AAVS1-specific and 
non-specific integrants.
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Fig. 6.7 Summarizing scheme of integration ability of different p5 constructs.
6.8 Replication analysis in HeLa cells of different p5 region fragments.
The p5 deleted region constructs were transfected in HeLa and 293T cells.
Both transfections was done using Effectene transfection reagent in 6 cm plates.
The day before transfection 3xl05 HeLa cells were seeded on 6 cm Petri dishes. 1 ug of 
plasmid DNA/dish was transfected.
After over night incubation cells were washed and fresh medium added for 4 hours and 
kept at 37°C 5% CO2. Cells were washed twice with PBS and transduced with TetRep 
MOI 10 in PBS (1 ml per 10 cm Petri dish) and incubated for 1 hour at 37°C 5% CO2. 
After transduction time fresh medium Dox supplemented was added to PBS containing 
virus. Transfected and transduced HeLa cells were kept in culture 36-48 hours after 
medium change in presence of Dox.
The same kind of experiment was done co-transfecting 0.5 ug of Rep expression plasmid 
with the p5 plasmids to study the difference between the two approaches.
36-48 hours after tranfection cell bulk population was recovered and HIRT DNA 
extraction was performed.
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The DNA recovered from HIRT extraction was digested with Dpnl and Mbol separately to 
clarify the replication role (Fig. 6.8). The presence of bands in the Mbol digestion is 
representative of DNA Rep mediated replication.
Southern blot analysis was performed to determine the DNA presence and status of the p5 
flanked cassettes for each bulk. Southern blot were probed with a GFP specific probe.
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Fig. 6.8. Identification of a minimal p5 element able to replicate in Rep-expressing cells. In vivo 
replication assay of the p5-containing plasmids. Total DNA extracted 48 h post transfection o f HELA and 
293T cells cotrasfected or transduced with Rep expressing plasmid or virus (left panel), was undigested (1) 
digested with either Dpnl (2) or Mbol (3) and analyzed by Southern blot using a GFP probe. On the right 
panel the same experiment without Rep. The two expected Dpnl digestion products (518 and 148 bp) 
hybridizing to the GFP probe are indicated by an arrow and are present also in the Mbol digestion if 
replicatio has occurred. The upper bands visible in the Mbol-digested samples represent input plasmid DNA. 
(see Materials and Methods).
With this analysis it is possible to conclude that replication we seen in the case of 
ITRp5ATATA was due to the presence of ITR. In fact p5ATATA alone is not able to 
replicate. The minimal element able to replicate is p5D10, the same construct but without 
TATA box is not able to replicate. The longer element, p5ATATA, in which the TATA 
box was mutagenised is not able to replicate. It is possible to argue that the TATA box is 
important for element replication and integration (Fig. 6.9).
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Fig. 6.9 Graphic representation of p5 region mapping and summarizing scheme of p5 replication 
capacity. Four different constructs were built to isolate the key region in the p5 element responsible for 
integration and tested for their replication capacity in vivo.
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Chapter 7
Expansion of vector tropism.
To obtain a new and flexible vector system it was necessary to expand the vector tropism, 
to have the possibility to transduce a high number of different kind of cells, and moreover 
cells relevant for gene therapy.
Efficient infection with Ad vectors based on serotype 5 (Ad 5) requires the presence on 
cells surface of coxsackievirus-adenovirus receptors (CAR) and av integrins (Fig.7.1) (145- 
154).
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Fig. 7.1 Schematic representation of Adeno 5 serotype mechanism of internalisation. Adeno 5 virus 
serotype interact with cells via both CAR receptor and a v integrin co-receptor. The cellular internalization is 
via endosomes. The endosomal membrane is then lysed in a process mediated by penton base and the content 
of virions is released in the cytoplasm. Virions partially encoated and DNA are tranported to the nucleus.
The paucity of these cellular receptors is thought to be the limiting factor for Ad gene 
transfer into different cell types e.g. hematopoietic stem cells.
We screened two different Ad serotypes for interaction with non-cycling human CD34+ 
cells, HEL and K562 cells on the basis of the level of transduction and transgene stability. 
A chimeric vector (Ad 5/35) which contained the short-shafted Ad 35 fiber incorporated 
into an Ad 5 capsid was generated. This substitution was seen to be sufficient to transfer all 
infection properties from Adeno 35 (Ad 35) to the chimeric vector. The retargeted, 
chimeric vector attached to a receptor different from CAR and entered cells by an av 
integrin-independent pathway (Fig. 7.2) (163).
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Fig. 7.2 Schematic representation of Adeno 5/35 hybrid serotype generation. The internalisation 
mechanism differs because Ad 5/35 serotype utilise an alternative internalisation pathway independent from 
CAR and a 5 integrin co-receptor. The short-shafted Ad 35 fiber was inserted into an Ad 5 capsid to generate 
a new Ad 5/35 serotype.
Our aim was to test if this was enough to overcome the Ad 5 limited cellular tropism, in 
particular cells poorly transduced from Ad 5 (like hematopoietic stem cells and 
hematopoietic derived cell lines).
7.1 CD34+ transduction with Ad 5 serotype.
Human CD34+ stem/progenitor cells were isolated from umbilical cord blood-derived 
mononuclear cells by immunomagnetic selection of positive cells, using a magnetic beads- 
conjugated anti-human CD34 (see Materials and Methods).
Cord blood-derived CD34+ cells were cultured for 24 hours in serum free medium 
containing 20% BIT 9500 serum-substitute in presence of cytokines and transduced with 
the Ad 5 single vector expressing ITRGN and Rep at different MOI to test the influence of 
MOI on transduction efficiency.
In particular we used MOI 300. This means that, theoretically 300 TU were used to infect 
one CD34+ cell.
24 hours post infection cells were analysed by flow cytometry for CD34, CD38 and GFP 
expression (Fig. 7.3). Under these conditions, more than 98% of cells retain CD34+
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phenotype (Fig. 7.3), while about 94% of CD34+ cells were also CD38‘, the more 
immature phenotype of the human HSCs (Fig. 7.3 middle panel). About 12% of total 
CD34 * cells were transduced as measured by the expression of GFP driven by the internal 
PGK promoter.
A comparison of the transduction efficiency between CD34+/CD38' and CD34+/CD38+ 
cells, also shows that the more immature CD38' subpopulation had a lower transduction 
efficiency in respect to the double positive subpopulation (11% vs 1%, Fig. 7.3 bottom 
panel).
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Fig. 7.3 FACS analysis of CD34+ cells transduced with Ad 5. FACS analysis was performed 24 hours after 
transduction. Cells were labelled with anti CD34 and CD38 and followed for GFP. In the UR region of the 
second panel is indicated the percentage of CD34+ cells transduced (red oval, around 11%). In the LR region 
of the third panel is indicated the percentage of CD38' cells tranduced (blue oval, around 10%). In the LR 
region of the last panel is indicated the percentage of CD34+ CD38' cells, the more immature phenotype 
(green oval, around 94%).
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To analyse transgene expression at the level of single colonies, CD34+ transduced cells 
were plated in methylcellulose to perform the colony forming cell in vitro (CFC or CFU) 
assay. MOI 300, 500 e 1000 in presence of Dox were utilised. Between 10 and 14 days 
after plating, methylcellulose clonal culture were scored for GFP expression by 
fluorescence microscopy. No colonies were scored for each group.
In summary, these results shown that high titer Ad/AAV viral stocks were generated using 
a HD system and the Ad 5 serotype is able to infect quiescent HSCs at a very low 
efficiency and no colonies were identified.
7.2 CD34+ transduction with Ad 5/35 serotype.
Human CD34+ stem/progenitor cells were isolated from umbilical cord-blood-derived 
mononuclear cells by immunomagnetic selection of positive cells, using a magnetic beads- 
conjugated anti-human CD34 (see Materials and Methods). Cord blood-derived CD34+ 
cells were cultured for 24 hours in serum free medium containing 20% BIT 9500 serum- 
substitute in presence of cytokines and transduced with the ITRGN vector at different 
multiplicity of infection (MOI) to test the influence of MOI on transduction efficiency. In 
particular we used MOI 300.
After 24 hours post infection cells were analysed by flow cytometry for CD34, CD38 and
GFP expression (Fig. 7.4). Under these conditions, about 98% cells retain CD34+
phenotype (Fig. 7.4), while about 86% of CD34+ cells were also CD38*, the more
immature phenotype of the human HSCs (Fig. 7.4). About 28% of total CD34+ cells were
transduced as measured by the expression of GFP driven by the internal PGK promoter.
A comparison of the transduction efficiency between CD34+/CD38* and CD34+/CD38+
cells, also shows that the more immature CD38* subpopulation had a higher transduction
efficiency in respect to the double positive subpopulation (26% vs 2%, Fig. 7.4). This
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observation suggests that Ad/AAV vectors are able to transduce quiescent human HSCs at 
a high efficiency, even more than cycling progenitor cells.
To analyse transgene expression at the level of single colonies, CD341 transduced cells, 
were plated in methylcellulose to perform the colony forming cell in vitro (CFC or CFU) 
assay. MOI 300, 500 and 1000 in presence of Dox were utilised. Between 10 and 14 days 
after plating, methylcellulose clonal culture were scored for GFP expression by 
fluorescence microscopy. Again no colonies were scored for each group.
In summary, these results shown that high titer Ad/AAV viral stocks were generated using 
a HD system and the Ad 5/35 serotype is able to infect quiescent HSCs at a good 
efficiency in respect to Ad 5 serotype but again no colonies were identified.
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Fig. 7.4 FACS analysis of CD34+ cells transduced with Ad 5/35. FACS analysis was performed 24h after 
transduction. Cells were labelled with anti CD34 and CD38 and followed for GFP. In the UR region o f the 
second panel is indicated the percentage of CD34+ cells transduced (red oval, around 28%). In the LR region 
of the third panel is indicated the percentage of CD38' cells tranduced (blue oval, around 25%). In the LR 
region of the last panel is indicated the percentage of CD34+ CD38" cells, the more immature phenotype 
(green oval, around 86%).
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7.3 Hematopoietic derived cell lines transduction with Ad 5 and Ad 5/35 
serotypes.
K562 and HEL cells were transduced with ITRGN Ad 5 serotype virus and with Ad 5/35 
version of ITRGN without Rep. Cells were transduced at different MOI 50, 100, 300, 500 
and 1000 to investigate the role of virus particles in transduction efficiency. The day before 
transduction 5x105 cells/well were plated in 6 wells plates and incubated all night in RPMI 
10% FCS antibiotic and L-Glutamine supplemented.
The day of the transduction media was sucked off and transductions were managed in 500 
ul serum free RPMI diluted viruses. Cells were incubated one hour at 37°C 5% CO2 
incubator. After transduction 10% serum (final concentration) was added to RPMI 
containing virus. Cell bulks were monitored 24 hours post transduction for one month for 
GFP expression by FACS analysis every three-four days (Fig. 7.5).
Cells harvested for GFP FACS scoring were also stained with trypan blue to investigate if  
MOI had influences in cell viability (data not shown). No evidence was seen regarding 
MOI/cell viability.
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Fig. 7.5 Graphic representation of HEL cells transduction with both Ad 5 and Ad 5/35 serotypes.
HEL were transduced with Ad non integrating vector ITRGN of two serotypes (Classical Ad 5 and Ad 5/35 
hybrid serotype) at various MOI and followed for one months for GFP expression and cell death. Plotted data 
showed that at lower MOI Ad 5/35 is the best transducing serotype in respect to Ad 5. Raising MOI a trend 
more similar between Ad5 and Ad 5/35 was obtained. Ad 5 seems to be more stable, there are more cells 
maintaining GFP expression along the time in the middle phase of transduction. Ad 5/35 shows a precocious 
pick at the beginning of infection in correspondence of which a higher number of cells were transduced with 
GFP but this pick dropped down in the middle phase following a constant reduction along the time. This 
phenomenon was not influenced by the cell death. The experiments were reproducted 3 times.
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Fig. 7.6 Graphic representation of K562 cells transduction with both Ad 5 and Ad 5/35 serotypes.
K562 were transduced with Ad non integrating vector ITRGN of two serotypes (Classical Ad 5 and Ad 5/35 
hybrid serotype) at various MOI and followed for one months for GFP expression and cell death. Plotted data 
showed that at lower MOI Ad 5/35 is the best transducing serotype in respect to Ad 5. Raising MOI a trend 
more similar between Ad 5 and Ad 5/35 was obtained. Ad 5 seems to be more stable, there are more cells 
maintaining GFP expression along the time in the middle phase of transduction. Ad 5/35 shows a precocious 
pick at the beginning of infection in correspondence of which a higher number of cells were transduced with 
GFP but this pick dropped down in the middle phase following a constant reduction along the time. This 
phenomenon was not influenced by the cell death. The experiments were reproducted 3 times.
Plotted data demonstrated that at lower MOI Ad5/35 is the best transducing serotype in 
respect to Ad5. In my hands it was possible to obtain a 2-3 fold increase of GFP transduced 
cells using Ad5/35 in respect to what I obtained with the same virus in a Ad 5 context. 
Raising MOI we obtained a trend more similar between Ad 5 and Ad 5/35 both in HEL 
and K562. In all cell lines we tested in particular at low MOI Ad 5 seems to be more 
stable, there are more cells maintaining GFP expression along the time in the middle phase 
of transduction. Ad 5/35 shows a precocious pick at the beginning of infection in
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correspondence of which a high number of cells were transduced with GFP but this pick 
dropped down in the middle phase following a constant reduction along the time. This 
phenomenon was not influenced by the cell death. The number of dead cells was 
practically the same between Ad 5 and 5/35. This phenomenon can be explained with a 
different internalisation mechanism. It seems that Ad 5/35 can transduce more cells at the 
beginning, but the internalisation system seems to influence DNA stability. For our 
purpose this doesn’t seem a great problem. For our model it is important to have a great 
amount of virus in the nucleus in the few hours after transduction.
Both virus serotypes stop to be expressed/present around twenty days after transduction.
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Chapter 8
Discussion
Gene targeting and homologous recombination technology underwent spectacular 
development in the last couple of decades, leading to the routine generation of transgenic 
animals with precise gene modifications by genetic manipulation of embryonic stem cells. 
However, the efficiency of this technology is still exceedingly low for clinical gene 
transfer, which almost invariably involves substantial numbers of rare and poorly 
cultivable cells (e.g., somatic stem cells). For clinical applications, the only available 
options are either extra-chromosomal expression or uncontrolled genomic insertion of 
therapeutic genes by means of a virus-derived gene transfer vector. Integrating vectors 
derived from murine oncoretroviruses (e.g., the Moloney murine leukemia virus, or MLV) 
have been used in hundreds of gene therapy trials since 1991 (197). Despite the known 
oncogenic potential of the parental viruses (198), retroviral vectors were considered 
relatively safe until lymphoproliferative disorders were reported in three patients treated 
with retrovirally-transduced hematopoietic progenitor cells for X-linked severe combined 
immunodeficiency (X-SCID). In all three patients, the vector inserted into, and activated, 
the T-cell proto-oncogene LMO-2, thereby contributing to the establishment and/or 
progression of the malignancies (199). These events indicated that insertional oncogenesis 
is an actual “genotoxic” risk associated to the use of retroviral vectors, which may severely 
limit a wider application of this type of technology. Another problem of these kind of 
vectors is the relatively small cassette size they can contain. Both retroviral and lentiviral 
vectors have an insert size limitation of 7-8 kb and moreover this kind of vectors do not 
easily accommodate introns or complex regulatory elements.
There are several possible solutions to the genotoxicity problem, which range from 
improving the current retroviral vector design to developing entirely new technology.
An ideal gene transfer vector should be capable of inserting a therapeutic transgene at a 
precise location into human DNA, where it can be efficiently expressed without perturbing 
the homeostasis of the rest of the genome and should be so versatile to target also big 
inserts in a safe way.
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For gene therapy applications, the development of vectors that target transgene integration 
to specific sites in the host genome is a major focus.
Indeed a virus that posses these properties does exist, and that is the wild type AAV (4, 5). 
AAV genome is a linear, single-stranded DNA filament which contains at both ends a 145- 
base inverted terminal repeat (ITR) encoding the origin of replication and the packaging 
signal (31), and two AAV-specific genes, rep and cap. The ITRs and the Rep protein are 
sufficient for replication of the AAV genome in the presence of Ad or herpes simplex virus 
(HSV) helper functions (AAV is incapable of completing its life cycle without a helper 
virus) (21). In the absence of helper functions, the same elements are sufficient to mediate 
the integration of the AAV genome into a 3-kb specific site on human chromosome 
19ql3.4qter (21). This site, called AAVS1, has been mapped to the first exon of myosin 
binding subunit 85 of protein phosphatase 1 (28). The AAVS1 site appears to be in an open 
chromatin conformation in the cell lines tested (74), which is thought to help AAV 
integration and viral gene expression. Integration into this site is mediated by the large 
AAV Rep proteins Rep68 or Rep78. Rep68/78 demonstrate sequence-specific 
endonuclease activity and ATP-dependent helicase activity, and can mediate 
rescue/excision of DNA flanked by AAV ITRs in the presence of Ad super-infection (21). 
Rep mediated rescue requires the presence of both a Rep binding site (RBS) and a terminal 
resolution site (trs) within the virus AAV ITR and genomic AAVS1 site, whereby the 
secondary structure of these sites appears to be crucial for Rep68/78-mediated DNA 
nicking. Rep-mediated rescue of a cassette flanked by AAV ITRs from ds DNA substrates 
and nicking within the AAVS1 site creates free DNA ends which allow for virus 
integration via non-homologous end-joining (NHEJ). It is therefore thought that rescue 
from incoming ds DNA is a prerequisite for integration (45, 48, 49, 50).
The ability of Rep68/78 to mediate integration into AAVS1 has been harnessed for site- 
specific integration of transgenes from co-transfected ds DNA plasmids. The frequency of 
AAVS1-specific integration by these plasmid-based methods has differed among studies
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from 20 to 50%, whereby integration frequency was measured upon drug selection (19, 16, 
14, 53, 18). However, plasmid transfection is not an efficient method for gene transfer. The 
production of Rep-expressing viral gene transfer vectors (based on adenovirus or HSV-1) 
is also problematic, because expression of Rep in packaging cells has been shown to 
severely reduce vector production (189). The vector yield could be increased by placing 
the rep gene under the control of promoters with low activity in packaging cells or by 
using tet or Cre/lox inducible gene expression systems (190).
There are a series of limitations in using Rep-based hybrid vectors.
Retroviral vectors, particularly the last generations derived from HIV, have a large 
tropism, and transduce >50% of their target cells (hematopoietic stem/progenitor cells, 
keratinocytes, neurons, hepatocytes) with negligible toxicity. High efficiency is mandatory 
for clinical application.
Rep-based hybrid vectors transduce relatively efficiently stable cell lines (10 to 20%) but 
much less primary cells, either in culture or in vivo (1-5%). Most of the papers published 
on the issue did not even try to address the issue of gene transfer in targets of clinical 
relevance.
Increasing Rep-mediated gene transfer efficiency appears very difficult. The wild-type 
AAV uses Rep to replicate as well as integrate, and 15% integration efficiency is probably 
the best compromise evolution has found between propagation and latency. Improving 
nature is going to be a tough task, and will probably require some serious protein 
engineering.
A second hurdle is the proportion of site-specific versus non-specific integration. Getting 
rid of non-specific integration is the reason why we are trying to use Rep or other 
sequence-specific integrases in the first place (191, 192). If 30-50% of the integrations are 
still random, the genotoxic risk for the target cells would diminish only by a factor of two 
or three compared to retroviral vectors, not really enough to make a difference in the real 
world -  hundreds of millions to billions of cells are transduced and administered in a
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typical gene therapy protocol. This is true unless the non-specific integrations have a 
substantially better safety profile compared to those of retroviral vectors, which prefer to 
integrate into active genes and around transcription start sites (193). Data on this point, 
however, are scattered and inconsistent. Some authors reported that AAV vectors tends to 
integrate into active genes (194), while others showed that non-specific, Rep-mediated 
integration of AAV-based cassettes targets essentially intergenic regions (195). Overall, 
there is not enough data to reach a conclusive answer on this crucial point. Paradoxically, 
in a system with only 50% site specificity, the nature of the non-specific events is going to 
be more important than site specificity itself.
Finally, there is an issue of integration-independent genotoxicity. Significant progress has 
been made also with other types of proteins, such as transposases or bacteriophage-derived 
integrases (191, 196). Integrases and transposases introduce, at variable extent, single and 
double-strand breaks into mammalian genomes. These breaks are potentially 
recombinogenic, and could cause mutations or genomic rearrangements as dangerous, if 
not more dangerous, than those caused by random vector insertion. The genotoxicity of 
recombinases, including that of Rep, has not been studied thoroughly enough to make 
reliable predictions about the safety of their use in humans. Appropriate regulation of their 
expression is clearly a crucial variable, but may not be the only one.
Large capacity Ad/AAV.
In this study we showed that a helper-dependent Ad 5 vector expressing Rep78 under the 
control of a doxicyclin-inducible system for site-specific transgene integration can be used 
to integrate a large expressing cassette flanked by AAV ITR expressed by another vector 
into the human genome in a site-specific way. Moreover we speculate that clones with high 
level Rep78 expression died off due to Rep-mediated toxicity. This is supported by the fact
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that the total number of clones that developed was 2 to 3 fold lower for Ad-Rep78 infected 
cells than in settings with AdhCol7 alone. Furthermore, the percentage of GFP expressing 
cells in all surviving clones was constant over time, underscoring that these cells did not 
have a proliferative disadvantage.
This study is a proof of principle that targeted integration of a 12-kb transgene can be 
achieved at high frequency. Though the inaccuracy of integration and genomic 
rearrangements are a concern, epidemiological studies show widespread wt AAV infection 
(80% of humans are AAV seropositive), while no known pathologies, including neoplastic 
malignancies, have been reported (21).
In my thesis work I studied a new generation of hybrid DNA vectors that combine the 
large capacity and infectivity of adenoviral vectors with the ability of the AAV Rep protein 
to direct the integration of AAV ITR-flanked sequences at specific sites into the human 
genome. In particular I focused my attention on testing the ability of Rep protein to 
integrate very large transgenes in respect to AAV genome size, on test new methods to 
improve this system both in transduction efficiency and in integration capacity. Because 
transduction of primary cells, particularly primary hematopoietic stem cells, with first- 
generation E1/E3 deleted recombinant Ad vectors is associated with toxicity due to viral 
gene expression (118), we used in our studies a helper-dependent (HD) Ad vectors, which 
are devoid of all viral genes (121).
A major difficulty in building viral vectors containing Rep expression cassettes is the 
negative effect of Rep on viral replication (23), which prevents packaging or reduces titers 
to values unacceptably low for practical use. To overcome these problems, I used a system 
developed in my lab in which a tight, drug-inducible transcriptional regulation system 
based on a minimal promoter under the control of the tetO element and a constitutively 
expressed tTS suppressor. This combination allowed efficient packaging of a HD-Ad 
vector containing Rep. Drug-induced activation of Rep allowed a good protein production 
control.
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The vector I developed was three times bigger than those previously developed in the 
laboratory, and the first concern was to understand whether this system was able to work in 
this situation. In particular, whether the Rep protein was able to integrate intact copies of 
the ITR-flanked cassette into the AAVS1 site in stable cell lines without recombination, in 
the absence of selective pressure and possibly with a good efficiency.
In all GFP expressing clones that were used for integration studies we did not detected 
Rep78 expression by western blot.
The efficiency of AAVS1-specific integration was a bit lower that what we obtained with 
the smaller cassette.
With this dual vector system, hCol7-GFP transgene integration into AAVS1 was seen in 
30% of analyzed integration sites, whereby transgenes integrated into AAVS1 expressed 
GFP at high and stable levels. In our study we obtained ~43% of stably transduced HeLa 
clones in which the AAVS1 locus is rearranged even in the absence of an integrated 
cassette. This is probably due to the ability of Rep to bind to the RBS in AAVS1, induce 
nicking at the nearby trs, and start unscheduled DNA replication before binding to, 
replicating, and eventually integrating an ITR-containing genome. The higher percentage 
obtained with respect to previous studies using a smaller cassette could be due to the 
cassette dimension, maybe due to abortive events and probably to the use of CMV 
promoter to ensure a higher Rep expression.
In the presence of exceedingly high or prolonged synthesis of Rep, the AAVS1 site could 
become a hot spot of chromosome fragility or genetic recombination in transduced cells, an 
obviously undesirable side effect of a Rep-based integration system. Drug-controlled Rep 
expression is expected to reduce these potential genotoxic effects, an additional safety 
characteristic of our hybrid vectors. Expression of Rep, a likely immunogenic protein, 
could potentially elicit a cytotoxic immune response against cells transduced in vivo by a 
Rep-expressing vector. The drug-controlled expression system is expected to reduce the 
immunogenicity of Rep to a minimum, although it introduces an additional immunogenic
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factor, the constitutively expressed Tet repressor protein. The immunogenic potential of 
the Tet repressor is a controversial issue, although it is conceivable that in cells or tissues 
in which episomal Ad vectors persist for long time (liver, for example) this might 
eventually turn out to be a problem. Anti-Rep and anti-Tet immune responses therefore 
need to be addressed in specific animal models for each vector delivery route. 
Adenovirus-based integrating vectors could find practical application in both ex vivo and in 
vivo gene transfer protocols. We demonstrated that the large capacity of the Ad vector 
backbone allows the incorporation of large genes and eventually a complex regulatory 
systems into the vectors, a current limitation of retroviral vector technology. A high 
proportion of site-specific integration and a general preference for nontranscribed regions 
would reduce both the risk of insertional oncogenesis and the problem of position- 
dependent variability or silencing of transgene expression (195).
In my hands it was not possible to obtain any clone from keratinocyte primary cells. In all 
the experiments I made transducing keratinocytes both with the small integrating cassette 
(GFP-ANGFR) and with the large integrating virus (hCol7 + GFP) it was impossible to 
expand clones derived from the transduction of keratinocyte stem cells. This could be due 
to different events:
- Ad 5 serotype is not able to transduce the more immature keratinocytes.
Rep78 is more toxic for these kind of cells.
The population of more immature keratinocytes could be so small that we weren’t able 
to clone enough cells to isolate any epidermal stem cell.
- Repopulating keratinocytes could silenciate the integrated cassete.
As discussed in my thesis the Ad 5 serotype need on the cell surface the presence of two 
receptor to transduce cells: CAR and the a v integrin. It is so possible that the epidermal 
stem cell population is lacking on one or both receptors. Transduction experiments with 
other serotypes could be an alternative and the solution to this problem.
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Rep 78 is a well known toxic protein, and maybe in the epidermal stem cell contest is too 
much toxic, giving the death of all the repopulating keratinocyte population. At the 
moment this problem can’t be by-passed, Rep is needed to obtain integration.
Different limiting dilution experiments were done to clone a repopulating stem cell stable 
transduced with our integrating cassette. From different transduced populations of 
keratinocytes, thousand of cells were cloned, but no one of this single cells arised a 
repopulating clone. This could be due to the impossibility to clone a so low abbundant 
population and a more extensive effort is needed.
Repopulating cells are very active cells and methylation or other chromatin modification 
during differentiation or duplication could give raise to integrated cassette silencing. In this 
case maybe we were able to integrate our cassettes into the genome of a repopulating 
epidermal stem cell, but we neglected that clone who wasn’t able to express the integrating 
cassette.
Optimisation of vector integration.
Previous reports demonstrated that the AAV-2 p5 promoter region contained a 
multifunctional element that was involved in rep gene expression, Rep-dependent 
replication, and site-specific integration (64, 27, 26). The aim of last part of my study was 
to isolate a minimal region of p5 able to integrate and investigate if the integration process 
is dependent on replication in the presence of Rep78 protein. In particular the main aim 
was to clarify the role of Rep mediated replication in AAV integration and if the presence 
of a p5 region flanking ITR in its wt position can improve the site specific integration 
frequency.
The minimal p5 element demonstrated functional in vivo replication assays was composed 
of a 55-bp region that included the TATA box, the Rep-binding site, the trs-1, and a
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potential hairpin structure surrounding the trs. The Rep-binding site, the trs-1, and the 
hairpin structure were absolutely required for replication assays, whereas the TATA box 
was seen to be dispensable for in vitro replication (180).
A critical step for the characterization of the minimal p5 element consisted in the 
identification of the Rep nicking sites within the p5 region. Indeed, a previous study by 
Wang et al. (67) had indicated the presence of a cryptic trs at the transcription initiation 
site, without indicating the strand that was cleaved. The subsequent finding by Wu et al. 
(50) of no detectable nicking near the p5 Rep-binding site further put in question the 
presence of this trs. Using nicking assays, Franqois et al. (180) confirmed the presence of a 
major trs at the transcription initiation site and localized it on the lower AAV’s DNA 
strand between nucleotides 287 and 288. In addition, they showed that at least four other 
minor trs sites could be detected within the p5 region. Most of these nicking sites were not 
required for p5 replication and the minimal element characterized in Franqois study 
(p5D10) contained only two trs sites, trs-1 and trs-12. The requirement for the former trs 
was demonstrated by the direct mutation of this site (p5ntfrs). The role of the second trs 
(trs-12) is presently unknown and difficult to evaluate since it localized within the Rep- 
binding site. Cleavage at this site could be explained by a nicking reaction occurring in 
trans by Rep protein bound on a DNA substrate, nicking a second DNA template. In both 
the viral ITR and the chromosome 19 AAVS1 region, the Rep proteins have been shown to 
cleave the DNA between two thymidine residues, resulting in the covalent attachment of 
Rep to the nicking site through a phosphotyrosyl linkage (7, 43, 46). It is interesting that 
none of the trs sites identified in the p5 resembled those found in the ITR or the AAVS1 
region except for the presence of a thymidine residue to the nicking site. Also, great 
variability was observed in the spacer sequence separating the Rep-binding site from each 
trs within the p5, further distinguishing this substrate from the AAVS1 locus and the ITR. 
These observations, together with the experimental evidence demonstrating that most of 
these nicking sites, beside the trs-1, were not required for p5 replication, raise questions
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about their biological relevance. Interestingly, an additional trs site was recently described 
within the ITR (181). In that study, nicking was observed only using a partially purified 
Rep preparation, further suggesting that a cellular factor was involved in this cleavage. 
Nevertheless, it remains possible that these cleavage sites, even if Rep dependent, 
represent artificial reaction products due to the conditions under which the nicking assay is 
performed. The sequence surrounding the major trs-1 was also important for replication of 
the p5 element. This domain can potentially form a hairpin structure that localizes the trs-1 
on the extruded loop. Previous analyses on the viral ITR demonstrated that a potential 
stem-loop was present at the trs and that the extrusion of this structure was mediated by the 
ATPdependent helicase activity of Rep (51). A secondary structure was also recently 
described near the trs within the AAVS1 locus (52). It was demonstrated (180) that 
deletion of the nucleotides forming the stem of the hairpin impaired p5 replication. This 
result strongly supports the existence of secondary structure at the trs-1 and also suggests 
that cleavage at this site required the separation of the DNA strands through the helicase 
activity of Rep. Interestingly, in the case of the p5, the hairpin and the trs-1 localize within 
the YY1 recognition site, and binding of this factor to this site was previously shown to 
mediate TBP-independent initiation of transcription in vitro and DNA strand separation. It 
is tempting to speculate that formation of the hairpin structure at the p5 trs-1 is also 
favored by YY1 binding, further putting into question the relationships between replication 
and transcription initiation. Additional mutations affecting the YY1 binding site but not the 
trs-I or the hairpin structure should help define the role of this cellular factor for Rep- 
dependent replication of the p5.
It was previously reported that TBP could bind to Rep78 in vitro and in vivo without, 
however, demonstrating any biological effect associated with this interaction (182). 
Franqois results (180) indicated that the TATA box was absolutely required for in vivo 
replication of a minimal or a wild-type p5 element. In addition, they demonstrated that 
when the TATA box was present, TBP stimulated Rep binding at the Rep-binding site and
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nicking at the trs-1. The biological relevance of these observations was further supported 
by enhancement of p5 replication observed in cells over-expressing TBP. On the basis of 
these findings and of previous observations concerning the Rep-ITR interactions, the 
following model can be proposed for the p5 element. In vivo, i.e., in live cells, in the 
absence of the TATA box, Rep proteins may not be able to bind the p5 Rep-binding site. If 
Rep binding occurs, it must not be very efficient and in any case, not sufficient to induce 
cleavage at the trs-1 since no replicative activity of the TATA-less p5 element was 
observed. In the presence of the TATA box, TBP increases the efficiency of Rep binding at 
the Rep-binding site, and also nicking at the trs-1, thus stimulating replication of the p5 
element. Recent studies on the ITR have suggested that the interaction of Rep with the 
RBE induced a change in DNA conformation that resulted in the stimulation of the 
extrusion of the trs by Rep helicase activity (51). Similarly, in the case of the p5, an 
attractive hypothesis is that the interaction of Rep with TBP induces a conformational 
change that enhances Rep recognition of the Rep-binding site and favors the extrusion of 
the trs. Indeed, TBP is known to bend DNA once bound to the TATA box. This hypothesis 
is also supported by previous studies demonstrating that nicking at the AAVS1 trs by Rep 
was dependent upon topological constraints (183). Finally, an additional argument comes 
from the observation that high mobility group chromosomal protein 1 (HMG-1) increased 
Rep binding and nicking at the trs in the ITR. This protein, which influences DNA 
flexibility, also interacts directly with Rep (184). A similar effect on Rep activities was 
also demonstrated with some viral and cellular single-stranded DNA binding proteins 
(185). Several additional experiments should be performed to validate this hypothesis. 
Also, it is worth noting that the model presented does not take into account the complex 
interaction between TBP and the other factors that constitute the transcription initiation 
complex or the observation that Rep can form multimeric complexes upon binding its 
recognition site (181). It is interesting that the TATA box was completely dispensable for 
in vitro replication of the p5 element. This observation points out a different requirement
for cellular factors between in vivo and in vitro replication assays and further strengthens 
the hypothesis according to which the conformation of DNA is an essential parameter. 
Indeed, the template for in vivo replication is supercoiled plasmid DNA eventually 
wrapped by cellular histones, whereas in vitro replication is performed using naked linear 
double-stranded DNA molecules. The TBP was previously shown to interact with 
numerous cellular and viral proteins that are transcriptional regulators (186, 187). 
However, only a few reports describe an effect of TBP on the replication of viral origins. 
In particular, TBP was shown to inhibit the replication of viruses such as simian virus 40 
and human papillomavirus by interacting with viral regulatory proteins or by preventing 
their binding to the origin of replication (14, 15). Franqois results (180) demonstrated a 
positive effect of TBP on the replication of a viral element. Interestingly, it was previously 
reported that TBP could enhance eukaryotic DNA replication by binding to the replication 
origin in an Saccharomyces cerevisiae model (188).
In conclusion, these studies have contributed to the definition of a minimal replication- 
competent p5 region. It remained to be defined whether this minimal p5 element is also 
able to direct site-specific integration of plasmid DNA as previously demonstrated with a 
wild-type p5 region (26, 27) and to determine if p5 replication is required for this effect. 
Indeed, previous studies have shown that replication of the viral ITR was not required for 
site-specific integration. And more importantly, it remained to address the question of the 
role of this element in the context of the ITRs. It is possible, as previously suggested by 
Tullis et al. (65), that this element is required for optimal DNA replication.
We tried to answer to all the open questions starting to investigate the possible role of p5 
element in an ITR contest. It remained to be defined if the minimal p5 element, alone, was 
able to direct a site-specific integration of plasmid DNA as previously demonstrated with a 
wt p5 region and if p5 replication is required for integration.
In our study using a different construct in respect to which Franqois used and we 
confirmed the importance of TATA box in the p5 sequence. In our construct in fact it is
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present the sequence containing the TATA box, but we abolished its function 
mutagenizing the TATA sequence to abolish the p5 promoter function.
The plasmid containing the p5ATATA sequence was able to integrate to a percentage 
similar to DIO plasmid, but in HIRT assay we showed that our construct was not replicated 
in presence of Rep protein.
Using the four constructs spanning different region of p5 region and using similar 
construct in except for the presence of TATA box region we obtained a series of 
interesting data.
First of all with a transfection approach we isolate a series of different clones. All the 
clones we then analysed showed the same percentage of integration, showing no difference 
in respect to the p5 region utilised.
We started our study modifying the 5’ ITR putting in the wt position a p5ATATA element. 
From our data analysing 50 clones, 25 for the wt ITR and 25 for the mutated one we didn’t 
see any dramatic effect on site-specific or overall integration. What we noticed was a very 
interesting and dramatic effect on vector copy number integrated in a site-specific way. In 
particular in the ITRp5ATATA contest we noticed a higher percentage of integration of 
multiple copies of the integrating cassette. The ITR wt was able to integrate only 1 or 2 
copies of the cassette into the AAVS1 locus, while the ITRp5ATATA was seen to be able 
to integrate more than 2-3 copies into the AAVS1 locus.
What also we noticed was the ability of both the plasmids (the first one with the ITR wt 
and the second one with the ITRp5ATATA) to replicate the integrating cassette in presence 
of Rep. Whether the integration boost in presence of the p5 region was due to replication 
increase of the cassette, or the integration was independent from cassette replication, 
remains an open question.
Our replication assay using four different region spanning the p5 region and containing or 
not the TATA box have clarified this aspect.
In my hands from these four regions I obtained data very similar to Franqois ones (180).
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In particular I confirmed the importance of TATA box on the replication efficiency. Both 
D12 and p5ATATA were unable to replicate in presence of Rep, but able to integrate in 
these conditions. It is possible to conclude that replication of ITRp5ATATA we observed 
was due to the presence of ITR and the integration boost was not due to a more abundant 
replication of the integrating cassette.
Our data regarding the insertion of a p5 element following the ITR leave open a series of 
interesting approaches to improve the Rep mediated integration.
Expansion of vector tropism.
During our study we also asked to ourselves how to improve the transduction potential in 
human cell lines and also primary cells that are generally poorly transducible with Ad 5 
serotype. We showed that HD-vectors containing B-group serotype 35 fiber knob domains 
(HD-Ad 5/35) efficiently transduced human leukemia cells and primary CD34+ cells. 
Another concern we wanted to face with was the relatively low transduction capacity of Ad 
5 virus to transduce certain cell types, in particular the hematopoietic derived cell lines, 
primary cells and CD34+ cells.
Currently existing adenovirus, rAAV, and onco-retrovirus vectors do not allow for 
efficient and stable transduction of human hematopoietic stem cells (HSCs). I used a 
capsid-modified adenovirus vector devoid of all viral genes for transient expression of 
GFP-DNGFr in hematopoietic derived stable cell lines and CD34.1 wanted to test if using 
two different fiber knob domain in the same capsid type there were differences in 
transduction efficiency.
In the first step I decide to test the difference in transduction capacity of these two viruses.
Without any doubt Ad 5/35 demonstrated to be able to transducer more efficiently
hematopoietic derived cell lines and a lower MOI. But Ad 5/35 along the time
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demonstrated a faster clearance from cells. Gene expression was lost faster than genes 
inserted with Ad 5. Our hypothesis was that maybe virus entrance was responsible for this 
phenomenon.
To evaluate our hypothesis that the primary attachment receptor largely determines the 
selection of intracellular trafficking routes by wild-type or capsid-modified Ads, we used 
Ad vectors with identical capsids except for the fiber knob domain, which is the capsid 
moiety responsible for high-affinity virus attachment to cell surface receptors. Anuj 
Gaggar et al. (163) demonstrate that the major difference in the trafficking of Ad 5 and Ad 
5/35 was that Ad 5/35 virus particles were readily found in late endosomes/lysosomes for 
up to 4 hours after infection, whereas Ad 5 virus escaped rapidly to the cytosol and never 
co-localized with late endosomal/lysosomal markers. EM analyses showed that at 2 hours 
after virus infection, the majority (more than 80%) of Ad 5 virus particles could be found 
as free particles in the cytoplasm and in the perinuclear space and only 3% were found in 
the endosomes. However, at the same time point, more than 60% of Ad 5/35 virions were 
found within endosomes. This is in agreement with observations made for wild-type 
subgroup B and C viruses as well as with studies performed with chimeric Ad 5/7 vectors 
(162). Shayakhmetov et al. (152) argue that the ability of the fiber knob to interact with 
different attachment receptors accounts for the different trafficking pathways observed for 
Ad 5 and Ad 5/35 vectors independently of the length of the fiber shaft domain. CAR 
appears to be required only to hold the virus particle in a suitable position in order to allow 
a v integrins to interact with the penton base. This interaction has been found to initiate the 
signaling allowing for virus internalization and endosome release. For the unknown Ad 35 
receptor this signaling might be absent or different, resulting in a different trafficking route 
for the incoming virus. Notably, Ad 5/35 and Ad 5 vectors have identical capsids except 
for the fiber knob domain. This implies that both of these vectors have the same net charge 
of the capsid. This is important, considering that the net charge of the capsid may affect the 
pathway and efficiency of Ad internalization.
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In my experiment I noticed that Ad 5/35 ensure a faster GFP expression in all cells we 
used but this not translate into a higher efficiency of gene transfer or level of transgene 
expression. My data indicate that this is at least in part due to a sort of genetic instability of 
viruses that passes from the endosomal/lysosomal cellular compartments. It seems that a 
earlier gene expression from that viruses do not correspond to a longer or constant gene 
expression. In general, molecules that enter cells via receptor-mediated endocytosis can 
follow one of two major routes: (i) the endocytic recycling pathway, in which membrane 
proteins and membrane-bound proteins are collected in a tubulovesicular compartment, 
termed the endocytic recycling compartment, prior to trafficking back to the cell surface; 
or (ii) the lysosomal pathway, in which a select set of membrane proteins, ligands that have 
dissociated from their receptors, and soluble materials occupy a compartment termed the 
sorting endosome, which later matures and acidifies to become a late endosome and finally 
a lysosome. It appears that trafficking of Ad 5/35 particles involves both pathways. Ad 
5/35 particles achieve proximity to the nucleus by remaining inside late 
endosomes/lysosomes. It appears also that some of the Ad 5/35 particles enter the 
endocytic recycling pathway and are released from the cell. Finally, in comparison to the 
Ad 5-CAR interaction, the binding of Ad 5/35 particles to the receptor may lead to more 
destructive changes in structures that determine the infectivity of Ad particles. Other 
factors that may influence Ad 5/35 trafficking remain to be investigated, including whether 
fiber release occurs during internalization and which signaling pathways are activated. The 
development of Ad vectors that interact with receptors different from CAR requires a 
better understanding of events that follow the internalization of viral particles.
As I wrote before it could be of interest to test the capability of this new hybrid serotype to 
transduce the keratinocyte repopulating stem cell population. No stem cell keratinocyte 
marker is known, so is not possible to select this population as it is possible in a CD34+ 
cell contest. The only proof of principle available in this case is transduce the total
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keratinocyte population and see if it is possible to isolate a clone with the integrated 
cassette.
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